

CURRICULUM VITAE
Norah Terrault, MD, MPH, FAASLD

Personal Information

Work:

Address:
 2250 Alcazar Street
 Suite 246 | MC-9078
 Los Angeles, CA 90033

Phone: 323-442-0172
 Fax: 323-865-9245
 Work Email: Terrault@usc.edu

Home:

Address
 4263 Palmero Drive
 Los Angeles, CA 90065

Citizenship: Canadian
 Permanent Resident: U.S.

Education and Professional Appointments

Education:

<i>Year</i>	<i>Degree, Field, Institution, City</i>
1985	B.MSc., University of Alberta, Edmonton
1987	MD, University of Alberta, Edmonton

Post-Graduate Training:

<i>Year</i>	<i>Degree, Field, Institution, City</i>
1987-1988	Intern, Internal Medicine, University of Toronto, Toronto
1988-1991	Resident and Chief Resident, Internal Medicine, University of Toronto, Toronto
1991-1993	Fellow, Gastroenterology, University of Toronto, Toronto
1993-1994	Research Fellow, Victor Feiman, GI/Hepatology, University of Toronto, Toronto
1994-1997	Research Fellow, Teresa Wright, GI/Hepatology, University of California, San Francisco
1997	MPH, University of California Berkeley, Berkeley

Academic Appointments:

1997-2002	Assistant Adjunct Professor	Medicine, University of California, San Francisco	San Francisco, CA
2002-2006	Assistant Professor	Medicine (Clinical X track), University of California, San Francisco	San Francisco, CA
2006-2010	Associate Professor	Medicine and Surgery (Clinical X track), University of California, San Francisco	San Francisco, CA
2010-2019	Professor	Medicine and Surgery, University of California, San Francisco	San Francisco, CA
2019-present	Professor of Medicine (with tenure)	Department of Medicine, Keck School of Medicine of USC	Los Angeles, CA

2020-current	Neil Kaplowitz Chair in Liver Medicine	Department of Medicine, Los Angeles, CA Keck School of Medicine of USC
--------------	--	---

Clinical Appointments:

<i>Year-Year</i>	<i>Appointment</i>	<i>Department, Institution, City, Country</i>
1997-2019	GI/Hepatology	UCSF Health (UCSF Medical Center Parnassus Campus
2019-present	GI/Hepatology	Keck Medicine, USC, Los Angeles
2019-present	GI/Hepatology	Los Angeles County-USC, Los Angeles

Administrative Appointments:

<i>Year</i>	<i>Description</i>	<i>Institution, City, State, Country</i>
2009-19	Director of Viral Hepatitis Center	UCSF
2010-12	Director, Transplant Hepatology Training	UCSF
2013-15	Director, Transplant Hepatology Training	UCSF
2019-present	Chief, Gastrointestinal and Liver Diseases	USC

Licensure, Certifications

Licensure:

<i>Year</i>	<i>License number, State, Status</i>
1988	Medical licensure, Ontario, Canada – inactive
1994	No. A60147, California -- active

Board Certification or Eligibility:

<i>Year</i>	<i>Board, State, Status</i>
1991	Diplomate of the American Board of Internal Medicine
2004	Recertification, American Board of Internal Medicine
2015	Recertification, American Board of Internal Medicine

Specialty Certification:

<i>Year</i>	<i>Specialty Certification, Status</i>
1993	Diplomate of the American Board of Gastroenterology
2004	Recertification, American Board of Gastroenterology
2006	Certificate of Added Qualification, Transplant Hepatology
2015	Recertification, Transplant Hepatology
2016	Recertification, American Board of Gastroenterology

Other Certifications or Examinations:

<i>Year</i>	<i>Certification or Exam, Status</i>
1992	Fellow in the Royal College of Physicians of Canada (FRCPC), Internal Medicine
1993	Fellow in the Royal College of Physicians of Canada (FRCPC), Gastroenterology

Honors, Awards

<i>Year</i>	<i>Description</i>	<i>Awarding agency, city</i>
1994	Canadian Liver Foundation Fellowship Award	Canadian Association for the Study of Liver Diseases
1996	Canadian Liver Foundation Fellowship Award (Declined)	Canadian Association for the Study of Liver Diseases

1996	Medical Research Council of Canada Fellowship Award (Declined)	Medical Research Council of Canada
1996	Dr. Saul Krugman Career Development Award	Hepatitis Foundation International
1997	Jan Albrecht Commitment to Clinical Research Award	American Association for the Study of Liver Diseases
2011	Nominee for Distinction in Mentoring Award	University of California San Francisco
2013	Mentor for ILTS Rising Star Award	International Liver Transplant Society
2015	Nominee for Clinician Scientist Award	American Society of Transplantation, Women's Health Community of Practice
2015, 2017, 2018	Nominated Top Doctor	US News and World Report
2021	Gold Medal Award	Canadian Association for the Study of Liver Diseases
2024	International Recognition Award	European Association for the Study of the Liver
2025	Highly Ranked Scholar	Scholar GPS

Teaching

Didactic Teaching:

UCSF

<i>Year-Year</i>	<i>Course Name</i>	<i>Units/Hrs</i>	<i>Role</i>
1999-2001	Medicine 132		Small group leader
1999-1999	Medicine 111		Lecturer
1999-2003	Internal Medicine Review for R3s (1999, 2001-3)		Lecturer
2000-2019	Gastroenterology fellow curriculum		Lecturer
2002-2003	Medicine IDS 101/131		Small group leader
2002-2011	Medicine Metabolism Block		Small group leader for GI section
2009-2018	Transplant hepatology fellow curriculum		Facilitator and lecturer
2010	Minicourse for PIBS Students		Lecturer

UC Berkeley

<i>Year-Year</i>	<i>Course Name</i>	<i>Units/Hrs</i>	<i>Role</i>
2003-2005	PH253B Epidemiology of Infectious Diseases	2 hours	Invited lecturer

USC

<i>Year-Year</i>	<i>Course Name</i>	<i>Units/Hrs</i>	<i>Role</i>
2020-22	Clinical Research Methods Course	2 hours	Organizer (2020), Lecturer (2020, 2021, 2022)

CME Courses Developed:

UCSF

<i>Year-Year</i>	<i>Course Name</i>	<i>Units/Hrs</i>	<i>Role</i>
2015-present	ECHO (Extension for Community Healthcare Outcomes) for PCPs	2.5 hours/month	Lecturer and facilitator

USC

<i>Year-Year</i>	<i>Course Name</i>	<i>Units/Hrs</i>	<i>Role</i>
2020-present	ECHO HCV Certification Program at USC		Organizer, Facilitator, Lecturer
2021	1 st Annual USC GI and Liver Diseases Update		Co-Organizer, Facilitator

Undergraduate, Graduate and Medical Student (or Other) Mentorship:

<i>Year-Year</i>	<i>Trainee Name</i>	<i>Trainee Type</i>	<i>Dissertation/Thesis/Project Title</i>
2006-2007	Julie Ishida	Doris Duke Fellowship Awardee	Influence of cannabis use on severity of hepatitis C disease
2007-2008	Kartik Krishnan	Undergraduate, Duke University	Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C.
2010-2013	Jacob Zipperstein	Undergraduate, UCB	Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C.
2017-2019	Thu Nguyen	Medical student, WVSOM	Liver and spleen volume as predictor of recompensation after HCV therapy
2017-2019	Celia Haering	Medical student, Summer Explore Research Fellowship	Influence of statin use on HBV fibrosis progression
2017-2019	Catlin Contag	Medical student Department of Medicine, Stanford University, Palo Alto	Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses

Graduate Student Thesis, Exam and Dissertation Committees:

<i>Year-Year</i>	<i>Trainee Name</i>	<i>Committee</i>	<i>Student Department</i>
2003-2005	Mandana Khalili	Masters	UCSF Epi/Biostats: Masters in Clinical Research
2003-2005	Scott Biggins	Masters	UCSF Epi/Biostats: Masters in Clinical Research
2009-2011	Danielle Brandman	Masters	UCSF Epi/Biostats: Masters in Clinical Research
2011-2013	Jennifer Flemming	Masters	UCSF Epi/Biostats: Masters in Clinical Research
2014-2016	Varun Saxena	Masters	UCSF Epi/Biostats: Masters in Clinical Research
2015-2017	Veeral Ajmera	Masters	UCSF Epi/Biostats: Masters in Clinical Research
2016-2018	Kali Zhou	Masters	UCSF Epi/Biostats: Masters in Clinical Research
2016-2018	Suzanne Sharpton	Masters	UCSF Epi/Biostats: Masters in Clinical Research
2017-2019	Brian Lee	Masters	UCSF Epi/Biostats: Masters in Clinical Research
2021-present	Divya Ayyala-Somayajula	Masters	USC Clinical, Biomedical and Translational Research

Postgraduate Mentorship:

<i>Year-Year</i>	<i>Trainee Name</i>	<i>If past trainee, current position and location</i>
1999-2000	Mandana Khalili	Professor of Clinical Medicine, UCSF

2001-2002	Shiobhan Weston	Private Practice, Dublin Ireland
2002-2003	Cindy Lai	Professor of Clinical Medicine, UCSF
2003-2004	Amandeep Shergill	Professor of Clinical Medicine, UCSF
2003-2005	Scott Biggins	Professor, University of Washington
2004-2005	David Kim	Attending GI Kaiser, Los Angeles
2004-2006	Rex Wang	Attending GI Kaiser, Sunnyside California
2005-2007	Alexander Kuo	Medical Director Liver Transplantation, Cedar Sinai Hospital
2006-2007	Carla Coffin	Professor, University of Calgary, Canada
2006-2008	Glen Lutchman	Medical Director, Swedish Hospital, Seattle
2006-2012	Danielle Brandman	Professor of Clinical Medicine, GI UCSF
2007-2009	Jennifer Guy	Clinical Chief of Hepatology, California Pacific Medical Center
2007-2010	Suejin Kim	Attending GI, Santa Cruz
2008-2009	Richard Kim	VP Marketing , BMS
2008-2010	Chelsea Sim	Oral Medicine Dentistry, Singapore
2008-2012	Jennifer Lai	Associate Professor (in Residence), GI UCSF
2008-2013	Rosa Valadao	Attending GI, Kaiser Permanente
2009-2017	Varun Saxena	Attending, Kaiser Permanente
2011-2013	Jennifer Flemming	Associate Professor, Queens University, Kingston, Canada
2012-2015	Chanda Ho	Hepatology Attending, California Pacific Medical Center
2013-2015	Isabel Campos	Faculty, University of Santiago de Compostela, Spain
2013-2017	Veeral Ajmera	Associate Professor and Medical Director of Liver Transplantation, University of California, San Diego
2014-2017	Jeanne-Marie Giard	Asst Professor, University of Montreal, Canada
2014-2019	Kavita Radhakrishnan	Attending GI, Kaiser Permanente
2015-2017	Tianyan Chen	Asst Professor, McGill University, Canada
2016-2017	Tatyana Kushner	Assoc. Professor, Mount Sinai Hospital, New York
2015-2019	Kali Zhou	Asst Professor, GI and Liver Diseases, University of Southern California
2015-2019	Suzanne Sharpton	Asst Professor, GI at Vanderbilt University
2016-2020	Brian Lee	Asst Professor, GI and Liver Diseases, University of Southern California
2017-2019	Prashant Kotwani	Fellow, Gastroenterology, UCSF
2019-2021	Michael Pimienta	Resident, Medicine, University of Southern California
2021-present	Divya Ayyala-Somayajula	Fellow, GI & Liver Diseases, University of Southern California
2022-present	Matthew Dukewich	Fellow, GI & Liver Diseases, University of Southern California
2023-present	Philip (Tiange) Zhang	Fellow, GI & Liver Diseases, University of Southern California

Mentorship of Faculty:

<i>Year-Year</i>	<i>Mentee Name</i>	<i>Mentee Department (at time of mentorship)</i>
2005-2010	Scott Biggins	University of Colorado
2007-2007	Kiram Bambha	UCSF
2010-2012	Oren Fix	UCSF
2010-2019	Bilal Hameed	UCSF

2011-2013	Alyson Fox	Columbia University
2012-2015	Jennifer Lai	UCSF
2012-2019	Danielle Brandman	UCSF
2012-2019	Jennifer Price	UCSF
2013-present	Jennifer Flemming	Queen's University, Canada
2014	Victoria Aguilera	Hospital U La Fe. Valencia, Spain
2014-present	Monika Sarkar	UCSF
2015-present	Isabel Campos	University of Santiago de Compostela, Spain
2017-present	Tatyana Kushner	Mount Sinai School of Medicine
2017-2019	Veeral Ajmera	UCSD
2019-present	Suzanne Sharpton	UCSD
2019-present	Kali Zhou	USC
2019-2023	Babak Orandi	UAB
2019-present	Hyosun Han	USC
2019-present	Liyun Yuan	USC
2019-present	Saro Khemichian	USC
2020-present	Brian Lee	USC
2020-present	Ani Kardashian	USC

Service

Department Service:

<i>Year-Year</i>	<i>Position, Committee</i>	<i>Organization/Institution</i>
2001-2019	Member, Cancer Center	UCSF
2007-2019	Member, Hepatology Training Grant Committee	UCSF
2008-2019	Member Transplant Hepatology Selection Committee	UCSF
2010-2019	Member, Gastroenterology Fellowship Selection Committee	UCSF
2011-2019	Ad hoc Internal Executive Committee	UCSF Liver Center
2019-present	Member, Gastroenterology Fellowship Selection Committee	USC
2019-present	Member, Transplant Hepatology Fellowship Selection Committee	USC
2019-present	Co-director Clinical-Translational-Biostats-Bioinformatics Core Research Center in Liver Diseases	USC
2022	Reviewer, KSOM Office of Research Pilot Funding Programs	USC

University Service:

<i>Year-Year</i>	<i>Position, Committee</i>	<i>Organization/Institution</i>
2009	Chair's Search Committee for Chief of Gastroenterology	UCSF
2009-2019	Clinical (HSC) and Clinical X Standing Search Committee	UCSF
2011-2013	Promotions Subcommittee	UCSF
2013-2014	Member, Committee on Committees	UCSF

2015-2019	Committee on Research	UCSF
2015-2019	Member, Resource Allocation Program Award Review Committee	UCSF
2020-2021	GEMS, Equity, and Representation Group	USC
2021	Panelist, Department of Medicine Residents	USC
2021	Women in Medicine, Panel Discussant, Mentor	USC
2021	Chair, Search Committee for Chief for Pulmonary, Critical Care Medicine	USC
2021-present	Search Committee for Chair of Radiology	USC
2021-present	Search Committee for Executive Director for Digestive Health Institute	USC
2023	Peer Reviewer, Carol Folt's President's Sustainability Initiative Award Reviewer Committee (PSIARC)	USC
2024	Search Committee for Chair of Pathology	USC
2024	Co-Chair, Search Committee for Associate Dean for Clinical Research	USC
2024	Co-Chair, Search Committee for Division Chief of Cardiovascular Medicine	USC
2024	Member, Search Committee for Southern California Clinical and Translational Science Institute (SC CTSI)	USC

Professional Service:

<i>Year-Year</i>	<i>Position, Committee</i>	<i>Organization/Institution</i>
1999-2004	AASLD	Clinical Research Committee Member (1999-2001) Chair (2002-2004)
2000-2000	HIV-HCV Task Force	Advisory Board Member
2000-2001	American Digestive Health Foundation	Vice-Chair, Digestive Health Initiative, Women's GI Health
2000-2003	AASLD Jan Albrecht Career Development Awards	Grant Reviewer
2002-2004	AASLD	Scientific Program Committee, Member
2002-2005	Hepatitis Foundation International	Board Member
2003-2003	Canadian Liver Foundation	External Reviewer for Operating Grant
2004-2008	BMS Collaborative Institute of Virology	Advisory Board Member for HIV/HBV
2004-2009	American Liver Foundation, Research Award Committee	Grant review
2004-2012	iMedOptions/Clinical Care Options for Hepatitis	Organizer, moderator and editor of enduring materials
2005-2005	HepCare National Experts' Clinical Consensus Panel and Report: Evidence-Based Guidelines for Optimizing Management of Patients with HCV and HIV, March 12-13, 2005.	Panel member
2005-2007	American Society of Transplantation	Practice Guideline Committee, Member

2005-2008	AASLD	Program Review Committee, Member
2006-2006	AASLD HBV satellite symposium "Consult the Experts", (organizer/moderator)	Satellite symposium, organizer/moderator
2007-2007	American Gastroenterology Association	Clinical Symposium organizer and Moderator
2007-2012	American Board of Internal Medicine	Transplant Hepatology Test Committee, member
2008-2008	AASLD	Nominating Committee, member
2010-2012	American Gastroenterology Association	Symposium organizer DDW2012, moderator
2011-2012	American Society of Transplant Physicians	Moderator ATC meeting
2011-present	AASLD Annual Meeting	Abstract reviewer; Moderator; Invited speaker for Post-graduate course (3), HCV symposium, Hepatitis Debrief, Early Morning Workshop, and Meet the Professor Lunch
2011-2013	AASLD	Governing board member, Counselor at large
2012-2012	AASLD Curriculum & Training (ACT) Task Force	Member
2012-2012	ACTHIV Annual Conference	Organizing committee
2012-2015, 2017	International Liver Transplant Society	Abstract reviewer (2012-2018); Moderator (2012, 2014, 2016, 2018)
2012-2012	AASLD Viral Hepatitis Single Topic Conference for 2013	Co-director
2013-present	AASLD ACT Program for PCPs	Steering Committee; Co-author, Reviewer
2014-2017	AASLD	Chair Hepatitis C Special Interest Group
2014-2018	IASL	Counselor, Governing Board
2015, 2017, 2018	Annual AASLD Hill Day: Advocacy with congressional leaders	California Representative
2015-2016	American Gastroenterology Association	Program Co-director (2016); Speaker Post-Grad Course (2015, 2016)
2015-2016	International Liver Transplant Society	Organizer, HCV and Liver Transplantation Consensus Conference; Chair writing group for HCV and transplant guidelines
2015-present	AASLD-IDSA HCV Guidance Committee	Writing group member
2016-2018	AASLD HBV Guidelines Committee	Writing group for HBV Guidance Update
2016-2019	American College of Gastroenterology	Speaker (2016-9), Program Planning (2019)
2017-present	GUILD Annual Update on GI & Hepatology	Co-Organizer, Speaker
2018	AASLD-EASL Masterclass	Miami Invited Faculty, Florida
2019-present	AASLD Foundation	Member Foundation Board of Trustees
2019-2020	AASLD Women's Initiative Committee	Member

2020-2021	American Society of Transplantation-Research Network Committee	Committee Member, Vice Chair (2021)
2021-present	Hepatitis B Foundation	Committee Member, Co-Chair of Emerging Scholars Scientific and Medical Advisory Board (eSAMB)
2021-present	ACTG Translational Sciences Group	Committee Member
2021-present	AASLD Viral Hepatitis Elimination Taskforce	Co-Chair
2021-present	HBV Forum	Steering Committee member
2022	European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)	Abstract reviewer (Viral Hepatitis, Late-Breakers)
2023	AASLD	President
2024	AASLD	Past-President
2024	AASLD	Chair, Nominating Committee
2024	AASLD	Member, Patient Advisory Group
2024	HBV Forum	Chair, Steering Committee
2024	NIH	Member, HIV Comorbidities and Clinical Studies (HCCS) Study Section

Consultantships and Advisory Boards:

<i>Year</i>	<i>Position, Board</i>	<i>Organization/Hospital/School, Institution</i>
1998	Consultant for Updated Recommendations for the Prevention and Control of Hepatitis C virus Infection	CDC
2003	Advisory board member for the NIH Action Plan for Liver Disease Research	NIDDK, Liver Disease Research Branch Working Group
2007	Expert testimony in support of healthcare coverage for uninsured individuals with chronic hepatitis B.	California legislative assembly (request by Assemblywomen Fiona Ma)
2007	Member of Viral Hepatitis Registry Advisory Committee	San Francisco Public Health Department
2017	Consultant/speaker: Common Elements, Clinical Trial Design and Endpoint Discussion for Alcoholic Hepatitis	Supported by the FDA, NIAAA and AASLD
2018	Advisory board for END Hep C SF	San Francisco Public Health Department
2017-present	Member of Medical Visionaries	NOhep
2018-2020	Advisory board member	HepCarestream/Hepatitis C Clinical Education Group, Inc.
2019	Advisory board member, The Task Force for Global Health	Coalition for Global Hepatitis Elimination
2020-present	External Advisory Board member of Yale NIDDK-support Liver Center	Yale School of Medicine

2024	Advisory Board member	GSK
2024	Advisory Board member	BlueJay

Professional Society Memberships:

<i>Year-Year</i>	<i>Society</i>
1994-1994	American Association for the Study of Liver Diseases (Trainee)
1994-1994	American Gastroenterology Association (Trainee)
1995-1996	Canadian Association of Gastroenterology (Member)
1995-present	Canadian Association for the Study of Liver Diseases (Member)
1997-present	American Association for the Study of Liver Diseases (Member)
1999-present	International Association for the Study of Liver Disease (Member)
2000-present	American Gastroenterology Association (Member)
2000-present	International Liver Transplantation Society (Member)
2003-present	American Society of Transplantation (Member)
2008-present	American College of Gastroenterology (Member)
2013-present	European Association for the Study of Liver Disease (International Member)

Community Service:

<i>Year-Year</i>	<i>Organization/Institution, City,</i>	<i>Role or Activity</i>
1999	American Liver Foundation	Better Living Grants, grant reviewer
2000	Kaiser Permanente Regional Research Committee	Grant reviewer
2003-2004	American Liver Foundation, Northern California Chapter	HCV Advocate newsletter contributor
2004-2004	3rd California Inter-County Hepatitis C Task Force Conference	Educator
2006-2007	CCO Hepatitis Teaching Modules	Editor
2006-2006	Patient Educational Video on Hepatitis C Treatment	Invited Speaker
2007-2007	Marin HCV Task Community Forum, San Rafael, CA.	Invited Speaker
2007-2007	American Liver Foundation, Oakland, CA.	Invited Speaker
2007-2016	San Francisco Public Health Department	Viral Hepatitis Registry Advisory Committee
2010-2015	SAK Kaiser Permanent-UCSF Gastroenterology Fellowship Award	Grant Review Committee Member
2012	GLIDE Health Services	Educator and HCV resource
2015-present	UCSF Project ECHO (Extension for Community Healthcare Outcomes)	Project Leader and Educator
2016-2019	End Hep C SF	Steering Committee Member
2021	American Liver Foundation	California Academic Debates (virtual), Judge

Research and Scholarship

Editorships and Editorial Boards:

<i>Year-Year</i>	<i>Position</i>	<i>Journal/Board Name</i>
1995-1995	Editorial Board	Advances in Gastroenterology, Hepatology and Clinical Nutrition

1998-2000	Associate Editor	Viral Hepatitis Reviews
2002-2006	Editorial Board	Clinical Gastroenterology and Hepatology
2004-2004	Guest Editor	Gastroenterology Clinics of North America
2004-2008	Editorial Board	Liver Transplantation
2008-2013	Editorial Board	Liver International
2009-2015	Deputy Editor	Liver Transplantation
2011-2016	Associate Editor	Hepatology
2014-2015	Guest Editor, Liver Section	Current Opinions in Organ Transplantation
2017-2021	Associate Editor	Hepatology Communications
2017-2018	Guest Editor	Liver Section, Current Opinions in Organ Transplantation
2018-2021	Editorial Board	Seminars in Liver Diseases
2018	Editor	Boyer T, Sanyal A, Lindor, K, Terrault NA: editors. 7th edition of Zakim and Boyer's Hepatology, A Textbook of Liver Disease. Publisher - Elsevier
2018-2021	Editorial Board	Gastroenterology

Manuscript Review:

<i>Year-Year</i>	<i>Journal</i>
1999-present	Ad hoc reviewer for the following journals (~1-5 papers per year): American Journal of Epidemiology, New England Journal of Medicine, Lancet Gastroenterology and Hepatology, JAMA Intern Medicine, JAMA Oncology, American Journal of Epidemiology, American Journal of Medicine, Journal of Clinical Virology, JAIDS, Plos One
1999-present	Ad hoc reviewer for the following journals (3-12 per year): American Journal of Transplantation, Gastroenterology, Liver Transplantation, Hepatology, Journal of Hepatology, JHep Reports, Gut, Transplantation, Clinical Gastroenterology and Hepatology, Liver International, Digestive Diseases and Sciences, Clinical Transplantation, Journal of Gastroenterology and Hepatology, Journal of Viral Hepatitis
1999-present	Abstract reviewer for annual AASLD meeting: 1999 (Hepatitis B), 2000-2004 (Hepatitis C and Liver Transplantation), 2005-2006 (Public Policy, Epidemiology and Decision Analysis); 2007-2008 (HCV Diagnosis and Natural History), 2009 (HCV Epidemiology: Non-B, non-C Comorbidities), 2010-15 (Hepatitis B Epidemiology, Diagnosis and Natural History); 2016-21 (Hepatitis B)
2000-2005	Abstract reviewer American Society of Transplantation Annual Meeting: (Hepatitis and Liver Transplantation)
2000-present	Abstract reviewer for International Liver Transplantation Society Meeting: 2000-2002 (Hepatitis C and Transplantation), 2005-2008 (Recurrent Disease and Infectious Disease), 2011-21 (Viral Hepatitis and Transplantation)
2001-present	Abstract reviewer for the American Gastroenterology Association annual meeting, 2001-2 (Hepatitis C Treatment); 2004-2006 (Epidemiology, Public Health); 2007-2009 (HCV Epidemiology); 2010-21 (Hepatitis B)

Grant Reviews:

<i>Year</i>	<i>Description</i>	<i>Awarding agency, City, State, Country</i>
1999	Reviewer for ancillary studies	NIH-NIDDK: Hepatitis C Anti-Viral Long-Term Therapy to Prevent Cirrhosis (HALT-C)
2006	Ad-hoc reviewer	NIH-NIDDK R01 renewals
2008	Ad-hoc reviewer	NIH-NIDDK Study Section for Hepatitis C Immunology
2017	Ad-hoc reviewer	NIH (NCI, NIAAA, NIMHD) Study Section: Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01/R21)

2017	Member, Study section	CIHR Fall 2017 Project Grant Competition, Virology & Viral Pathogenesis (VVP) review committee
2022	Member, Study section	NIH-NIAID: NIAID IICT
2022	Member, Study section	NIH DABP SEDH Study Section
2022	Member, Study section	NIAID Clinical Trial and SBIR Phase II Clinical Trial Implementation
2024	Ad-hoc reviewer	NIH-NIDDK Study Section for T32

Program Reviews:

<i>Year</i>	<i>Description</i>	<i>Awarding agency, City, State, Country</i>
2018	Board of Scientific Counselors	NIDDK Board of Scientific Counselors Spring 2018 meeting, Bethesda, MD (remote)
2020	Ad-hoc Member	NIAID BSC (virtual)
2021	Ad-hoc Member	NIDDK BSC (virtual)

Major Areas of Research Interest:

Research Areas

1. Defining pathogenesis, natural history and treatment of chronic liver diseases and its complications including cirrhosis and liver cancer.
2. Prevention and management of recurrent liver diseases in transplant recipients

Active Clinical Trials:

<i>IRB Approval</i>	<i>Description</i>	<i>Trial</i>
Jul. 2021	CLIMB	Helio Health (Helio) / Prospective Clinical Trial to Detect Liver Cancer Through Quantification of Cfdna Methylation in Blood Samples
Feb. 2022	DURECT	A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis
Apr. 2022	LIMT-2	Eiger-Hep D LIMT-2 Phase 3 Clinical Study

Other Support – Current:

Grant No.	R01 MD015971-03 (Setiawan, Terrault)	Dates of Award	1/1/2021-11/30/2025
Agency	NIMHD		
Title: Mechanisms of Advanced NAFLD Disparities in Hispanics: A Multilevel Analysis			
Description: The major goal of this project is to undertake a comprehensive determination of lifestyle, clinical, genetic, sociocultural and immunologic factors associated with risk of advanced NAFLD among Hispanics and NHWs.			
Role: PI (multiple PI grant)			

Grant No.	U01DK130197 (Terrault, Stolz)	Dates of Award	9/21/2021-9/20/2026
Agency	NIH-NIDDK		
Title: Liver Cirrhosis Network Description: The major goal of this project are: (1) to establish an informational database of patients with compensated cirrhosis to study the epidemiology, natural history of cirrhosis regression and progression supported by a serum, tissue and DNA repository, and (2) to evaluate the safety and efficacy of statin therapy in preventing decompensation in patients with compensated cirrhosis Role: PI (multiple PI grant)			
Project No.	1T32 DK127977-01A1	Project Dates	7/1/2022-6/30/2027
Agency	NIDDK		
Title: Translational Research Training in Hepatology Description: This postdoctoral training program for gastroenterology fellows (MD or MD-PhD) will provide research opportunities across the translational (T1 to T4) spectrum with rigorous training and robust mentorship in support of the next generation of physician-scientists. Role: PD			

Grant No.	1R01AA030960-01	Dates of Award	7/1/2023-6/30/2030
Agency	NIAAA		
Title: ¼ American Consortium of the Early Liver Transplantation – Prospective Alcohol-Associated Liver Diseases Cohort Evaluation (ACCELERATE-PACE) Description: The major goal of this project is to inform early liver transplant (let) selection criteria, develop risk prediction scores for let-free survival and recompensation; identify effective treatments (medical, behavioral) for alcohol use disorder among patients with severe ALD and post-eLT; and evaluate clinical outcomes among let candidates and recipients, including mortality, transplantation, post-LT complications (e.g. cancer, cardiovascular events, graft rejection/failure), and quality of life. Role: PD			

Other Support - Past:

Other Support: Pass			
Grant No.	U50 CCU915546 (Reingold)	Dates of Award	5/1/1998-12/31/2020
Agency	DHHS CDC		
Title: Sentinel Surveillance for Chronic Liver Disease			
Description: To define the burden of chronic liver disease in the U.S.			
Role: Coinvestigator			

Grant No.	U50 CCU915651	Dates of Award	2/1/2000-1/31/2005
Agency	DHHS CDC		
Title: Applied Research in Emerging Infections HCV Infection-Sexual Transmission			
Description: To define the risk of sexual transmission of HCV among monogamous couples.			
Role: PI			
Grant No.	R01 AA 12879 (Peters)	Dates of Award	9/30/2000-7/30/2006
Agency	NIH-NIAAA		
Title: HCV & Alcohol: Epidemiology and Host-Virus Correlates			
Description The main goal of this study is to determine the contribution of “light” or “moderate” alcohol ingestion to the histological severity of disease and the rate of disease progression in persons with chronic hepatitis C virus (HCV) infection			
Role: Coinvestigator			

Grant No.	U01 DK60346 (Terrault)	Dates of Award	9/30/2000-7/30/2006
Agency	NIH-NIDDK		
Title: Resistance of Antiviral Therapy in Chronic Hepatitis C Description: The main goals of this project are to accurately define the sustained response rates with optimal anti-viral therapy in African-Americans and provide important insights into the factors underlying differences in response compared to non-Hispanic whites. Role: Coinvestigator			

Grant No.	U01 DK62444 (Freise)	Dates of Award	9/30/2000-7/30/2006
Agency	NIH-NIDDK		
Title: Adult to Adult Living Donor Liver Transplantation Cohort Study Description: The primary goal of this study will be to provide valuable information on the outcomes of AALDLT. This information is needed to aid decisions made by physicians, patients, and potential donors. The study will establish and maintain the infrastructure required to accrue and follow sufficient numbers of patients being considered for and undergoing AALDLT to provide generalizable data from adequately powered studies Role: Coinvestigator			

Grant No.	U01 AI052748 (Stock)	Dates of Award	8/1/2003-8/31/2013
Agency	NIH-NIAID		
Title: Solid Organ Transplantation in HIV: Multiple-site Study Description: The primary aim of this study is to evaluate the safety and efficacy of solid organ transplantation in people with HIV disease by conducting a prospective, multi-center cohort of HIV-positive patients who undergo kidney or liver transplantation. Role: Coinvestigator			

Grant No.	U01 DK082944 (Terrault, Cooper, Khalili)	Dates of Award	9/30/2008-5/31/2021 (NCE)
Agency	NIH-NIDDK		
Title: Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection Description: The major goal of this project are: (1) to establish an informational database of CHB patients to study the epidemiology, natural history and pathogenesis of CHB supported by a serum, tissue and DNA repository, and (2) to compare the efficacy of combination antivirals versus monotherapy in treatment-naïve CHB Role: PI (multiple PI grant)			

Grant No.	R01 AI069952 (Bacchetti)	Dates of Award.	3/1/2006-2/28/2009
Agency	NIH-NIAID		
Title: Statistical Methods for Modeling Hepatitis C Fibrosis Progression Description: To develop new statistical methods for the analysis of hepatitis C (HCV) disease progression as measured by fibrosis scores from liver biopsies, with particular attention to how much HIV co-infection accelerates progression Role: Coinvestigator			

Grant No.	U19 AI088790 (McCune)	Dates of Award	4/10/2010-3/31/2015
Agency	NIH-NIAID		
Title: Bay Area Hepatitis C Cooperative Research Center Description: The main goal of this proposal is to determine the underlying innate and adaptive immune factors that contribute to non-response to HCV treatment (peginterferon, ribavirin ± protease inhibitors Role: Coinvestigator			

Grant No.	R01 DK034238 (Kim)	Dates of Award	8/10/2012-6/30/2016
Agency	NIH/NIDDK Mayo Clinic Subcontract		
Title: Models for Optimal Liver Transplant Outcomes Models for Optimal Liver Transplant Outcomes			
Description: The main goal of this study is to refine models for predicting wait-list outcomes (beyond MELD).			
Role: Coinvestigator			

Grant No.	US A125775 (Terrault)	Dates of Award	8/10/2012- 6/30/2016
Agency	Gilead Sciences		
Title: UCSF Hepatitis C Tele ECHO			
Description: The main goal of this study is to increase knowledge and skills of primary care physicians in rural and suburban CA to improve the diagnosis and treatment of patients with HCV.			
Role: PI (Investigator initiated study)			

Grant No.	IN-US-342-4311 (Terrault)	Dates of Award	8/1/2014-11/30/2022
Agency	Gilead Sciences		
Title: Towards Elimination of Hepatitis C in California; Building a PCP Network of HCV Champions			
Description. The goals of this project is to the expand the capacity to diagnosis and treat patients with chronic hepatitis in rural Northern California by training primary care providers in these communities. Novel outreach and educational/support measures are being testing to optimize outcomes.			
Role: PI (investigator-initiated study)			

Grant No.	CO-US-342-4579 (Niemann)	Dates of Award	3/31/2018-4/1/2020
Agency	Gilead Sciences		
Title: "PRO-ACT: Prevention of De Novo HCV with Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant"			
Description. Multicenter study to evaluate the safety and efficacy of sofosbuvir-velpatasvir in the treatment of HCV-negative transplant recipients of livers and kidneys for HCV viremic donors.			
Role: Co-PI (investigator-initiated study)			

Grant No.	T32DK127977 (Terrault, Goran)	Dates of Award	5/11/2021-6/30/2023
Agency	NIH-NIDDK		
Title: Translational Research in Hepatology			
Description: The goal of this T32 Training Program is to prepare GI trainees to assume a faculty-level position and compete successfully for independent research funding across the spectrum of translational liver diseases research to address the significant burden of liver disorders in the U.S. and globally.			
Role: PI (multiple PI grant)			

Grant No.	R01MD01597 (Setiawan, Terrault)	Dates of Award	12/1/2021-11/30/2022
Agency	NIH-NIDDK		
Title: Mechanisms of Advanced NAFLD Disparities in Hispanics: A Multi-level Analysis			
Description: The major goal of this project are to develop a multi-level factors associated with phenotypic spectrum of NAFLD and disease progression and contribute significantly to the understanding of the etiology and mechanisms that influence disparities in NAFLD in high-risk Hispanic population			
Role: PI (multiple PI grant)			

Project No.	N/A	Project Dates	9/1/2022-3/31/2024
Agency	Siemens Healthcare Diagnostics, Inc.		

Title: Investigating Associations Between Liver Inflammation and Liver Fibrosis with Cardiovascular Disease in the CARDIA Cohort Description: The major goal of this project is to evaluate the relative contribution of alcohol and metabolic risk factors to liver fibrosis progression among participants in the CARDIA cohort, and to determine if liver inflammation is an independent predictor of cardiovascular disease Role: PI

Grant No.	U01 DK061738-22 (Terrault)	Dates of Award	6/15/2002-6/30/2024
Agency	NIDDK		
Title:	Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)		
Description.	The major goals of this project are to establish a large Clinical Center patient database capturing the spectrum of NAFLD/NASH and to explore the hypothesis that familial/genetic factors contribute to the pathogenesis of NASH and its natural history		
Role:	PI		

Invited Lectures, Symposia, Keynote Addresses

International:

<i>Year</i>	<i>Type</i>	<i>Title, Location</i>
2000	Invited lectureship	Federal University of Bahia, Salvador, Brazil
2005	Invited lecture	AGA-JSGE Joint Symposium, Tokyo, JAPAN. April 15-17, 2005.
2006	Invited lecture	EASL Monothematic Conference, Paris, FRANCE. January 13-14, 2006.
2006	Invited lecture	12th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), Paris, FRANCE. July 1-6, 2006.
2006	Invited lecture	IX International Symposium on Viral Hepatitis, Sao Paulo, BRAZIL. October 6-8, 2006.
2007	Invited lecture	9th Congress of the Catalan Transplant Society, Barcelona, SPAIN. February 24-28, 2007.
2007	Invited lecture	Indian Association for the Study of Liver Disease (INASL), New Dehli, INDIA. March 16-18, 2007.
2007	Invited lecture	Barcelona 7th International Meeting on Therapy of Liver Diseases, Barcelona, SPAIN. September 11-15, 2007.
2007	Invited lecture	Viral Hepatitis in Amazonia First Annual Meeting, Amazonia, BRAZIL. December 2-6, 2007.
2008	Invited lecture	European Association for the Study of Liver Diseases (EASL) Annual meeting, Milan, ITALY. April 23-27, 2008.
2008	Invited lecture	13th International Congress on Infectious Diseases, Kuala Lumpur, MALAYSIA. June 19-22, 2008.
2008	Visiting Lectureship	Update on HCV Therapy - Tokyo and Fukuoka, JAPAN. September 8-12, 2008.
2009	Invited lecture	Symposium on Chronic Hepatitis and Liver Diseases, Taipei, TAIWAN. Dec. 5-7, 2009.
2009	Invited lecture	Canadian Digestive Diseases Week, Banff, CANADA. February 27-March 2, 2009.

2009	Invited lecture	8th International Meeting on Therapy of Liver Diseases, Barcelona, SPAIN. September 23-25, 2009.
2009	Invited lecture	Un Amigo Por Ano, Buenos Aires, ARGENTINA. September 17, 2009.
2009	Invited lecture	XXXVI Chilean Congress of Gastroenterology, La Serena, CHILE. Oct 21-24, 2009.
2010	Invited lecture	Canadian Digestive Diseases Week, Toronto, CANADA. February 26-March 2, 2010.
2010	Invited lecture	Brazilian Association for the Study of Liver Disease, Florianopolis, BRAZIL November 22-24, 2010.
2011	Invited lecture	Asian-Pacific Association for the Study of Liver Diseases (APASL) Annual Meeting, Bangkok, THAILAND. February 17-20, 2011
2011	Invited lecture	Indian National Association for the Study of Liver Diseases Annual Meeting, Chandigarh, INDIA, March 25-27, 2011.
2012	Invited lecture	First International Congress on Infections and Organ Transplantation, Varese, ITALY. April 12-13, 2012
2013	Invited lecture	New Challenges in Diagnosis and Treatment of Liver Disease, Jerusalem, ISRAEL. January 30-31, 2013
2013	Invited lecture	Fourth International Congress - Infections and Organ Transplantation - The state of the art on prevention and treatment of bacterial, viral and fungal infections - Stresa, ITALY, May 8-10, 2013
2013	Invited lecture	Asian-Pacific Association for the Study of Liver Disease - HCV treatment in transplant recipients and wait-list candidates - Singapore, June 5-9, 2013
2014	Invited lecture	9as Jornadas de Atualização em Doenças infecciosas - Liver Transplantation in coinfectd patients -PORTUGAL, January 29-31, 2014
2014	Invited lecture	CASL/CDDW - HIV and Liver Transplantation, Toronto, CANADA. February 8-10, 2014
2014	Invited lecture	EASL - Experience with Boceprevir and Telaprevir in Liver Recipients, London, UK. April 8, 2014
2014	Invited lecture	Second International Congress on Viral Hepatitis and Organ Transplantation, Stresa, ITALY, May 19-20, 2014
2014	Invited lecture	International Liver Transplant Society Annual Meeting - Taking HCV out of the transplant equation-Improving post-transplant outcomes, London, UK, June 4, 2014
2014	Invited lecture	2nd New Insights in Gastrointestinal and Liver Diseases-The future around the corner in HCV/HBV Infections - Milan, ITALY, June 13, 2014
2014	Invited lecture	Japan Society of Hepatology Single Topic Conference - Management of HBV in Transplant Recipients - Hiroshima, JAPAN, Nov. 20-21, 2014.
2014	Invited lecture	Indian National Association for the study of Liver (INASL) - Management of HBV in Pregnancy; Treatment of Immunotolerant Children - New Dehli, INDIA, July 31-Aug 4, 2015
2015	Invited lecture	European Association for the Study of Liver Disease - Peritransplant management of HCV, Vienna, AUSTRIA, April 22, 2015.
2015	Invited lecture	Amazon- Brazil XVIII INTERNATIONAL SYMPOSIUM ON VIRAL HEPATITIS - Management of HCV in Cirrhotics and Difficult to Treat Populations. Salvador and Belem, BRAZIL, July 22-27, 2015.
2015	Invited lecture	5th Summit on Liver Diseases - Treatment of HCV in Patients with Cirrhosis, Istanbul, TURKEY, September 5-6, 2015
2016	Invited lecture	EASL-ILTS Annual Meeting, Barcelona, Spain, April 12-16, 2016

2016	Invited lecture	ApEx-MGH Nephrology Board Review Course, Mumbai, India, April 27-May 1, 2016
2016	Invited lecture	IASL Meeting-Beijing, China, May 6-7, 2016
2016	Invited lecture	Third International Congress on Viral Hepatitis and Organ Transplantation HOT Topics - Comparing Experiences and Perspectives-Varese, Italy, May 12-14, 2016
2016	Invited lecture	Singapore Hepatitis Conference (SHC) 2016, May 27-29, 2016
2016	Invited lecture	Alberta, Canada- Alberta Digestive Diseases Week Summit Lake Louise, June 3-5, 2016
2016	Invited lecture	Veracruz, Mexico-Mexican Association of Hepatology Meeting, June 22-23, 2016
2016	Invited lecture	Santos, Brazil-Infectious Disease Conference, August 25-27, 2016
2016	Invited lecture	EASL-AASLD HCV Special Conference - NEW Perspectives in Hepatitis C Virus Infection – The roadmap for cure, Paris
2016	Invited lecture	Beijing Youan Hospital, October 14-16, 2016
2016	Invited lecture	Australia/New Zealand-23rd National Symposium on Hepatitis B & C 2016, November 26th, 2016
2016	Invited lecture	Milan- 2nd HELM - The Evolving Concept of Management and Treatment of Liver Diseases, December 2-3 2016
2017	Invited lecture	Shanghai, China-APASL 2017 26th Conference of the Asian Pacific Association for the Study of Liver, February 15-19, 2017
2017	Invited lecture	Maui, Hawaii-GUILD 2017 Conference, February 19-22, 2017
2017	Invited lecture	Prague, Czech Republic-2017 Joint International Congress of ILTS, ELITA & LICAGE, May 24-27, 2017
2017	Invited lecture	Ulaanbaatar, Mongolia-The First EU-Mongolia Hepatology Conference, August 17-19, 2017
2017	Invited lecture	Lima, Peru-International Course on Liver Diseases, Lima 2017, August 26-27, 2017
2017	Invited lecture	Taipei, Taiwan Digestive Diseases Week, September 29-October 1, 2017
2018	Invited lecture	Lisbon-2018 Portuguese Conference on Infectious Diseases, Jan 25-26, 2018
2018	Invited lecture	Myanmar GI & Liver Society National Conference Feb 16-18, 2018
2018	Invited lecture	International Liver Transplant Society, Lisbon, May 23-27, 2018
2018	Invited lecture	HK-International Digestive Disease Forum in Hong Kong on June 9-10, 2018
2018	Invited lecture	IHPBA 2018, Geneva, Switzerland, September 3-7 2018
2018	Invited lecture	GESA AGW2018, Brisbane, Australia. September 7-9, 2018
2018	Invited lecture	Pakistan Association for the Study of Liver Disease, December 14-16, 2018
2019	Invited lecture	Paris-12th Paris Hepatology Conference January 13-15, 2019
2019	Invited lecture	8 th International Conference on Coagulation and Liver Disease, Netherlands, September 27-28.2019
2019	Invited lecture	APASL-PALD Annual Conference, Pakistan, December 6-8, 2019
2020	Invited lecture	India Annual Liver Conference, India January 3-6, 2020
2020	Invited lecture	Paris-13th Paris Hepatology Conference January 12-14, 2020
2020	Invited lecture	EASL ILC-Digital April 18-20, 2020
2020	Invited lecture	Virtual GI Grand Rounds, University of Sao Paulo, October 7, 2020
2020	Invited lecture	Pakistan Association of Hepatology, Annual Congress, September 25-27, 2020 (hybrid)
2020	Invited lecture	UEG Annual meeting, October 13, 2020

2020	Invited lecture	Korean Digestive Diseases Week, November 19-21, 2020
2021	Invited lecture	TASL-AASLD Connect, January 16, 2021
2021	Invited lecture	IASL Annual Conference, Korea, July 15-16, 2021 (virtual)
2021	Invited lecture	International Digestive Diseases Forum, Hong Kong, September 3-5, 2021 (hybrid)
2021	Invited lecture	Pakistan Association of Hepatology, Annual Congress, Lahore, September 24-26, 2021 (hybrid)
2022	Invited lecture	Turkish Association for the Study of the Liver (TASL) January 14, 2022 (virtual)
2022	Invited lecture	Best of ACG India, April 17, 2022 (Virtual)
2022	Invited lecture	International Society of Liver Transplantation, Istanbul, May 4-7, 2022 (hybrid)
2022	Invited faculty	EASL-AASLD HBV Endpoints Conference, London, June 3-4, 2022
2022	Invited lecture	EASL ILC London, June 23-26, 2021 (hybrid)
2022	Invited speaker	Indian National Association for the Study of the Liver (INASL), New Delhi, August 4-7 2022 (hybrid)
2022	Invited speaker	ALEH Annual meeting, Buenos Aires, September 7-10, 2022
2022	Invited lectureship	Conférence Gilles-Pomier-Layrargues Keynote, Montreal, September 30, 2022 (virtual)
2022	Invited lecture	Japan Digestive Disease Week (JDDW), October 27, 2022 (virtual)
2022	Invited lecture	Pakistan Society for the Study of Liver Diseases (PSSLD) Conference, Karachi, December 2-4, 2022
2023	Invited speaker	Indian Society of Gastroenterology Conference (ISGCON), Jaipur, January 5-8, 2023
2023	Invited speaker	Asian Pacific Association for the Study of the Liver (APASL), Taipei, February 15-16, 2023
2023	Invited speaker	Paris Hepatology Conference, March 27-29, 2023 (virtual)
2023	Invited speaker	Global Hepatitis Summit, Paris, April 25-27, 2023
2023	Invited lecture	AASLD-TASL Hepatology CONNECT Conference, Ankara, Turkey, April 28-29, 2023
2023	Invited faculty	EASL Congress, Vienna, Austria, June 21-24, 2023
2023	Invited speaker	Dr. DV Datta Memorial Oration, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, August 1-2, 2023
2023	Invited lecture	INASL, Bhubaneswar, India, August 3-6, 2023
2023	Invited speaker	ALEH Annual Congress, Bogota, Colombia, August 29-September 1, 2023
2023	Invited speaker	APASL-STC, Busan, Korea, September 21-23, 2023
2023	Invited speaker	CASL-STC, Calgary, Canada, September 29-October 1, 2023
2023	Invited speaker	ACG Annual Scientific Meeting, Vancouver, Canada, October 20-25, 2023
2023	Invited speaker	HEP-DART, Los Cabos, Mexico, December 3-7, 2023
2023	Invited speaker	TASL-AASLD Joint Symposium, Taipei, December 15-17, 2023
2024	Invited speaker	Paris Hepatology Conference, March 18-19, 2024
2024	Invited speaker	AASLD-ESLC Joint Program, April 18-19, 2024, Cairo
2024	Invited speaker	EASL Congress, Milan, Italy, June 5-7, 2024
2024	Invited speaker	Asociación Mexicana de Hepatología (AMH) National Congress of Hepatology, Mexico City, Mexico, July 4-5, 2024
2024	Invited speaker	University of Alberta, Wensel-Sherbaniuk Lecture, Edmonton, Alberta, Canada, November 21-22, 2024
2024	Invited speaker	Emirates International Gastroenterology and Hepatology Conference, Dubai, UAE, December 6-9, 2024
2025	Invited speaker	Liver Health in Pregnancy, Hepato Gastroenterology Foundation (HGV) and

		Euroasian Gastroenterological Association, Turkey, January 9, 2025 (webinar)
2025	Invited speaker	The Regional Expansion Advanced Learning (REAL) Webinar, ILTS and ALEH, Argentina, January 9, 2025
2025	Co-Chair, Speaker	GUILD, St. Thomas, Aruba, January 12-15, 2025
2025	Invited speaker	Best of ACG, Kolkata, Bangalore, and Delhi, India, January 17-19, 2025

National:

<i>Year</i>	<i>Type</i>	<i>Title, Location</i>
2003	Invited lectureship	University of Pittsburgh, GI and Transplant Divisions
2005	Invited lecture	American Society of Transplantation 9th Annual Winter Symposium, Banff, Canada.
2005	Invited lecture	6th Annual American Transplant Congress. Satellite Symposium. Seattle, WA.
2005	Invited lecture	IDSA Annual Meeting, Meet the Professor, HCV and HIV Coinfection" San Francisco
2005	Visiting lectureship	Virginia Commonwealth University, GI/Hepatology Division
2005	Invited lecture	AABB Annual Meeting, Satellite Symposium, "HBV-NAT Testing", Seattle
2005	Visiting lectureship	Baylor College of Medicine, Houston, GI/Hepatology Division
2005	Visiting lectureship	University of Wisconsin, Hepatology & Liver Transplant Division
2006	Invited lecture	ASCO 2006 Gastrointestinal Cancers Symposium. San Francisco, CA
2006	Invited lecture	26th Annual Dialysis Conference. San Francisco, CA.
2006	Invited lecture	American Gastroenterology Association, DDW-2006: satellite symposium. Los Angeles, CA
2006	Invited lecture	World Transplant Congress, Boston, MA.
2006	Invited lecture	NATCO (North American Transplant Coordinators Organization) 2006 Annual Meeting. Chicago, IL.
2006	Invited lecture	American Nephrology Nurses Association (ANNA) Annual Meeting: Boston, MA
2006	Visiting lectureship	University of Pennsylvania, GI/Hepatology
2006	Invited lecture	ICAAC Annual Meeting. San Francisco, CA
2007	Invited lecture	AST Winter Symposium, Phoenix, AZ. Phoenix, AZ
2007	Visiting lectureship	Brooke Army Medical Center and University of Texas Health Science Center
2007	Invited lecture	American Transplant Congress (ATC) Annual Meeting, San Francisco, CA.
2007	Invited lecture	DDW Combined Clinical Symposia, Washington, DC, May 19-22, 2007.
2007	Invited lecture	International Liver Transplant Society (ILTS) Anesthesia Conference, San Francisco, CA.
2007	Invited lecture	AASLD 58th Annual Meeting, Clinical Update series, Boston, MA
2008	Invited lecture	American Gastroenterology Association. DDW 2008: Postgraduate course; Clinical Updates, Combined Clinical Symposia, San Diego, CA

2008	Visiting professorship	NIH NIDDK, Liver Diseases Branch
2008	Invited lecture	American College of Gastroenterology Annual Meeting, Orlando, FL
2008	Invited lecture	American Transplant Congress, Pre-Meeting Symposia, Toronto, Canada
2008	Invited lecture	AASLD 59th Annual meeting: Post-graduate course; Career Development Workshop; General Hepatology Update; and Early Morning Workshop, San Francisco, CA
2009	Invited lecture	13th International Symposium on Viral Hepatitis and Liver Disease, Washington, DC.
2009	Invited lecture	Hepatitis Summit: Transforming our Domestic Response to Hepatitis B and C, Washington, DC.
2009	Invited lecture	AASLD 60th Annual Meeting: Early Morning Workshop, Meet-the-Professor, and Symposium. Boston, MA.
2010	Invited lecture	American Gastroenterology Association, Annual Digestive Diseases Week: Clinical Symposium and Postgraduate course. San Diego CA.
2011	Invited lecture	American Transplant Congress Annual Meeting, Philadelphia, PA.
2011	Invited lecture	CONO-2011 First Annual Combination and Novel HCV Therapies Conference, New York, NY.
2011	Invited lecture	18th International Symposium of HCV and Related Viruses. Seattle, WA.
2012	Invited lecture	ASCO 2012 Gastrointestinal Cancers Symposium. San Francisco, CA.
2012	Invited lecture	AASLD Viral Hepatitis Single Topic Conference. Atlanta, GA.
2012	Invited lecture	ACTHIV Annual Meeting, Denver, CO.
2012	Invited lecture	International Liver Transplant Society Annual Meeting, San Francisco, CA.
2012	Invited lecture	American Gastroenterology Association, DDW-2012, San Diego, CA.
2012	Invited lecture	American Transplant Congress: The Science, the Art and the Allure of Liver Transplantation and a Viral Hepatitis symposium. Boston, MA.
2012	Invited lecture	ID-Week 2012. Annual Meeting of the Infectious Diseases Society of America. San Diego, CA.
2012	Invited lecture	52nd ICAAC Interscience Conference on. Antimicrobial Agents and Chemotherapy. San Francisco, CA.
2012	Invited lecture	AASLD 63rd Annual Meeting: Meet the Professor, Clinical Research Workshop. Boston, MA.
2013	Invited lecture	AGA-ASGE Clinical Congress, San Diego, CA. January 17-19, 2013,
2014	Invited lecture	40th Remington Winter Course, Snowmass, Colorado.
2014	Invited lecture	GALA Conference, Miami, Florida, March 1, 2014
2014	Invited lecture	American College of Physicians, Orlando, Florida, April 11-12, 2014
2015	Invited lecture	American Gastroenterology Association, DDW-2014, Chicago, May 2-6, 2014
2015	Invited lecture	World Transplant Congress, San Francisco, CA
2015	Invited lecture	AASLD Annual Meeting, San Francisco, CA
2015	Invited lecture	International Liver Transplantation Society Annual Meeting, Chicago, IL.
2016	Invited lecture	Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA
2015	Invited lecture	Infectious Diseases Society of America: ID Week, Chicago, IL
2016	Invited lecture	VCU Remington Infectious Diseases Course, Montana
2016	Invited lecture	American Association of Gastroenterology, Annual Meeting, DDW, San Diego, CA.
2016	Invited lecture	AASLD: Clinical Hepatology: State-of-the-Art Management, Chicago, IL
2017	Invited lecture	AASLD Annual Meeting, Boston, MA

2017	Invited lecture	American Society of Transplantation, Consensus meeting, HCV-Positive Donors, Chicago, IL
2017	Invited lecture	American Gastroenterology Association, DDW-2107, Chicago, IL
2018	Invited faculty	NIAAA Workshop: Common Elements, Clinical Trial Design and Endpoint Discussion for Alcoholic Hepatitis, Silver Spring MD, March 26, 2018
2018	Invited lecture	Austin AASLD's Clinical Hepatology Update, May 4-5, 2018
2018	Invited speaker	Houston-19th Annual Hot Topics in Liver Disease Conference, July 21, 2018
2018	Invited speaker	AASLD Transplant Hepatology Board Review Course, Dallas August 18-19, 2018
2018	Invited speaker	ID Week, San Francisco, CA. October 4, 2018
2018	Invited lecture	AASLD Annual Meeting, San Francisco, CA November 8-13, 2018
2019	Invited lecture	EASL-AASLD HCV Symposium, Miami, FL. February 1-2, 2019
2019	Co-organizer and Invited lecture	EASL-AASLD HBV Endpoint conference, London, March 8-10, 2019
2019	Invited Professorship	MD Anderson: Cancer Prevention and Control Division, August 23, 2019
2019	Invited speaker	Texas Society for Gastroenterology and Endoscopy Annual Conference, Houston Texas, September 20-21, 2019
2019	Invited speaker	AASLD: Improving Outcomes in Alcohol-Associated Liver Disease conference, October 4-5, 2019
2019	Invited speaker	National Liver Conference, San Antonio, Texas, October 25-26, 2019
2019	Invited speaker	ACG Postgraduate course, San Antonio, Texas, October 27-28, 2019
2019	Invited speaker	AASLD: The Liver Meeting, Boston, November 8-12, 2019
2019	Invited speaker	HEP DART, Hawaii, December 9-12, 2019
2020	Moderator, invited speaker	AASLD: COVID-19 and the Liver Webinar, August 6, 2020
2020	Invited speaker	VCU Annual GI/Hepatology Update
2020	Invited speaker	Henry Ford Medicine Grand Rounds, September 3, 2020
2020	Invited speaker	Mayo Clinic Arizona Medicine Grand Rounds, October 22, 2020
2020	Invited speaker	University of Wisconsin GI/Hepatology Grand Rounds, December 8, 2020
2020	Virtual Lectureship	University of Cincinnati, William and Rebecca Balistreri Lectureship in Hepatology, October 14, 2020
2020	Invited speaker	AASLD, Virtual Liver Meeting, November 12-15, 2020 (virtual)
2020	Invited speaker	APASL-AASLD Research Symposium, February 4, 2021
2021	Invited speaker	American Transplant Congress, May 30-June 4, 2020
2021	Invited speaker	NIDDK Hepatitis Delta Symposium, September 9, 2021
2021	Invited speaker	AASLD Virtual Liver Meeting, November 13-16, 2021
2022	Invited speaker	University of Arkansas, February 7 2022 (virtual)
2022	Invited speaker	DDW, San Diego, May 21-24, 2022
2022	Invited speaker	Houston Methodist Transplant Grand Rounds, May 10, 2022
2022	Invited lectureship	Women in GI, Srinivasan Memorial Women's Lecture, University of Pennsylvania, May 11, 2022 (virtual)
2022	Invited speaker	AASLD Reproductive Health ETC, July 22, 2022 (virtual)
2022	Invited faculty	NIAAA AUD-ALD Workshop, July 2022
2022	Invited speaker	University of Alabama, Update in Gastroenterology and Hepatology, August 13, 14, 2022
2022	Invited faculty	AASLD Emerging Topic Conference (ETC): Controversies and Consensus in Alcohol—associated Liver Disease, October 1-2, 2022

2022	Invited speaker	University of Cincinnati Internal Medicine Medical Grand Rounds, Leon Schiff Lecture, October 12, 2022
2022	Invited speaker	VCU Inaugural Virginia Liver Colloquium, October 13-14, 2022
2022	Invited speaker	AASLD The Liver Meeting, Washington DC, November 4-8, 2022
2023	Co-Chair, Speaker	GUILD, Maui, February 18-22, 2023
2023	Invited speaker	AASLD North American Viral Hepatitis Elimination Summit, Los Angeles, CA, March 24-25, 2023
2023	Invited Speaker	University of Iowa Miller Lecture and Internal Medicine Grand Rounds, March 9, 2023
2023	Invited Speaker	AASLD ETC – NASH Cirrhosis: From Mechanics to Management, Los Angeles, CA, March 25-26, 2023
2023	Invited lecture	American Gastroenterology Association (AGA), DDW-2023, Chicago, May 6-9, 2023
2023	Invited speaker	Rutgers New Jersey Medical School Department of Medicine Grand Rounds, May 16, 2023 (virtual)
2023	Invited speaker	University of North Carolina Internal Medicine Grand Rounds, Fried Lecture in Chronic Liver Disease, Chapel Hill, September 28, 2023
2023	Invited speaker	AASLD The Liver Meeting, Boston, November 10-14, 2023
2024	Co-Chair, Speaker	GUILD, Aruba, January 14-17, 2024
2024	Co-Chair, Speaker	GUILD, Maui, February 18-21, 2024
2024	Invited faculty	AASLD ETC: Precision Medicine in MASLD, Las Vegas, March 8-9, 2024
2024	Invited speaker	ILTS Annual Congress, Houston, May 1-4, 2024
2024	Invited speaker	AGA DDW, Washington DC, May 18-21, 2024
2024	Invited lecture	9 th Annual Fenton Schaffer Lectureship, Icahn School of Medicine at Mount Sinai, New York, May 22, 2024
2024	Invited speaker	ACG Midwest Postgraduate Course, Minneapolis, MN, August 24-25, 2024
2024	Invited speaker	American Liver Foundation (ALF) Steatotic Liver Disease Project ECHO Series, September 3, 2024 (webinar)
2024	Invited speaker	Emerging Topics in Liver Disease Conference, Houston, TX, September 21, 2024 (virtual)
2024	Invited speaker	Texas Society of Gastroenterology and Endoscopy (TSGE) Annual Conference, Austin, TX September 22, 2024 (virtual)
2024	Visiting professorship	Hugh R. Butt Visiting Professor in the Division of Gastroenterology & Hepatology (GIH) and GIH Fellowship Research Retreat, Rochester, MN, October 10-11, 2024
2024	Invited speaker	AASLD The Liver Meeting, San Diego, November 15-19, 2024

Local/Regional Invited Grand Rounds, CME Lectures:

2005	Invited speaker	UCLA Immunosuppression Summit. Santa Monica, CA. June 18, 2005.
2006	Invited speaker	Kaiser Permanente San Francisco, Grand Rounds, San Francisco, CA
2006	Invited speaker	Scripps Hepatitis C Training Program, Las Vegas, NV.
2006	Invited speaker	SoCAL AASLD Review, Laguna Niguel, CA.
2007	Invited speaker	Scripps Hepatitis B and ID Training Program, San Francisco, CA
2007	Invited speaker	UCSF Kidney Transplant Update 2007
2008	Invited speaker	UC Davis Primary Care Update, Monterey, CA.
2008	Invited speaker	Northern California Gastroenterology Association Annual Meeting

2009	Invited speaker	WAPA, Annual Recertification Course and Winter Conference for Physician Assistants, Seattle, WA.
2008	Invited speaker	Annual Controversies in Transplantation, University of Colorado, Breckenridge, CO, March 6-10, 2008.
2008-2016	Invited speaker	UCSF Transplant Conference (2008, 2010, 2012, 2014, 2015, 2016)
2009	Invited speaker	UCSF Liver Transplant Conference 2009
2009	Invited speaker	Annual Controversies in Transplantation, University of Colorado, Breckenridge, CO. March 5-8, 2009.
2010	Invited speaker	Annual Controversies in Transplantation, University of Colorado, Breckenridge, CO. March 4-7, 2010
2011	Invited speaker	Simply Speaking HBV: a Rush University Medical Center (RUMC) CME program: San Francisco
2012	Visiting professor	University of Calgary, Calgary, Canada
2012	Invited speaker	Post-Conference Update of AASLD, Sacramento, CA. January 12, 2012.
2012	Invited speaker	Simply Speaking HBV: a Rush University Medical Center (RUMC) CME program: San Francisco, San Diego
2014		Young Investigator's Forum - Controversies in Transplantation, Breckenridge, Colorado
2014	Invited speaker	Simply Speaking HBV: a Rush University Medical Center (RUMC) CME program: San Francisco, San Diego, Hawaii
2015	Invited speaker	KP Internal Medicine Review, Anaheim, CA. September 18, 2015
2015	Invited speaker	Northern California Society for Clinical Gastroenterology Annual AASLD review, December 2, 2015
2015	Invited professorship	Mayo Clinic, Scottsdale, Arizona
2015	Invited speaker	Southern California Kaiser Permanente (SCKP) Transplant Symposium, February 28, 2015
2015	Invited speaker	SF Scripps Institute Hepatitis B/C Course, July 18, 2015
2016	Invited speaker	Annual Controversies in Transplantation, University of Colorado, Breckenridge, CO, March 4-6, 2016
2017	Invited speaker	Scripps Institute 32nd Annual New Treatments in Chronic Liver Diseases Symposium, March 31-April 1, 2017
2017	Invited speaker	Loma Linda Liver Disease Day, Las Vegas, NV October 8, 2017
2017	Invited speaker	Annual Controversies in Transplantation, University of Colorado, Breckenridge, CO, March 2-4, 2017
2018	Invited speaker	NCSCG post-DDW Conference, San Francisco, July 14, 2018
2018	Invited speaker	NCSCG Post-AASLD Symposium, San Francisco, Dec. 8, 2018
2012-2018	Organizing group and invited speaker	The Nathan Bass UCSF Liver Transplant Annual Conference (2012-2018)
2018	Invited speaker	Annual Controversies in Transplantation, University of Colorado, Breckenridge, CO, March 1-3, 2019`
2019	Invited lecture	ACG Western Conference, Las Vegas, January 19-20, 2019
2019	Invited speaker	Women's reception, Southern California Society of Gastroenterology, June 22, 2019
2019	Invited speaker	Kaiser Permanente Orange County, Gastroenterology conference, October 9, 2019

2019	Invited speaker	MAT Project Echo at UCLA, November 25, 2019
2019	Invited speaker	OHSU Best of AASLD Conference, December 13-14, 2019
2020	Invited speaker	GUILD Gastroenterology and Hepatology Update, February 16-19, 2020
2020	Invited speaker	USC Family Medicine Grand Rounds, January 28, 2020
2020	Invited speaker	UCSD 8th Annual Advances in Gastroenterology & Hepatology Feb 1-2, 2020
2020	Invited speaker	USC Family Medicine Grand Rounds, January 28, 2020
2020	Invited speaker	USC Alumni Day November 13th, 2020
2021	Invited speaker	Scripps Annual Liver Congress, June 26-27, 2021
2022	Organizer & Moderator	USC Annual GI and Liver Update, September 18-19, 2021 (hybrid)
2021	Invited speaker	USC Medicine Grand Rounds August 13, 2021
2021	Invited speaker	Southern California Society of Gastroenterology, December 4, 2021
2022	Invited speaker and organizer	USC Frontiers of GI and Hepatology Practice in 2022, September 24-25, 2022 (hybrid)
2022	Invited speaker & moderator	LAC Viral Hepatitis Stakeholder Meeting, September 29, 2022
2023	Invited Speaker	Baylor College of Medicine Internal Medicine Grand Rounds, February 2, 2023
2023	Invited Speaker	University of California – Irvine (UCI) Annual Gastroenterology and Hepatology Symposium, February 24-25, 2023
2023	Invited speaker	Kaiser Permanente National HIV, Liver Disease, STI and LGBTQ+ Health Conference, Las Vegas, March 10-11, 2023
2023	Invited Speaker	San Bernardino County Medical Society's Primary Care Providers' Guide to Hepatitis C Webinar, March 15, 2023
2023	Invited speaker	National Cancer Institute (NCI) Translational Liver Cancer (TLC) Consortium Meeting, Los Angeles, March 16-17, 2023
2023	Invited speaker	American Transplant Congress (ATC), San Diego, June 3-7, 2023
2023	Invited speaker	Fountain Valley Regional Hospital, Update on the Treatment of Hepatitis C, July 14, 2023 (virtual)
2023	Invited speaker	Annual USC Update in GI and Liver Disease: Controversies and Guidelines in 2023, September 8-9, 2023
2023	Invited speaker	Southwest Liver Disease Symposium, Phoenix, AZ, October 7, 2023
2023	Invited speaker	Southern California Society of Gastroenterology (SCSG) Liver Symposium, Dana Point, CA, December 9-10, 2023
2024	Invited speaker	Northern California Society for Clinical Gastroenterology (NCSCG) Liver Symposium, San Jose, CA, January 20, 2024
2024	Invited faculty	Annual USC Update in GI and Liver Disease: Controversies and Guidelines in 2024, September 13-24, 2024
2024	Invited speaker	Breakthroughs in MASH Diagnosis and Management: A Liver Connect City Series, Arcadia, CA, November 2, 2024
2024	Invited guest	Los Angeles County Hep C Summit, Los Angeles, CA, December 12, 2024

Publications

H-index: 99

i10-index: 388

Refereed Journal Articles:

1. Odze R, Quinn P, **Terrault N**, Gallinger S. Advanced Gastroduodenal Polyposis with Ras Mutations in a Patient with Familial Adenomatous Polyposis. *Human Pathology*. 24(4):442-8, 1993.
2. **Terrault NA**, Combs C, Lake JR, Roberts JP, Ascher NL, Wright TL. Interferon alpha for the treatment of recurrent hepatitis B following liver transplantation. *Liver Transplant Surg*. 2:132-8, 1996.
3. Zhou S, **Terrault NA**, Ferrell L, Hahn, J, Simmonds P, Lau JYN, Roberts JP, Lake, JR, Ascher NL, Wright TL. Severity of Liver Disease in Liver Transplant Recipients with Hepatitis C Virus Infection: Relationship to Genotype and Level of Viremia. *Hepatology*. 24:1041-6, 1996. (First and second authors contributed equally)
4. **Terrault NA**, Zhou S, Combs, C, Hahn JA, Lake JR, Roberts JP, Ascher NL, TL Wright. Prophylaxis using a fixed dosing schedule of hepatitis B immunoglobulin in liver transplant recipients. *Hepatology*. 24:1327-1333, 1996.
5. Berenguer M, **Terrault NA**, Piatak M, Yun A, Kim JP, Lau JYN, Lake JR, Roberts JP, Ascher NL, Wright TL. Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. *Gastroenterology*. 111:1569-756, 1996.
6. Reiser M, **Terrault N**, Nelson DR, Mizokami M, Ferrell L, Lake JR, Roberts JP, Ascher NL, Wright TL, Lau JYN. Antibody to the Host Cellular Gene Derived Epitope GOR I Liver Transplant Recipients with Hepatitis C Virus Infection. *Transplantation*. 63:609-12, 1997.
7. Ku N-O, Wright TL, **Terrault NA**, Gish R, Omary MB. Mutation in human keratin 18 in association with cryptogenic cirrhosis. *J Clin Invest*. 99:19-23, 1997.
8. **Terrault NA**, Dailey PJ, Ferrell L, Collins MC, Wilber JC, Urdea MS, Bhandari BN, Wright TL. Hepatitis C virus: Quantitation and distribution in liver. *J Med Virol*. 51:217-224, 1997. First and second authors contributed equally.
9. Pessoa MG, **Terrault NA**, Ferrell L, Kim JP, Kolberg J, Detmer J, Collins M, Yun A, Lake JR, Roberts JP, Ascher NL, Wright TL. Detection of quantitation of hepatitis G virus (HGV) in patients with cryptogenic liver disease undergoing liver transplantation. *Hepatology*. 25:1266-70, 1997.
10. Ishitani M, MdGory R, Dickson R, Caldwell S, Bickston S, McCullough S, Pruett T, **Terrault N**, Roberts J, Ascher N, Wright T, Lake, J. Retransplantation of patients with severe post-transplant hepatitis B in the first allograft. *Transplantation*. 64:410-4, 1997.
11. Hossaba H, **Terrault NA**, El-Gohary A, Scheffel C, Jou C, Brackett J, Hunt J, Lou S, Wright TL. Antibody to GBV-C second envelop glycoprotein (Anti GBV-C E2): is it a marker of immunity? *J Med Virol*. 53:354-60, 1997.
12. Pessoa MG, **Terrault NA**, Detmer J, Kolberg J, Collins ML, Hassoba H, Wright TL. Quantitation of hepatitis G virus and hepatitis C virus in the liver: Evidence that HGV is not a hepatropic virus. *Hepatology*. 27:877-80, 1998.
13. Taga S, Washington MK, **Terrault NA**, Wright, TL, Somberg, K, Ferrell L. Cholestatic hepatitis C in liver allografts. *Liver Transplant Surg*. 4:304-10, 1998.
14. **Terrault NA**, Zhou, S, McGory R, Pruett T, Lake JR, Roberts JP, Ascher NL, Wright TL. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. *Hepatology*. 28:555-61, 1998.
15. **Terrault NA**. Epidemiological evidence for perinatal transmission of hepatitis C virus. *Viral Hepatitis Reviews*. 4:245-58, 1998.
16. Pessoa MG, **Terrault NA**, Ferrell L, Detmer J, Kolberg J, Collins ML, Viele M, Lake JR, Roberts JP, Ascher NL, Wright TL. Hepatitis following liver transplantation: Role of known and unknown viruses. *Liver Transplant Surg*. 4:461-68, 1998.
17. Hassoba HM; Pessoa MG; **Terrault NA**; Lewis NJ; Hayden M; Hunt JC; Qiu X; Lou SC; Wright TL. Anti-envelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. *J Med Virology*. 56(3):253-8, 1998.
18. Yao, FY, **Terrault NA**, Friese C, Maslow L, Bass NM. Lamivudine reduces the need for

- liver transplantation and improves survival in patients with severely decompensated cirrhosis with actively replicating hepatitis B infection: A controlled study. *Hepatology*. 24:411-6, 2001.
19. Teo EK, Han S, **Terrault N**, Luketic V, Jensen D, Keeffe E, Lok ASF. Liver transplantation for hepatitis B patients: Do Asians fare worse than Whites? *Hepatology*. 34:126-32, 2001.
 20. Martino R, **Terrault N**, Ezerzer F, Mikulis D, Diamant NE. Dysphagia in a patient with lateral medullary syndrome: Insight into the central control of swallowing. *Gastroenterology*. 12:420-6, 2001.
 21. Stock P, Roland M, Carlson L, Freise C, Hirose R, **Terrault N**, Frassetto L, Coates T, Roberts J, Ascher N. Solid organ transplantation in HIV-positive patients. *Transplant Proc*. 33(7-8):3646-8, 2001.
 22. Galun E, Eren R, Matot E, Shouval D, **Terrault N**, Keeffe EB, Dagan S. Clinical evaluation (Phase 1) of a combination of two human monoclonal antibodies to HBV: Safety and anti-viral properties. *Hepatology*. 35(3):673-9, 2002.
 23. Crippin JS, McCashland T, **Terrault N**, Sheiner P, Charlton M. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. *Liver Transpl*. 8(4):350-5, 2002.
 24. Kim WR, Brown RS Jr, **Terrault NA**, El-Serag H. Burden of liver disease in the United States: summary of a workshop. *Hepatology*. 36(1):227-42, 2002.
 25. Feng S, Buell JF, Cherikh WS, Deng MC, Hanto DW, Kauffman HM, Leichtman AB, Lorber MI, Maters RG, McBride MA, Metzger RA, Nolte FS, O'Connor KJ, Roth D, **Terrault NA**, Henry ML. Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. *Transplantation*. 74(12):1657-63, 2002.
 26. Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, Everhart JE, Moseley RH, **Terrault N**, Ackerson L, Selby JV. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. *Arch Intern Med*. 163(6):728-34, 2003.
 27. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown RS Jr, Luketic VA, **Terrault N**, Lok AS. Hepatitis B virus genotypes in the United States: Results of a nationwide study. *Gastroenterology*. 125(2):444-5, 2003.
 28. Augenbraun M, Goedert JJ, Thomas D, Feldman J, Seaberg E, French AL, Robison E, Nowicki M, **Terrault N**. Incident Hepatitis C Virus Infection in Women with HIV: A Report from the Women's Interagency HIV Study. *JAIDS*. 15;37(10):1357-64, 2003.
 29. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, **Terrault NA**, Colombo M, Tillmann H, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Westland C, Xiong S, Choy GS, Van Doren S, Fry J, Brosgart CL. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. *Hepatology*. 38(6):1419-27, 2003.
 30. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, **Terrault NA**, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. *Transplantation*. 76(2):370-5, 2003.
 31. Khalili M*, Watson Lim J, Bass N, Ascher NL, Roberts JP, **Terrault NA**. New Onset Diabetes Mellitus After Liver Transplantation: The Critical Role of Hepatitis C Infection. *Liver Transplant*. 10(3):349-55, 2004.
 32. Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, Jortani SA, Kuramoto K, Ng V, Valdes R, Valsamakis A, **Terrault N**. Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT® HCV RNA 3.0 Assay (bDNA). *J Clin Microbiol*. 42(2):563-569, 2004.
 33. Yao FY, Saab S, Bass NM, Hirose R, Ly D, **Terrault N**, Lazar AA, Bacchetti P, Ascher NL, Roberts JP. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. *Hepatology*. 39(1):230-8, 2004.

34. A. French, L Benning, K Anastos, M Augenbaum, M Nowicki, K. Sathasivam, **NA Terrault**. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: Impact of hepatitis C coinfection. *Clin Infect Dis*.1;39(3):402-10, 2004.
35. McTaggart RA, **Terrault NA**, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. *Liver Transplant*. 10(8):975-85, 2004.
36. A.K. Shergill*, M. Khalili*, S. Straley, K. Bollinger, J.P. Roberts, N.A. Ascher, **NA. Terrault**. Applicability and tolerability of preemptive antiviral therapy in hepatitis C infected liver transplant recipients. *Am J Transplant*. 5:118-24, 2005.
37. D Patel, **NA Terrault**, FY Yao, NM Bass, U Ladabaum. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. *Clin Gastroenterol Hepatol*. 3:75-84, 2005.
38. SW Biggins*, HJ Rodriguez, P Bacchetti, NM Bass, JP Roberts, **NA Terrault**. Serum Sodium Predicts Mortality in Patients Listed for Liver Transplantation. *Hepatology*. 41:32-39, 2005.
39. SR Weston*, W Leyden, R Murphy, NM Bass, BP Bell, MM Manos, **NA Terrault**. Racial-Ethnic Distribution of Newly Diagnosed Nonalcoholic Fatty Liver Among Participants of the Chronic Liver Disease Surveillance Study. *Hepatology*. 41(2):372-9, 2005.
40. Davis GL, Nelson DR, **Terrault N**, Pruett TL, Schiano TD, Fletcher CV, Sapan CV, Riser LN, Li Y, Whitley RJ, Gnann JW Jr. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. *Liver Transpl*. 11(8):941-9, 2005.
41. **Terrault NA**, Pawlotsky JM, McHutchison J, Anderson F, Krajden M, Gordon S, Zitron I, Perrillo R, Gish R, Holodniy M, Friesenhahn M. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. *J Viral Hepat*. 12(5):465-72, 2005.
42. Khalili M*, Vardanian AJ, Hamerski CM, Wang R, Bacchetti P, Roberts JP, **Terrault NA**. Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years. *Clin Transplant*. 20(1):1-9, 2006.
43. Dickson RC, **Terrault NA**, Ishitani M, Reddy KR, Sheiner P, Luketic V, Soldevila-Pico C, Fried M, Jensen D, Brown RS Jr, Horwith G, Brundage R, Lok A. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. *Liver Transpl*. 12(1):124-33, 2006.
44. **Terrault NA**, Carter J, Carlson L, Roland M, Stock P. Outcomes of Patients with Hepatitis B Virus and Human Immunodeficiency Virus Infections Referred for Liver Transplantation. *Liver Transplant*. 12(5):801-7, 2006.
45. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, **Terrault N**, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F; HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology*. 130(6):1636-42, 2006.
46. Biggins SW*, Kim WR, **Terrault NA**, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G. Evidence-Based Incorporation of Serum Sodium Concentration Into MELD. *Gastroenterology*. 130(6):1652-1660, 2006.
47. Fontana RJ, Kleiner DE, Bilonick R, **Terrault N**, Afdhal N, Belle SH, Jeffers LJ, Ramcharan D, Ghany MG, Hoofnagle JH; Virahep-C Study Group. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. *Hepatology*. 44(4):925-35, 2006.
48. Conjeevaram HS, Fried MW, Jeffers LJ, **Terrault NA**, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD for the Virahep-C Study

- Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. *Gastroenterology*. 131(2):470-7, 2006.
49. Yao FY, Gautam M, Palese C, Rebres R, **Terrault N**, Roberts JP, Peters MG. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. *Clin Transplant*. 20(5):617-23, 2006.
 50. **Terrault NA**, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS Jr, Everson GT, Reddy KR, Fair JH, Kulik LM, Pruett TL, Seeff LB; A2ALL Study Group. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. *Liver Transpl*. 13(1):122-9, 2007.
 51. Galun E, **Terrault NA**, Eren R, Zauberman A, Nussbaum O, Terkieltaub D, Zohar M, Buchnik R, Ackerman Z, Safadi R, Ashur Y, Misrachi S, Liberman Y, Rivkin L, Dagan S. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. *J Hepatol*. 46(1):37-44, 2007.
 52. Trotter JF, Wisniewski KA, **Terrault NA**, Everhart JE, Kinkhabwala M, Weinrieb RM, Fair JH, Fisher RA, Koffron AJ, Saab S, Merion RM; A2ALL Study Group. Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. *Hepatology*. 46(5):1476-84, 2007.
 53. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, **Terrault N**, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S; Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. *Liver Transpl*. 13(3):349-60, 2007.
 54. Ishida JH*, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, **Terrault NA**. Influence of cannabis use on severity of hepatitis C disease. *Clin Gastroenterol Hepatol*. 6(1):69-7, 2008.
 55. Roland ME, Barin B, Carlson L, Frassetto LA, **Terrault NA**, Hirose R, Freise CE, Benet LZ, Ascher NL, Roberts JP, Murphy B, Keller MJ, Olthoff KM, Blumberg EA, Brayman KL, Bartlett ST, Davis CE, McCune JM, Bredt BM, Stablein DM, Stock PG. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. *Am J Transplant*. 8(2):355-65, 2008.
 56. Manos MM, Leyden WA, Murphy RC, **Terrault NA**, Bell BP. Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. *Hepatology*. 47(4):1150-7, 2008.
 57. Bihl F, Loggi E, Chisholm JV 3rd, Biselli M, Morelli MC, Cursaro C, **Terrault NA**, Bernardi M, Bertolotti A, Andreone P, Brander C. Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection. *Liver Transpl*. 14(4):478-85, 2008.
 58. Howell CD, Dowling TC, Paul M, Wahed AS, **Terrault NA**, Taylor M, Jeffers L, Hoofnagle JH; Virahep-C Study Group. Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. *Clin Gastroenterol Hepatol*. 6(5):575-83, 2008.
 59. Kuo A*, Tan V, Lan B, Khalili M, Feng S, Roberts JP, **Terrault NA**. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. *Liver Transpl*. 14(10):1491-7, 2008.
 60. Bell BP, Manos MM, Zaman A, **Terrault N**, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. *Am J Gastroenterol*. 103(11):2727-36, 2008.
 61. Burton JR Jr, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, **Terrault N**, Rosen HR; Virahep-C Study Group. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy.

- J Hepatol.* 49(3):329-38, 2008.
62. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S, Peters M, **Terrault N**, Freise CE, Ascher NL, Roberts JP. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. *Hepatology.* 48(3):819-27, 2008.
 63. **Terrault NA**, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, Hoofnagle JH, Belle SH; VIRAHEP-C Study Group. Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. *Clin Gastroenterol Hepatol.* (12):1403-11, 2008.
 64. Shaked A, Ghobrial RM, Merion RM, Shearon TH, Emond JC, Fair JH, Fisher RA, Kulik LM, Pruett TL, **Terrault NA**; A2ALL Study Group. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. *Am J Transplant.* 9(2):301-8, 2009.
 65. Behler CM, **Terrault NA**, Etzell JE, Damon LE. Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. *J Med Case Rep.* 3:7335, 2009.
 66. Biggins SW, Bambha K, **Terrault N**, Inadomi J, Roberts JP, Bass N. Transplant Tourism: The Impact on Domestic Patient Care Decisions. *Clin Transplant.* 23(6):831-8, 2009.
 67. **Terrault NA**, Tran TT, Schiff E, McGuire BM, Brown RS Jr., Tupper R, Ramanathan S, Enejosa J, Zhong L, Zong J - for the Study 531 Team. Pharmacokinetics of Tacrolimus Co-administered with Adefovir Dipivoxil to Liver Transplant Recipients. *Liver International.* 29(8):1178-83, 2009.
 68. Evon D, Ramcharran D, Belle S, **Terrault NA**, Fontana R, Fried MW for the Virahep-C Study Group. Prospective Analysis of Depression During Treatment for Hepatitis C: Results of the VIRAHEP-C Study. *Am J Gastroenterol.* 104(12):2949-58, 2009.
 69. Frederick T, Burian P, **Terrault N**, Cohen M, Augenbraun M, Young M, Seaberg E, Justman J, Levine AM, Mack WJ, Kovacs A. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). *AIDS Patient Care STDS.* 23(11):915-23, 2009.
 70. Kim WR, **Terrault NA**, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. *Gastroenterology.* 137(5):1680-6, 2009.
 71. Hayman AV, Sofair AN, Manos MM, Thomas A, **Terrault N**, Ness GV, Stabach N, Robert M, Rumore G, Corless C, Bell B, Bialek S, Zaman A. Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. *Medicine (Baltimore).* 88(5):302-6, 2009.
 72. Ferrucci LM, Bell BP, Dhotre KB, Manos MM, **Terrault NA**, Zaman A, Murphy RC, Vanness GR, Thomas AR, Bialek SR, Desai MM, Sofair AN. Complementary and alternative medicine use in chronic liver disease patients. *J Clin Gastroenterol.* 44(2):e40-5, 2010.
 73. Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, **Terrault NA**, Murphy RC, Stabach N, Huie S, Van Ness G, Bell BP, Bialek S. The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. *J Clin Gastroenterol.* 44(4):301-7, 2010.
 74. Coffin CS*, Stock PG, Carlson L, Berg CL, Dove LM, Fred Poordad F, Curry MP, Regenstein FG, Sherman K, **Terrault NA**. Virologic and Clinical Outcomes of Hepatitis B Virus Infection in HIV-HBV Coinfected Transplant Recipients. *Am J Transplant.* 10(5):1268-75, 2010.
 75. Kuniholm MH, Kovacs A, Gao X, Xue X, Marti D, Thio CL, Peters MG, **Terrault NA**, Greenblatt RM, Goedert JJ, Cohen MH, Minkoff H, Gange SJ, Anastos K, Fazzari M, Harris TG, Young MA, Strickler HD, Carrington M. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. *Hepatology.* 51(5):1514-22, 2010.
 76. Bacchetti P, Boylan Ross, **Terrault NA**, Monto, A, Berenguer M. Non-Markov Multistate

Modeling Using Time-Varying Covariates, with Application to Progression of Liver Fibrosis due to Hepatitis C Following Liver Transplant. *Internat J Biostat.* 6(1);1-14, 2010. PMID: 20305705 PMCID: PMC2836212

77. Merion RM, Shearon TH, Berg CL, Everhart JE, Abecassis MM, Shaked A, Fisher RA, Trotter JF, Brown RS Jr, **Terrault NA**, Hayashi PH, Hong JC; A2ALL Study Group. Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. *Ann Surg.* 251(3):542-9, 2010.
78. McHutchison JG, Manns MP, Muir AJ, **Terrault NA**, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. *N Engl J Med.* 362(14):1292-303, 2010.
79. Lai J*, **Terrault NA**, Vittinghoff E, Biggins S, Height Explains the Gender Difference in Wait-list Mortality Under the MELD-Based Liver Allocation System. *Am J Transplant.* 10(12):2658-64, 2010.
80. Coffin CS*, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, **Terrault NA**. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. *J Viral Hepat.* 18(6):415-23, 2011. PMID:2062662.
81. Lai JC*, Feng S, Roberts JP, **Terrault NA**. Gender Differences in Donor Quality are Predictive of Graft Loss. *Am J Transplant.* 11(2):296-302, 2011. PMID: 21219572.
82. Trotter JF, Gillespie BW, **Terrault NA**, Abecassis MM, Merion RM, Brown RS Jr, Olthoff KM, Hayashi PH, Berg CL, Fisher RA, Everhart JE; Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. *Liver Transpl.* 17(4):409-17, 2011. PMID: 21445924
83. Lai JC*, Verna EC, Brown RS Jr, O'Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, **Terrault NA**; for the ConsoRtiUm to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. *Hepatology.* 54(2):418-24, 2011. PMID: 21538434.
84. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team (**NA Terrault**). Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med.* 364(25):2405-16, 2011. PMID: 2169630
85. Coffin CS*, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, **Terrault NA**. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. *Liver Transpl.* 17(8):955-62, 2011. PMID: 21462295.
86. Bzowej N, Nelson DR, **Terrault NA**, Everson GT, Teng LL, Prabhakar A, Charlton MR; for the PHOENIX Study Group. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. *Liver Transpl.* 17(5):528-538, 2011. PMID: 21506241
87. Bacchetti P, Boylan R, Astemborski J, Shen H, Mehta SH, Thomas DL, **Terrault NA**, Monto A. Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. *PLoS One.* 6(5):e20104, 2011. PMID: 21637766.
88. Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, Everson GT, Hong JC, **Terrault N**, Hayashi PH, Fisher RA, Everhart JE. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. *Hepatology.* 54(4):1313-21, 2011. PMID: 21688284.
89. Brandman D*, Pingitore A, Lai JC, Roberts JP, Ferrell L, Bass NM, **Terrault NA**. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver

- transplant recipients with recurrent hepatitis C virus. *Liver Transpl*. 17(12):1380-6, 2011. PMID: 21770018 PMCID: PMC3712627
90. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team (**NA Terrault**). Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med*. 15;365:1014-24, 2011. PMID: 21916639.
 91. Brandman D*, Biggins SW, Hameed B, Roberts JP, **Terrault NA**. Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality. *Liver Int*. 32(1):158-64, 2012. PMID: 22098119.
 92. Lai JC*, O'Leary JG, Trotter JF, Verna EC, Brown RS, Stravitz RT, Duman JD, Forman LM, **Terrault NA**; for the ConsoRtiUm to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Risk of advanced fibrosis with grafts from hepatitis C antibody positive donors: A multicenter cohort study (CRUSH-C). *Liver Transpl*. 18(5):532-8, 2012. PMID: 22271671.
 93. Saxena V*, Lai JC*, O'Leary JG, Verna EC, Brown RS Jr, Stravitz RT, Trotter JF, Krishnan K, **Terrault NA**; for the ConsoRtiUm to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Donor-recipient race mismatch in African-American liver transplant patients with chronic hepatitis C. *Liver Transpl*. 18:524-31, 2012. PMID: 22140019
 94. Verna EC, Valadao R*, Farrand E, Pichardo EM, Lai JC*, **Terrault NA**, Brown RS Jr. Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. *Liver Transpl*. 18(4):461-7, 2012. PMID: 22467547
 95. **Terrault NA**, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, Ragni MV, Barin B, Simon D, Olthoff KM, Johnson L, Stosor V, Jayaweera D, Fung J, Sherman KE, Subramanian A, Michael Millis J, Slakey D, Berg CL, Carlson L, Ferrell L, Stablein DM, Odum J, Fox L, Stock PG; for the HIV-TR Investigators. Outcomes of liver transplantation in HCV-HIV coinfecting recipients. *Liver Transpl*. 18(6):716-26, 2012. PMID: 22328294.
 96. Biggins SW*, Bambha KM, **Terrault NA**, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts JP. Projected future increase in aging HCV-infected liver transplant candidates: A potential effect of HCC. *Liver Transpl*. 18(12):1471-8, 2012. PMID: 23008049
 97. Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, **Terrault NA**, Yetzer ES. Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients with HCV Genotype 1 Infection. *Gastroenterology*. 145(4): 790-800.e3, 2013 Jun 26. doi:pii: S0016-5085. PMID: 23811112
 98. **Terrault NA**, Dodge JL, Murphy EL, Tavis J, Kiss A, Levin T.R., Gish R, Busch M, Reingold AL, Alter MJ. Sexual Transmission of HCV Among Monogamous Heterosexual Couples: The HCV Partners Study. *Hepatology*. 57(3):881-9, 2013. PMID:23175457.
 99. Freeman J, Emond J, Gillespie BW, Appelbaum PS, Weinrieb R, Hill-Callahan P, Gordon EJ, **Terrault N**, Trotter J, Ashworth A, Dew MA, Pruett T; A2ALL Study Group. Computerized assessment of competence-related abilities in living liver donors: the Adult-to-Adult Living Donor Liver Transplantation Cohort Study. *Clin Transplant*. 27(4):633-45, 2013. doi: 10.1111/ctr.12184. Epub 2013 Jul 16. PMID: 23859354
 100. Gordon SC, Pockros PJ, **Terrault NA**, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. *Hepatology*. 56(5):1651-60, 2012. doi: 10.1002/hep.25842. Epub 2012 Oct 9. Erratum in: *Hepatology*. 2013 Sep;58(3):1193. PMID: 22610658.
 101. Gordon SC, Hamzeh FM, Pockros PJ, Hoop RS, Buikema AR, Korner EJ, **Terrault NA**.

- Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. *Aliment Pharmacol Ther.* 38(7):784-93, 2013. doi: 10.1111/apt.12454. Epub 2013 Aug 25. PMID: 23981040
102. Shores NJ*, Dodge JL, Feng S, **Terrault NA**. Donor Risk Index for African American liver transplant recipients with hepatitis C virus. *Hepatology.* 58(4):1263-9, 2013. doi: 10.1002/hep.26478. Epub 2013 Aug 6. PMID: 23696235.
 103. Lucey MR, **Terrault N**, Ojo L, Hay JE, Neuberger J, Blumberg E, Teperman LW. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Liver Transpl.* 19(1):3-26, 2013. doi: 10.1002/lt.23566. PMID: 23281277.
 104. **Terrault NA**, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish RG, Busch MP, Reingold AL, Alter MJ. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. *Hepatology.* 57(3):881-9, 2013. doi: 10.1002/hep.26164. Epub 2013 Feb 7. PMID: 23175457.
 105. Everson GT, **Terrault NA**, Lok AS, Rodrigo del R, Brown RS Jr, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE; Adult-to-Adult Living Donor Liver Transplantation Cohort Study. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. *Hepatology.* 57(5):1752-62, 2013. doi: 10.1002/hep.25976. Epub 2013 Jan 17. PMID: 22821361.
 106. Driver TH, **Terrault N**, Saxena V*. Acute Hepatitis C in an HIV-Infected patient: A Case Report and Review of Literature. *J Gen Intern Med.* 28(5): 734-738, 2013. (epub 2012 Nov 14). PMID:23151989
 107. Schwartz JB, Lai J*, Lizaola B, Kane L, Weyland P, **Terrault NA**, Stotland N, Bikle D. Variability in free 25(OH) vitamin D levels in clinical populations. *J Steroid Biochem Mol Biol.* 144 Pt. A: 156-8, 2013 Nov 15. doi: 10.1016.PMID: 24240067
 108. Hartigan-O'Connor DJ, Lin D, Ryan JC, Shvachko VA, Cozen ML, Segal MR, **Terrault NA**, Lanier LL, Manos MM, McCune JM. Monocyte Activation by Interferon α Is Associated With Failure to Achieve a Sustained Virologic Response After Treatment for Hepatitis C Virus Infection. *J Infect Dis.* 209(10): 1602-12, 2014. PMID: 24325966
 109. Schwartz JB, Lai J, Lizaola B, Kane L, Markova S, Weyland P, **Terrault NA**, Stotland N, Bikle D. A comparison of direct and calculated free 25(OH) Vitamin D levels in clinical populations. *J Clin Endocrinol Metab.* 99(5):1631-7, 2014. PMID: 24483159.
 110. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, **Terrault NA**, Burton JR Jr, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. *N Engl J Med.* 371(25):2375-82, 2014. PMID: 25386767.
 111. **Terrault N**, Reddy KR, Poordad F, Curry M, Schiano T, Juhl J, Shaikh O, Dove L, Shetty K, Millis M, Schiff E, Regenstein F, Barnes D, Barin B, Peters M, Roland M, Stock P; for the HIVTR Investigators. Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV-HIV Coinfected Liver Transplant Recipients. *Am J Transplant.* 14(5):1129-35, 2014. doi: 10.1111/ajt.12668. PMID: 24636466
 112. Saxena V*, Manos MM, Yee HS, Catali L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, **Terrault NA**. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. *Aliment Pharmacol Ther.* 39(10):1213-24, 2014. doi: 10.1111/apt.12718. PMID: 24654657
 113. **Terrault NA**, Stravitz RT, Lok AS, Everson GT, Brown RS Jr, Kulik LM, Olthoff KM, Saab S, Adeyi O, Argo CK, Everhart JE, Rodrigo del R; A2ALL Study Group. Hepatitis C disease severity in living versus deceased donor liver transplant recipients: An extended observation study. *Hepatology.* 59(4):1311-9, 2014. doi: 10.1002/hep.26920. PMID: 24677192.
 114. Sarkar M*, Shvachko VA, Ready JB, Pauly MP, **Terrault NA**, Peters MG, Manos MM. Characteristics and Management of Patients with Chronic Hepatitis B in an Integrated Care

- Setting. *Dig Dis Sci*. 59(9):2100-8, 2014. PMID: 24728968
115. Sherman KE, **Terrault N**, Barin B, Rouster SD, Shata MT; HIV-TR Investigators. Hepatitis E infection in HIV-infected liver and kidney transplant candidates. *J Viral Hepat*. 21(8):e74-7, 2014.
 116. **Terrault NA**, Hassanein T, Howell CD, Joshi S, Lake J, Sher L, Vargas H, McIntosh J, Tang S, Jenkins TM. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. *J Hepatol*. 61(6):1253-9, 2014. PMID: 25048952.
 117. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Forns X, **Terrault NA**. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. *Gastroenterology*. 148(1):108-17, 2015. doi: 10.1053/j.gastro.2014.10.001. Epub 2014 Oct 7. PMID: 25304641.
 118. Goel A*, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, **Terrault N**. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. *Liver Transpl*. 20(10):1221-8, 2014. doi: 10.1002/lt.23945./> PMID: 25045002.
 119. Flemming JA*, Yang JD, Vittinghoff E, Kim WR, **Terrault NA**. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. *Cancer*. 120(22):3485-93, 2014. doi: 10.1002/cncr.28832. Epub 2014 Jul 16. PMID: 25042049.
 120. Flemming JA,* Vagefi PA, Freise CE, Yao FY, **Terrault NA**. Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience. *Liver Transpl*. 20(10):1202-10, 2014. PMID: 24961679.
 121. Lai JC*, Feng S, **Terrault NA**, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. *Am J Transplant*. 14(8):1870-9, 2014. doi: 10.1111/ajt.12762. Epub 2014 Jun 16. PMID: 24935609.
 122. Burton JR Jr, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, **Terrault NA**. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. *J Hepatol*. 61(3):508-14, 2014. doi: 10.1016/j.jhep.2014.04.037. Epub 2014 May 5. PMID: 24801415.
 123. Goel A*, **Terrault N**. Response to Letter to the Editor. *Liver Transpl*. 2014 Dec 19. doi: 10.1002/lt.24066. No abstract available. PMID: 25530165
 124. Biggins SW, Gralla J, Dodge JL, Bambha KM, Tong S, Barón AE, Inadomi J, **Terrault N**, Rosen HR. Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index. *Am J Transplant*. 14(11):2588-94, 2014. PMID: 25243648.
 125. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, **Terrault N**, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; for the NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet*. 385(9972):956-65, 2015. PMID: 25468160.
 126. Flemming JA*, Kim WR, **Terrault NA**. Reply to prediction of hepatocellular carcinoma: Using a complex risk model or assisting for smoking cessation? *Cancer*. 1;121(7): 1150-1151, 2015. doi: 10.1002/cncr.29183. No abstract available. Epub ahead of print 2014 Dec 2. PMID: 25470366
 127. Lai JC*, Shoback DM, Zipperstein J, Lizaola B, Tseng S, **Terrault NA**. Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. *Dig Dis Sci*. 60(6):1813-1819, 2015. PMID: 25563723
 128. Tejada-Strop A, Drobeniuc J, Mixson-Hayden T, Forbi JC, Le NT, Li L, Mei J, **Terrault N**, Kamili S. Disparate detection outcomes for anti-HCV IgG and HCV RNA in dried blood

- spots. *J Virol Methods*. 212:66-70, 2015. PMID: 25445800.
129. Ghany MG, Perrillo R, Li R, Belle SH, Janssen HL, **Terrault NA**, Shuhart MC, Lau DT, Kim WR, Fried MW, Sterling RK, Di Bisceglie AM, Han SH, Ganova-Raeva LM, Chang KM, Lok AS; Hepatitis B Research Network; Hepatitis B Research Network. Characteristics of adults in the hepatitis B research network in north america reflect their country of origin and hepatitis B virus genotype. *Clin Gastroenterol Hepatol*. 13(1):183-92, 2015. PMID: 25010003.
 130. Campos-Varela I*, Straley S, Agudelo EZ, Carlson L, **Terrault NA**. Sofosbuvir, Simeprevir plus Ribavirin for Treatment of HCV Recurrence in HIV-HCV Coinfected Liver Transplant Recipients. *Liver Transpl*. 21(2):272-4, 2015. PMID: 25332190.
 131. Curry MP, Forns X, Chung RT, **Terrault NA**, Brown R Jr, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. *Gastroenterology*. 148(1):100-107, 2015. PMID: 25261839.
 132. Campos-Varela I*, Lai JC, Verna EC, O'Leary JG, Todd Stravitz R, Forman LM, Trotter JF, Brown RS, **Terrault NA**; for the Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatitis C Genotype Influences Post-Liver Transplant Outcomes. *Transplantation*. 99(4):835-40, 2015. PMID: 25211520.
 133. Khalili M, Lombardero M, Chung RT, **Terrault NA**, Ghany MG, Kim WR, Lau D, Lisker-Melman M, Sanyal A, Lok AS; HBRN: Hepatitis B Research Network; HBRN Hepatitis B Research Network. Diabetes and Prediabetes in Patients with Hepatitis B Residing in North America. *Hepatology*. 62(5): 1364-1374, 2015. doi: 10.1002/hep.28110. PMID: 26390278.
 134. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, **Terrault NA**, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N; SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. *Gastroenterology*. 149(3):649-59, 2015. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15. PubMed PMID: 25985734.
 135. Lai JC, Covinsky KE, Hayssen H, Lizaola B, Dodge JL, Roberts JP, **Terrault NA**, Feng S. Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation. *Liver Int*. 35(9):2167-73, 2015. doi: 10.1111/liv.12792. Epub 2015 Feb 12. PubMed PMID: 25644788; PubMed Central PMCID: PMC4517979.
 136. Ho CK*, Maselli JH, **Terrault NA**, Gonzales R. High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments. *Dig Dis Sci*. 60(7):2183-9, 2015. doi: 10.1007/s10620-015-3594-z. Epub 2015 Feb 28. PubMed PMID: 25724166.
 137. Dirchwolf M, Dodge JL, Gralla J, Bambha KM, Nydam T, Hung KW, Rosen HR, Feng S, **Terrault NA**, Biggins SW. The corrected donor age for hepatitis C virus-infected liver transplant recipients. *Liver Transpl*. 21(8):1022-30, 2015. doi: 10.1002/lt.24194. PubMed PMID: 26074140.
 138. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, **Terrault N**, Khalili M, Sterling RK, Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith JW, Levine DL, Traub D, Ho S, Valiga ME, Johnson GS, Doo E, Lok AS, Chang KM; Hepatitis B Research Network. Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. *Gastroenterology*. 150(3):684-695.e5, 2016. doi: 10.1053/j.gastro.2015.11.050. Epub 2015 Dec 10. PMID: 26684441

139. Saxena V*, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, Winston B, Redd J, Ready J, **Terrault NA**. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. *Hepatology*. 62(3):715-25, 2015. doi: 10.1002/hep.27922. Epub 2015 Jul 30. PubMed PMID: 26033798; PubMed Central PMCID: PMC4549204.
140. Verna EC, Saxena V*, Burton JR Jr, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, **Terrault NA**; CRUSH-C Consortium. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. *Transplantation*. 99(8):1644-51, 2015. PMID: 25715116.
141. Khalili M, Lombardero M, Chung RT, **Terrault NA**, Ghany MG, Kim WR, Lau D, Lisker-Melman M, Sanyal A, Lok AS; HBRN. Diabetes and prediabetes in patients with hepatitis B residing in North America. *Hepatology*. 62(5):1364-74, 2015. PMID 26390278.
142. Lanini S, Nanni Costa A, Grossi PA, Procaccio F, Ricci A, Capobianchi MR, **Terrault NA**, Ippolito G. Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis. *Liver Int*. 36(3):410-7, 2016. doi: 10.1111/liv.12938. [Epub Aug 12] PubMed PMID: 26264452.
143. Flemming JA*, Saxena V*, Shen H, **Terrault NA**, Rongey C. Facility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA. *Dig Dis Sci*. 61(1):62-9, 2016. PMID: 26363933.
144. Campos-Varela I*, Dodge JL, Stock PG, **Terrault NA**. Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus. *Clin Transplant*. 30(9):1140-5, 2016. PMID:27411037
145. Brown RS Jr, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR Jr, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, **Terrault NA**; Hepatitis C Therapeutic Registry Research Network Study Group. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. *Liver Transpl*. 22(1):24-33, 2016. PMID: 26519873
146. Ho CK*, Boscardin CK, Gleason N, Collado D, Terdiman J, **Terrault NA**, Gonzales R. Optimizing the pre-referral workup for gastroenterology and hepatology specialty care: consensus using the Delphi method. *J Eval Clin Pract*. 22(1):46-52, 2016. doi: 10.1111/jep.12429. [Epub 2015 Jul 30] PubMed PMID: 26223584.
147. Lai JC, Covinsky KE, Hayssen H, Lizaola B, Dodge J, Roberts JP, **Terrault NA**, Feng S. Response to clinical assessments of health status as a potential marker to identify patients who are too sick to undergo transplantation. *Liver Int*. 36(4):611, 2016. doi: 10.1111/liv.13026. No abstract available. PMID: 26584013
148. Flemming JA*, Saxena V*, Shen H, **Terrault NA**, Rongey C. Facility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA. *Dig Dis Sci*. 61(1):62-9, 2016. PMID: 26363933.
149. Saxena V*, Korashy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, **Terrault NA**; HCV-TARGET. Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Impaired Renal Function. *Liver Int*. 36(6):807-16, 2016. PMID: 26923436
150. Ajmera VH*, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, **Terrault NA**. Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. *Am J Gastroenterol*. 111(5):658-64, 2016. doi: 10.1038/ajg.2016.57. Epub 2016 Mar 22. PMID: 27002796
151. Levitsky J, Verna EC, O'Leary JG, Bzowej NH, Moonka DK, Hyland RH, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, **Terrault NA**. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients. *N Engl J Med*. 375(21):2106-2108, 2016. PMID:27959735

152. Sarkar M, Dodge JL, Roberts JP, **Terrault N**, Yao F, Mehta N. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. *Ann Hepatol*. 15(4):545-9, 2016. PMID:27236153
153. Ajmera VH*, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, **Terrault NA**. Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. *Am J Gastroenterol*. 111(5):658-64, 2016. PMID:27002796.
154. Campos-Varela I*, Moreno A, Morbey A, Guaraldi G, Hasson H, Bhamidimarri KR, Castells L, Grewal P, Baños I, Bellot P, Brainard DM, McHutchison JG, **Terrault NA**. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy. *Aliment Pharmacol Ther*. 43(12):1319-29, 2016. PMID:27098374
155. **Terrault NA**, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fried MW, Nelson DR; HCV-TARGET Study Group. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. *Gastroenterology*. 151(6):1131-1140, 2016. PMID: 27565882
156. Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akushevich L, Lok AS, Pockros PJ, Vainorius M, **Terrault NA**, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. *Aliment Pharmacol Ther*. 45(1):115-126, 2017. doi: 10.1111/apt.13823.PMID:27790729
157. Ajmera V*, Perito ER, Bass NM, **Terrault NA**, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat BE; NASH Clinical Research Network.. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. *Hepatology*. 65(1):65-77, 2017. PMID:27532276
158. Yang JD, Abdelmalek MF, Guy CD, Gill RM, Lavine JE, Yates K, Klair J, **Terrault NA**, Clark JM, Unalp-Arida A, Diehl AM, Suzuki A; Nonalcoholic Steatohepatitis Clinical Research Network..Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. *Clin Gastroenterol Hepatol*. 15(1):127-131, 2017. PMID:27523635
159. Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akushevich L, Lok AS, Pockros PJ, Vainorius M, **Terrault NA**, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. *Aliment Pharmacol Ther*. 45(1):115-126, 2017. doi: 10.1111/apt.13823. Epub 2016 Oct 28. PMID: 27790729
160. Flemming JA*, Kim WR, Brosgart CL, **Terrault NA**. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. *Hepatology*. 65(3):804-812, 2017. doi: 10.1002/hep.28923. Epub 2016 Dec 24. PMID: 28012259
161. Walsh CE, Workowski K, **Terrault NA**, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. *Haemophilia*. 23(2):198-206, 2017. PMID: 28124511
162. Sarkar M, Wellons M, Cedars MI, VanWagner L, Gunderson EP, Ajmera V, Torchen L, Siscovick D, Carr JJ, Terry JG, Rinella M, Lewis CE, **Terrault N**. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. *Am J Gastroenterol*. 112(5): 755-762, 2017. doi: 10.1038/ajg.2017.44. [Epub ahead of print] PMID: 28291240
163. Butt Z, Dew MA, Liu Q, Simpson MA, Smith AR, Zee J, Gillespie BW, Abbey SE, Ladner DP, Weinrieb R, Fisher RA, Hafliger S, **Terrault N**, Burton J, Sherker AH, DiMartini A.

- Psychological Outcomes of Living Liver Donors From a Multicenter Prospective Study: Results From the Adult-to-Adult Living Donor Liver Transplantation Cohort Study2 (A2ALL-2). *Am J Transplant*. 17(5):1267-1277, 2017. PMID: 27865040
164. Radhakrishnan K*, Chi A, Quan DJ, Roberts JP, **Terrault NA**. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. *Transplantation*. 101(9):2079-2082, 2017. PMID: 2888019
 165. Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS Jr, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, **Terrault N**, Rizzetto M, Müllhaupt B. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. *Ann Hepatol*. 16(3):375-381, 2017. PMID: 28425407.
 166. VanWagner LB, Ning H, Allen NB, Ajmera V, Lewis CE, Carr JJ, Lloyd-Jones DM, **Terrault NA**, Siddique J. Alcohol Use and Cardiovascular Disease Risk in Patients with Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 153(5): 1260-1272.e3, 2017. PMID: 28802566
 167. Dew MA, Butt Z, Liu Q, Simpson MA, Zee J, Ladner DP, Holtzman S, Smith AR, Pomfret EA, Merion RM, Gillespie BW, Sherker AH, Fisher RA, Olthoff KM, Burton JR Jr, **Terrault NA**, Fox AN, DiMartini AF. Prevalence and Predictors of Patient-Reported Long-Term Mental and Physical Health After Donation in the Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL). *Transplantation*. 102(1):105-118, 2018. PMID: 28885494.
 168. Campos-Varela I*, Agudelo EZ, Sarkar M, Roberts JP, **Terrault NA**. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. *Transpl Infect Dis*. 20(1), 2018. PMID: 29125670
 169. Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, **Terrault N**, Chung RT. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. *Hepatology*. 67(6):2085-2095, 2018. PMID: 29222916; PMCID: PMC5991982.
 170. Méndez-Lagares G, Lu D, Chen C, **Terrault N**, Segal MR, Khalili M, Monto A, Shen H, Manos MM, Lanier LL, Ryan JC, McCune JM, Hartigan-O'Connor DJ. Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. *J Immunol*. 200:1124-1132, 2018. PMID: 29263212; PMCID: PMC5780234.
 171. Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, **Terrault NA**, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. *Clin Gastroenterol Hepatol*. 16(11):1811-1819, 2018. PMID: 29306043; PMCID: PMC6034985.
 172. Hameed B, **Terrault NA**, Gill RM, Loomba R, Chalasani N, Hoofnagle JH, VanNatta ML; NASH CRN. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. *Aliment Pharmacol Ther*. 47(5):645-656, 2018. PMID: 29333665; PMCID: PMC5931362.
 173. Ajmera V*, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, Neuschwander-Tetri BA, **Terrault N**; Nonalcoholic Steatohepatitis Clinical Research Network. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. *Clin Gastroenterol Hepatol*. 16(9):1511-1520, 2018. PMID: 29378307; PMCID: PMC6098737.
 174. Wang GP, **Terrault N**, Reeves JD, Liu L, Li E, Zhao L, Lim JK, Morelli G, Kuo A, Levitsky J, Sherman KE, Frazier LM, Ramani A, Peter J, Akushevich L, Fried MW, Nelson DR. Prevalence and impact of baseline resistance-associated substitutions on the efficacy of

- ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCVinfection. *Sci Rep*. 8(1):3199, 2018. doi: 10.1038/s41598-018-21303-2. PubMed PMID: 29453451; PubMed Central PMCID: PMC5816647.
175. Huang AC*, Mehta N, Dodge JL, Yao FY, **Terrault NA**. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. *Hepatology*. 68(2):449-461, 2018. PMID: 29476694; PMCID: PMC6097892.
 176. El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, Charlton M, Manns M, Afdhal NH, Mukamal K, McHutchison J, Brainard DM, **Terrault N**, Curry MP. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. *Gastroenterology*. 154(8):2111-2121, 2018. PMID: 29535028.
 177. **Terrault N**, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. *Gastroenterology*. 155(3):705-718, 2018. doi: 10.1053/j.gastro.2018.05.025. Epub 2018 May 17. PubMed PMID: 29778606.
 178. Dave S, Dodge JL, **Terrault NA**, Sarkar M. Racial and Ethnic Differences in Graft Loss Among Female Liver Transplant Recipients. *Transplant Proc*. 50(5):1413-1423, 2018. doi: 10.1016/j.transproceed.2018.02.059. PubMed PMID:29880364.
 179. Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, **Terrault NA**, Lisker-Melman M, Sanyal A, Lok AS; Hepatitis B Research Network (HBRN); Harvard Consortium. Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. *Diabetes Care*. 41(6):1251-1259, 2018. doi: 10.2337/dc18-0040. Epub 2018 Mar 29. PubMed PMID:29599296; PubMed Central PMCID: PMC5961397.
 180. Campos-Varela I, Agudelo EZ, **Terrault NA**. Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct-acting antivirals era: A case series. *Clin Transplant*. 32(7):e13303, 2018. doi: 10.1111/ctr.13303. Epub 2018 Jun 25. PubMed PMID: 29851150.
 181. VanWagner LB, Ning H, Allen NB, Siddique J, Carson AP, Bancks MP, Lewis CE, Carr JJ, Speliotes E, **Terrault NA**, Rinella ME, Vos MB, Lloyd-Jones DM. Twenty-five-year trajectories of insulin resistance and pancreatic β -cell response and diabetes risk in nonalcoholic fatty liver disease. *Liver Int*. 38(11):2069-2081, 2018. doi: 10.1111/liv.13747. Epub 2018 Apr 24. PubMed PMID:29608255.
 182. Lee BP*, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, **Terrault NA**. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. *Gastroenterology*. 155(2):422-430, 2018. PMID: 29655837.
 183. Sarkar M, **Terrault N**, Duwaerts CC, Tien P, Cedars MI, Huddleston H. The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. *Curr Opin Gynecol Obstet*. 1(1):24-33, 2018. Epub 2018 Apr 5. PubMed PMID: 30112518; PubMed Central PMCID: PMC6089370.
 184. Kushner T*, Cohen J, Tien PC, **Terrault NA**. Evaluating Women's Preferences for Hepatitis C Treatment During Pregnancy. *Hepatol Commun*. 2(11):1306-1310, 2018. PMID:30411077; PMCID: PMC6211328.
 185. Feld JJ, **Terrault NA**, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network (HBRN). Entecavir and peginterferon alfa-2a in adults with HBeAg-positive immune tolerant chronic hepatitis B virus infection. *Hepatology*. 69(6):2338-2348, 2019. Epub ahead of print. PMID: 30549279.
 186. Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, **Terrault N**, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ.

- Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH. *Liver Int.* 39(5): 924-932, 2019. doi: 10.1111/liv.13974. [Epub ahead of print] PubMed PMID: 30253043.
187. Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, **Terrault N**, Chung RT, Chhatwal J. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. *Clin Gastroenterol Hepatol.* 17(4): 739-747.e8, 2019. PMID: 30138735.
 188. Loomba R, Sanyal AJ, Kowdley KV, **Terrault N**, Chalasani NP, Abdelmalek MF, McCullough AJ, Shringarpure R, Ferguson B, Lee L, Chen J, Liberman A, Shapiro D, Neuschwander-Tetri BA. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. *Gastroenterology.* 156(1):88-95.e5, 2019. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15. PubMed PMID: 30222962.
 189. Ajmera VH*, **Terrault NA**, VanWagner LB, Sarkar M, Lewis CE, Carr JJ, Gunderson EP. Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. *J Hepatol.* 126-132, 2019. PMID: 30392752.
 190. Sharpton SR*, **Terrault NA**, Posselt AM. Outcomes of Sleeve Gastrectomy in Obese Liver Transplant Candidates. *Liver Transpl.* 25(4):538-544, 2019. doi: 10.1002/lt.25406. [Epub ahead of print] PubMed PMID: 30588743.
 191. Lee BP*, Vittinghoff E, Hsu C, Han H, Therapondos G, Fix OK, Victor DW, Dronamraju D, Im GY, Voigt MD, Rice JP, Lucey MR, Eswaran S, Chen PH, Li Z, Maddur H, **Terrault NA**. Predicting Low-Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The SALT Score. *Hepatology.* 69(4): 1477-1487, 2019. PubMed PMID: 30561766.
 192. Kushner T, **Terrault NA**. Hepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of Care. *Hepatol Commun.* 3(1):20-28, 2019. doi: 10.1002/hep4.1282. eCollection 2019 Jan. Review. PMID: 30619991; PMCID: PMC6312659.
 193. Brouwer WP, Zhao Q, Hansen BE, Lau D, Khalili M, **Terrault NA**, Di Bisceglie AM, Perrillo RP, Fried MW, Wong D, Feld JJ, Belle SH, Janssen HLA; Hepatitis B Research Network (HBRN). Improved Definition of HBV Phenotypes based on Genotype-specific Levels of Hepatitis B s Antigen. *Clin Gastroenterol Hepatol.* 2019 Jan 7. [ePub ahead of print] PubMed PMID: 30630104.
 194. Lee BP*, Vittinghoff E, Dodge JL, Cullaro G, **Terrault NA**. National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States. *JAMA Intern Med.* 179(3):340-348, 2019. PMID: 30667468.
 195. Sarkar M, VanWagner LB, Terry JG, Carr JJ, Rinella M, Schreiner PJ, Lewis CE, **Terrault N**; Coronary Artery Risk Development in Young Adults (CARDIA) Cohort. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. *Am J Gastroenterol.* 114(5):758-763, 2019. PMID: 30730350.
 196. Zhou K*, Contag C*, Whitaker E, **Terrault N**. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. *Lancet Gastroenterol Hepatol.* 4(3):227-238, 2019. doi: 10.1016/S2468-1253(18)30308-X. Epub 2019 Jan 22. PubMed PMID: 30679109.
 197. Brahmania M, Lombardero M, Hansen BE, **Terrault NA**, Lok AS, Perrillo RP, Belle SH, Di Bisceglie AM, Feld JJ, Lee WM, Fried MW, Janssen HLA; Hepatitis B ResearchNetwork. Association Between Severe Serum Alanine Aminotransferase Flares andHepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated PatientsWith Chronic HBV Infection. *Clin Gastroenterol Hepatol.* pii: S1542-3565(19)30143-0, 2019. doi: 10.1016/j.cgh.2019.02.005. [Epub ahead of print] PubMed PMID: 30743006
 198. Di Bisceglie AM, King WC, Lisker-Melman M, Khalili M, Belle SH, Feld JJ, Ghany MG, Janssen HLA, Lau D, Lee WM, Ling SC, Cooper S, Rosenthal P, Schwarz KB, Sterling RK, Teckman JH, **Terrault N**; Hepatitis B Research Network (HBRN). Age, race and viral genotype are associated with the prevalence of Hepatitis B e antigen in children and adults

- with chronic Hepatitis B. *J Viral Hepat.* 2019 Apr. doi: 10.1111/jvh.13104. [Epub ahead of print] PubMed PMID: 30974509.
199. Lee BP*, Im GY, Rice JP, Weinberg E, Hsu C, Fix OK, Therapondos G, Han H, Victor DW, Eswaran S, Maddur H, **Terrault NA**. Underestimation of Liver Transplantation for Alcoholic Hepatitis in the National Transplant Database. *Liver Transpl.* 25(5):706-711, 2019. doi: 10.1002/lt.25448. Epub 2019 Mar 29. PubMed PMID: 30882995.
 200. Lee BP*, Samur S, Dalgic OO, Bethea ED, Lucey MR, Weinberg E, Hsu C, Rinella ME, Im GY, Fix OK, Therapondos G, Han H, Victor DW, Voigt MD, Eswaran S, **Terrault NA**, Chhatwal J (co-senior authors). Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients with Alcohol-Associated Hepatitis. *Gastroenterology*. pii: S0016-5085(19)35705-1, 2019. doi:10.1053/j.gastro.2019.04.012. [Epub ahead of print] PubMed PMID: 30998988.
 201. Chang KM, Traum D, Park JJ, Ho S, Ojio K, Wong DK, Wahed AS, **Terrault NA**, Khalili M, Sterling RK, Janssen HLA, Shuhart MC, Lau DT, Roberts LR, Johnson GS, Kaplan DE, Betts MR, Lee WM, Lok ASF; Hepatitis B Research Network (HBRN). Distinct phenotype and function of circulating V δ 1+ and V δ 2+ $\gamma\delta$ T-cells in acute and chronic hepatitis B. *PLoS Pathog.* 15(4):e1007715, 2019. doi:10.1371/journal.ppat.1007715. [Epub ahead of print] PubMed PMID: 30998783
 202. Bzowej NH, Tran TT, Li R, Belle SH, Smith CI, Khalili M, Chung R, Tsai N, **Terrault N**; Hepatitis B Research Network (HBRN). Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study. *Am J Gastroenterol.* 2019 May 1. doi: 10.14309/ajg.0000000000000221. [Epub ahead of print] PubMed PMID: 31082876.
 203. Kushner T*, Tholey D, Dodge J, Saberi B, Schiano T, **Terrault N**. Outcomes of liver transplantation for acute fatty liver disease of pregnancy. *Am J Transplant.* 19(7):2101-2107, 2019 Jul. doi: 10.1111/ajt.15401. Epub 2019 May 16. PubMed PMID: 31017355.
 204. Giard JM*, Dodge JL, **Terrault N**. Superior Wait-List Outcomes in Patients with Alcohol-Associated Liver Disease Compared to Other Indications for Liver Transplantation. *Liver Transpl.* 2019 May 7. doi: 10.1002/lt.25485. [Epub ahead of print] PubMed PMID: 31063642.
 205. Sharpton SR*, Maraj B, Harding-Theobald E, Vittinghoff E, **Terrault NA**. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. *Am J Clin Nutr.* pii: nqz042, 2019 May 24. doi: 10.1093/ajcn/nqz042. [Epub ahead of print] PubMed PMID: 31124558; PubMed Central PMCID: PMC6599739.
 206. Zhou K*, **Terrault NA**. Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study. *Clin Gastroenterol Hepatol.* pii: S1542-3565(19)30598-1, 2019 Jun 4. doi: 10.1016/j.cgh.2019.05.047. [Epub ahead of print] PubMed PMID: 31173892.
 207. Cornberg M, Lok AS, **Terrault NA**, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference†. *J Hepatol.* 2020 Mar;72(3):539-557. doi: 10.1016/j.jhep.2019.11.003. [Epub 2019 Nov 12.] PMID: 31730789
 208. Lee BP*, **Terrault NA**. Liver Transplantation in Unauthorized Immigrants in the United States. *Hepatology.* 2020 May;71(5):1802-1812. doi: 10.1002/hep.30926. [Epub 2020 Jan 24.] PMID: 31487391
 209. Poordad F, **Terrault NA**, Alkhouri N, Tian W, Allen LF, Rabinovitz M. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. *Int J Hepatol.* 2020 Jan 25;2020:5421632. doi: 10.1155/2020/5421632. eCollection 2020. PMID: 32047671
 210. Brahmania M, Liu S, Wahed AS, Yim C, Hansen BE, Khalili M, **Terrault NA**, Lok AS, Ghany M, Wang J, Wong D, Janssen HLA; Hepatitis B Research Network. Alcohol,

- tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America. *Ann Hepatol.* 2020 Jul-Aug;19(4):437-445. doi: 10.1016/j.aohep.2020.01.005. [Epub 2020 Feb 8]. PMID: 32139262
211. Burton JR Jr, **Terrault NA**, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. *Transplantation.* 2020 Mar;104(3):476-481. doi: 10.1097/TP.0000000000003014. PMID: 31634329 Review.
 212. Lau KC, Joshi SS, Gao S, Giles E, Swidinsky K, van Marle G, Bathe OF, Urbanski SJ, **Terrault NA**, Burak KW, Osioy C, Coffin CS. Oncogenic HBV variants and integration are present in hepatic and lymphoid cells derived from chronic HBV patients. *Cancer Lett.* 2020 Jun 28;480:39-47. doi: 10.1016/j.canlet.2020.03.022. Epub 2020 Mar 27. PMID: 32229190
 213. Verna EC, Morelli G, **Terrault NA**, Lok AS, Lim JK, Di Bisceglie AM, Zeuzem S, Landis CS, Kwo P, Hassan M, Manns MP, Vainorius M, Akushevich L, Nelson DR, Fried MW, Reddy KR. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. *J Hepatol.* 2020 Sep;73(3):540-548. doi: 10.1016/j.jhep.2020.03.031. Epub 2020 Mar 31. PMID: 32243960
 214. Roth D, Bloom RD, Molnar MZ, Reese PP, Sawinski D, Sise ME, **Terrault NA**. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. *Am J Kidney Dis.* 2020 May;75(5):665-683. doi: 10.1053/j.ajkd.2019.12.016. Epub 2020 Apr 9. PMID: 32279907
 215. Lee BP*, Vittinghoff E, Pletcher MJ, Dodge JL, **Terrault NA**. Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease. *Hepatology.* 2020 Jul;72(1):130-139. doi: 10.1002/hep.31027. Epub 2020 May 8. PMID: 31705545
 216. Zhou K*, Dodge JL, Grab J, Poltavskiy E, **Terrault NA**. Mortality in adults with chronic hepatitis B infection in the United States: a population-based study. *Aliment Pharmacol Ther.* 2020 Jul;52(2):382-389. doi: 10.1111/apt.15803. Epub 2020 May 20. PMID: 32432816
 217. Wang J, Wu AH, Stanczyk FZ, Porcel J, Nouredin M, **Terrault NA**, Wilkens LR, Setiawan VW. Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population. *Clin Gastroenterol Hepatol.* 2020 Aug 12:S1542-3565(20)31121-6. doi: 10.1016/j.cgh.2020.08.012. Online ahead of print. PMID: 32801014
 218. Flemming JA*, Mullin M, Lu J, Sarkar MA, Djerboua M, Velez MP, Brogly S, **Terrault NA**. Outcomes of Pregnant Women With Cirrhosis and Their Infants in a Population-Based Study. *Gastroenterology.* 2020 Nov;159(5):1752-1762.e10. doi: 10.1053/j.gastro.2020.07.052. Epub 2020 Aug 8. PMID: 32781083
 219. Kushner T*, Chen Z, Tressler S, Kaufman H, Feinberg J, **Terrault NA**. Trends in Hepatitis B Infection and Immunity Among Women of Childbearing Age in the United States. *Clin Infect Dis.* 2020 Jul 27;71(3):586-592. doi: 10.1093/cid/ciz841. PMID: 31504302
 220. Orandi BJ*, Purvis JW, Cannon RM, Smith AB, Lewis CE, **Terrault NA**, Locke JE. Bariatric surgery to achieve transplant in end-stage organ disease patients: A systematic review and meta-analysis. *Am J Surg.* 2020 Sep;220(3):566-579. doi: 10.1016/j.amjsurg.2020.04.041. Epub 2020 Jun 13. PMID: 32600846
 221. Lisker-Melman M, Khalili M, Belle SH, **Terrault NA**, Lin HS, Smith CI, Chung RT, Tsai N, Bzowej NH, Tran TT, Schwarzenberg SJ; Hepatitis B Research Network (HBRN). Maternal knowledge of the risk of vertical transmission and offspring acquisition of hepatitis B. *Ann Hepatol.* 2020 Jul-Aug;19(4):388-395. doi: 10.1016/j.aohep.2020.04.006. Epub 2020 May 20. PMID: 32507734
 222. **Terrault NA**, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy

- in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. *Hepatology*. 2020 Sep 14. doi: 10.1002/hep.31551. Online ahead of print. PMID: 32926749
223. Sarkar M, Brady CW, Fleckenstein J, Forde KA, Khungar V, Molleston JP, Afshar Y, **Terrault NA**. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2020 Sep 18. doi: 10.1002/hep.31559. Online ahead of print. PMID: 32946672
 224. Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, **Terrault NA**, Lilly LB, Selzner N, Sapisochin G. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. *Transplantation*. 2020 Oct;104(10):2087-2096. doi: 10.1097/TP.0000000000003115. PMID: 31978002
 225. Campos-Varela I*, Dodge JL, Berenguer M, Adam R, Samuel D, Di Benedetto F, Karam V, Belli LS, Duvoux C, **Terrault NA**. Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States. *Transplantation*. 2020 Oct;104(10):2078-2086. doi: 10.1097/TP.0000000000003107. PMID: 32969987
 226. Lee BP*, Dodge JL, **Terrault NA**. Excess Mortality After Liver Transplantation in Young Women With Alcohol-Associated Liver Disease. *Am J Gastroenterol*. 2020 Oct 28. doi: 10.14309/ajg.0000000000001007. Online ahead of print. PMID: 33136566
 227. Zhou K*, Pickering TA, Gainey CS, Cockburn M, Stern MC, Liu L, Unger JB, El-Khoueiry AB, **Terrault NA**. Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. *JNCI Cancer Spectr*. 2020 Nov 2;5(1):pkaa100. doi: 10.1093/jncics/pkaa100. eCollection 2021 Feb. PMID: 33442663
 228. Flemming JA*, Djerboua M, Groome PA, Booth CM, **Terrault NA**. NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. *Hepatology*. 2021 Jun 26. doi: 10.1002/hep.32032. Epub ahead of print. PMID: 34174003.
 229. Zhou K*, Dodge JL, Yuan L, **Terrault NA**. Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults. *Dig Dis Sci*. 2021 Jun 26. doi: 10.1007/s10620-021-07124-w. Epub ahead of print. PMID: 34173916.
 230. Ghany MG, King WC, Lisker-Melman M, Lok ASF, **Terrault N**, Janssen HLA, Khalili M, Chung RT, Lee WM, Lau DTY, Cioherty GA, Sterling RK. Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. *Hepatology*. 2021 Jun 16. doi: 10.1002/hep.32018. Epub ahead of print. PMID: 34133774.
 231. Sherman KE, Kottlil S, Rouster SD, Abdel-Hameed EA, Boyce CL, Meeds HL, **Terrault N**, Shata MT. Hepatitis E Infection in a Longitudinal Cohort of Hepatitis C Virus and HCV/HIV Coinfected Persons. *AIDS Res Hum Retroviruses*. 2021 Jul;37(7):534-541. doi: 10.1089/AID.2020.0303. Epub 2021 May 10. PMID:33794657; PMCID: PMC8260885.
 232. Sharpton SR*, **Terrault NA**, Tavakol MM, Posselt AM. Sleeve gastrectomy prior to liver transplantation is superior to medical weight loss in reducing posttransplant metabolic complications. *Am J Transplant*. 2021 Mar 29. doi:10.1111/ajt.16583. Epub ahead of print. PMID: 33780129.
 233. Campos-Varela I*, Dodge JL, **Terrault NA**, Brandman D, Price JC. Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus. *Am J Transplant*. 2021 Sep;21(9):3148-3156. doi: 10.1111/ajt.16569. Epub 2021 Jul 8. PMID: 33749113.
 234. Lee BP*, Dodge JL, Leventhal A, **Terrault NA**. Retail Alcohol and Tobacco Sales. During COVID-19. *Ann Intern Med*. 2021 Jul;174(7):1027-1029. doi:10.7326/M20-7271. Epub 2021 Mar 2. PMID: 33646843; PMCID: PMC7983313.
 235. Traum D, Wang YJ, Schwarz KB, Schug J, Wong DK, Janssen H, **Terrault NA**, Khalili M, Wahed AS, Murray KF, Rosenthal P, Ling SC, Rodriguez-Baez N, Sterling RK, Lau DT,

- Block TM, Feldman MD, Furth EE, Lee WM, Kleiner DE, Lok AS, Kaestner KH, Chang KM. Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver. *JCI Insight*. 2021 Apr 8;6(7):e146883. doi:10.1172/jci.insight.146883. PMID: 33621209; PMCID: PMC8119221.
236. Kushner T*, Kaplowitz E, Mei R, Xu C, Acker A, Rosenbluth E, Oredein I, Sarkar M, **Terrault N**, Bansal M, Forde KA. Adherence to pregnancy hepatitis B care guidelines in women and infants in the United States and evaluation of two interventions to improve care: A multicentre hospital-based study. *J Viral Hepat*. 2021 Apr;28(4):582-591. doi: 10.1111/jvh.13459. Epub 2021 Jan 20. PMID:33372359.
 237. Abdallah MA, Kuo YF, Asrani S, Wong RJ, Ahmed A, Kwo P, **Terrault N**, Kamath PS, Jalan R, Singal AK. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. *J Hepatol*. 2021Jun;74(6):1355-1361. doi: 10.1016/j.jhep.2020.12.003. Epub 2020 Dec 14. PMID:33326814.
 238. Lee BP*, Im GY, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakhete N, Mobley C, Victor DW, Mehta N, Dinges L, Rinella M, Schiano TD, Lucey MR, **Terrault N**. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. *Clin Gastroenterol Hepatol*. 2020 Dec 3:S1542-3565(20)31558-5. doi: 10.1016/j.cgh.2020.11.024. Epub ahead of print.PMID: 33279780.
 239. Peters MG, Kottlil S, **Terrault N**, Amara D, Husson J, Huprikar S, Florman S, Sulkowski MS, Durand CM, Luetkemeyer AF, Rogers R, Grab J, Haydel B, Blumberg E, Dove L, Emond J, Olthoff K, Smith C, Fishbein T, Masur H, Stock PG. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. *Am J Transplant*. 2021 May;21(5):1780-1788. doi: 10.1111/ajt.16427. Epub 2020 Dec 23. PMID: 33277801;PMCID: PMC8096639.
 240. Zhou K*, Gainey CS, Dodge JL, Setiawan VW, Liu L, Cockburn MG, **Terrault NA**. Diverging Incidence Trends for Hepatocellular Carcinoma in Rural and Urban Settings in the United States. *Clin Gastroenterol Hepatol*. 2021 Aug 27:S1542-3565(21)00912-5. doi: 10.1016/j.cgh.2021.08.032. Epub ahead of print.PMID: 34461301.
 241. Lee BP*, Dodge JL, **Terrault NA**. Changes and mediators of survival disparity among Black liver transplant recipients in the United States. *Am J Transplant*. 2021 Aug 10. doi: 10.1111/ajt.16767. Epub ahead of print. PMID: 34374495.
 242. Orandi BJ*, Lewis CE, MacLennan PA, Qu H, Mehta S, Kumar V, Sheikh SS, Cannon RM, Anderson DJ, Hanaway MJ, Reed RD, Killian AC, Purvis JW, **Terrault NA**, Locke JE. Obesity as an isolated contraindication to kidney transplantation in the end-stage renal disease population: A cohort study. *Obesity (Silver Spring)*. 2021 Sep;29(9):1538-1546. doi: 10.1002/oby.23195. Epub 2021 Aug 2. PMID:34338423.
 243. Flemming JA, Djerboua M, Groome PA, Booth CM, **Terrault NA**. NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. *Hepatology*. 2021 Dec;74(6):3330-3344.doi: 10.1002/hep.32032. Epub 2021 Aug 15. PMID: 34174003.\
 244. Ghany MG, King WC, Lisker-Melman M, Lok ASF, **Terrault N**, Janssen HLA, Khalili M, Chung RT, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. *Hepatology*. 2021Nov;74(5):2395-2409.
 245. Lee BP, Dodge JL, **Terrault NA**. Changes and mediators of survival disparity among Black liver transplant recipients in the United States. *Am J Transplant*.2021 Dec;21(12):3883-3893. doi: 10.1111/ajt.16767. Epub 2021 Aug 10. PMID:34374495.
 246. Lee BP, Dodge JL, **Terrault NA**. Medicaid expansion and variability in mortality in the USA: a national, observational cohort study. *Lancet PublicHealth*. 2022 Jan;7(1):e48-e55. doi: 10.1016/S2468-2667(21)00252-8. Epub 2021 Dec2. PMID: 34863364.

247. Kardashian A, Dodge JL, **Terrault NA**. Food Insecurity is Associated With Mortality Among U.S. Adults With Nonalcoholic Fatty Liver Disease and Advanced Fibrosis. *Clin Gastroenterol Hepatol*. 2021 Dec 16:S1542-3565(21)01267-2. doi:10.1016/j.cgh.2021.11.029. Epub ahead of print. PMID: 34958747.
248. Feld JJ, King WC, Ghany MG, Chang KM, **Terrault N**, Perrillo RP, Khalili M, Hinerman AS, Janssen H, Lok AS; Hepatitis B Research Network (HBRN). Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. *Clin Gastroenterol Hepatol*. 2022 Jul 16:S1542-3565(22)00653-X. doi:10.1016/j.cgh.2022.06.015. Epub ahead of print. PMID: 35843468.
249. Yuan L, Hanlon CL, **Terrault N**, Alqahtani S, Tamim H, Lai M, Saberi B. Portrait of Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. *Am J Gastroenterol*. 2022 Mar 1;117(3):433-444. doi: 10.14309/ajg.0000000000001591. PMID: 35083985.
250. King WC, Sterling RK, Hinerman AS, Lok ASF, Cioherty GA, Ghany MG; HBRN HBV Novel Assays Group (Corporate authorship), Wahed AS, Chung RT, Janssen HLA, Khalili M, Lau DTY, Lee WM, Lisker-Melman M, **Terrault N**. Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating e But Not Surface Antigen Clearance. *Clin Gastroenterol Hepatol*. 2022 Jul 16:S1542-3565(22)00660-7. doi: 10.1016/j.cgh.2022.06.019. Epub ahead of print. PMID: 35850413.
251. Mullin M, Djerboua M, Sarkar M, Lu J, Velez MP, Brogly S, **Terrault NA**, Flemming JA. Pregnancy Is Not Associated with an Increased Risk of Decompensation, Transplant, or Death in Compensated Cirrhosis. *Int J Hepatol*. 2022 Jul 6;2022:9985226. doi: 10.1155/2022/9985226. PMID: 35845752; PMCID: PMC9279084.
252. Lee BP, Cullaro G, Vosooghi A, Yao F, Panchal S, Goldberg DS, **Terrault NA**, Mahmud N. Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database. *J Hepatol*. 2022 May;76(5):1122-1126. doi: 10.1016/j.jhep.2021.12.040. Epub 2022 Jan 21. PMID: 35074470; PMCID: PMC9018597.
253. Kushner T, Djerboua M, Biondi MJ, Feld JJ, **Terrault N**, Flemming JA. Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission. *J Hepatol*. 2022 May 26:S0168-8278(22)00331-2. doi:10.1016/j.jhep.2022.05.016. Epub ahead of print. PMID: 35643203.
254. Leventhal AM, Cho J, Ray LA, Liccardo Pacula R, Lee BP, **Terrault N**, Pedersen E, Lee JO, Davis JP, Jin H, Huh J, Wilson JP, Whaley RC. Alcohol use trajectories among U.S. adults during the first 42 weeks of the COVID-19 pandemic. *Alcohol Clin Exp Res*. 2022 Jun;46(6):1062-1072. doi:10.1111/acer.14824. Epub 2022 May 9. PMID: 35532741; PMCID: PMC9246926.
255. Woreta TA, Van Natta ML, Lazo M, Krishnan A, Neuschwander-Tetri BA, Loomba R, Mae Diehl A, Abdelmalek MF, Chalasani N, Gawrieh S, Dasarthy S, Vuppalaanch R, Siddiqui MS, Kowdley KV, McCullough A, **Terrault NA**, Behling C, Kleiner DE, Fishbein M, Hertel P, Wilson LA, Mitchell EP, Miriel LA, Clark JM, Tonascia J, Sanyal AJ; NASH Clinical Research Network. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. *PLoS One*. 2022 Apr 15;17(4):e0266859. doi:10.1371/journal.pone.0266859. PMID: 35427375; PMCID: PMC9012361
256. Lee BP, Roth N, Rao P, Im GY, Vogel AS, Hasbun J, Roth Y, Shenoy A, Arvelakis A, Ford L, Dawe I, Schiano TD, Davis JP, Rice JP, Eswaran S, Weinberg E, Han H, Hsu C, Fix OK, Maddur H, Ghobrial RM, Therapondos G, Dilkina B, **Terrault NA**. Artificial intelligence to identify harmful alcohol use after early liver transplant for alcohol-associated hepatitis. *Am J Transplant*. 2022 Jul;22(7):1834-1841. doi: 10.1111/ajt.17059. Epub 2022 Apr 25. PMID: 35416409.
257. Zhou K, Dodge JL, Yuan L, **Terrault NA**. Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults. *Dig Dis Sci*. 2022

- Jul;67(7):3340-3355. doi: 10.1007/s10620-021-07124-w. Epub 2021 Jun 26. PMID: 34173916.
258. **Terrault NA**, Wahed AS, Feld JJ, Cooper SL, Ghany MG, Lisker-Melman M, Perrillo R, Sterling RK, Khalili M, Chung RT, Rosenthal P, Fontana RJ, Sarowar A, Lau DTY, Wang J, Lok AS, Janssen HLA. Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort. *Hepatology*. 2022 Mar;75(3):709-723. doi: 10.1002/hep.32231. Epub 2022 Jan 26. PMID: 34743343; PMCID: PMC8943823.
 259. Zhou K, Thompson LK, Liu L, **Terrault NA**, Cockburn MG. Geographic hotspot detection for late-stage hepatocellular carcinoma: novel approach to cancer control. *Cancer Causes Control*. 2022 May;33(5):701-710. doi: 10.1007/s10552-022-01555-0. Epub 2022 Jan 27. PMID: 35084657.
 260. Purvis JW, Orandi BJ, Dhall D, McLeod C, Gutierrez Sanchez LH, Gray M, Frey K, Sheikh SS, Cannon RM, **Terrault NA**, Lewis CE, Locke JE. Hepatic macrosteatosis in the US pediatric deceased liver donor population. *Pediatr Transplant*. 2022 Feb;26(1):e14155. doi: 10.1111/ptr.14155. Epub 2021 Sep 30. PMID: 34590386; PMCID: PMC8752486.
 261. Zhou K, Gainey CS, Dodge JL, Setiawan VW, Liu L, Cockburn MG, **Terrault NA**. Diverging Incidence Trends for Hepatocellular Carcinoma in Rural and Urban Settings in the United States. *Clin Gastroenterol Hepatol*. 2022 May;20(5):1180-1185.e2. doi: 10.1016/j.cgh.2021.08.032. Epub 2021 Aug 27. PMID: 34461301.
 262. Ames JB, Djerboua M, **Terrault NA**, Booth CM, Flemming JA. Rising Healthcare Costs and Utilization among Young Adults with Cirrhosis in Ontario: A Population-Based Study. *Can J Gastroenterol Hepatol*. 2022 Mar 9;2022:6175913. doi: 10.1155/2022/6175913. PMID: 35308801; PMCID: PMC8926479.
 263. Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, **Terrault NA**, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD). *Aliment Pharmacol Ther*. 2022 Jun;55(11):1441-1451. doi: 10.1111/apt.16874. Epub 2022 Mar 17. PMID: 35302256; PMCID: PMC9098681.
 264. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. *Lancet Gastroenterol Hepatol*. 2022 May;7(5):396-415. doi:10.1016/S2468-1253(21)00472-6. Epub 2022 Feb 16. PMID: 35180382.
 265. Leventhal AM, Cho J, Ray LA, Pacula RL, Lee BP, **Terrault N**, Pedersen E, Lee JO, Davis JP, Jin H, Huh J, Wilson JP, Whaley RC. Alcohol use trajectories among U.S. adults during the first 42 weeks of the COVID-19 pandemic. *Alcohol Clin Exp Res*. 2022 Jun;46(6):1062-1072. doi: 10.1111/acer.14824. Epub 2022 May 9. PMID: 35532741; PMCID: PMC9246926
 266. Kardashian A, Dodge JL, **Terrault NA**. Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: A U.S. population-based study. *Aliment Pharmacol Ther*. 2022 Sep 29. doi: 10.1111/apt.17219. Epub ahead of print. PMID: 36173037.
 267. Lee BP, Dodge JL, **Terrault NA**. Geographic Density of Gastroenterologists Is Associated With Decreased Mortality From Alcohol-Associated Liver Disease. *Clin Gastroenterol Hepatol*. 2022 Aug 4:S1542-3565(22)00719-4. doi: 10.1016/j.cgh.2022.07.020. Epub ahead of print. PMID: 35934291.
 268. Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, Gadano A, Popescu CP, Stepanova T, Asselah T, Diaconescu G, Yim HJ, Heo J, Janczewska E, Wong A, Idriz N, Imamura M, Rizzardini G, Takaguchi K, Andreone P, Arbune M, Hou J, Park SJ, Vata A, Cremer J, Elston R, Lukic T, Quinn G, Maynard L, Kendrick S, Plein H, Campbell F, Paff M, Theodore D, B-Clear Study Group. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis

- B Infection. N Engl J Med. 2022 Nov 24;387(21):1957-1968. doi: 10.1056/NEJMoa2210027. Epub 2022 Nov 8. PMID: 36346079
269. Weinberg EM, Dukewich M, Jakhete N, Stonesifer E, Im GY, Lucey MR, Shetty K, Rice JP, Victor DW 3rd, Ghobrial MR, Shetty A, Rutledge SM, Florman SS, Hsu C, Shoreibah M, Aryan M, Orandi BJ, Han H, **Terrault N**, Lee BP. Early Liver Transplantation for Severe Alcohol-Associated Hepatitis and a History of Prior Liver Decompensation. Am J Gastroenterol. 2022 Dec 1;117(12):1990-1998. doi: 10.14309/ajg.0000000000001901. Epub 2022 Jul 11. PMID: 35853462
 270. Blach S, Brown KA, Brown RS, Gholam PM, **Terrault NA**, Estes C, Razavi HA. Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress. J Infect Public Health. 2023;16(1):64-70. PMID: 36473359
 271. Lee BP, Dodge JL, **Terrault NA**. Liver transplant for alcohol-associated liver disease continues to rise 2 years into the COVID-19 pandemic especially among young adults. J Hepatol. 2023;78(4):e139-e141. PMID: 36567054.
 272. Medeiros RP, **Terrault NA**, Mazo DF, Oliveira CP, Dodge J, Zitelli PM, Lopes MH, Carrilho FJ, Pessoa MG. Impaired anti-HBV vaccine response in non-cirrhotic chronic HCV is not overcome by double dose regimen: randomized control trial Ann Hepatol. 2023 Mar-Apr;28(2):100891. PMID: 36572211
 273. Lee BP, Dodge JL, **Terrault NA**. Geographic Density of Gastroenterologists is Associated with Decreased Mortality from Alcohol-Associated Liver Disease. Clin Gastroenterol Hepatol. 2023;21(6):1542-1551.e6. PMID: 35934291.
 274. Feld JJ, King WC, Ghany MG, Chang KM, **Terrault N**, Perrillo RP, Khalili M, Hinerman AS, Janssen H, Lok AS; Hepatitis B Research Network (HBRN). Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2023 Jun;21(6):1503-1512. PMID: 35843468.
 275. **Terrault NA**, Lok AS, Wahed AS, Ghany MG, Perrillo RP, Fried MW, Wong DK, Khalili M, Lau DTY, Sterling RK, Di Bisceglie AM, Lisker-Melman M, Cooper SL, Chung RT, Patel K, Roberts LR, Belle SH, Janssen HLA; Hepatitis B Research Network. Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. Am J Gastroenterol. 2023 Jul 1;118(7):1214-1225. PMID: 36599136 Clinical Trial.
 276. Kardashian A, Dodge JL, **Terrault NA**. Quantifying the Negative Impact of Fast-food Consumption on Liver Steatosis Among United States Adults With Diabetes and Obesity Clin Gastroenterol Hepatol. 2023;21(12):3176-3178.e3. PMID: 36638832
 277. Hsu CC, Dodge JL, Weinberg E, Im G, Ko J, Davis W, Rutledge S, Dukewich M, Shoreibah M, Aryan M, Vosooghi A, Lucey M, Rice J, **Terrault NA**, Lee BP. Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis. Hepatology. 2023 Apr 1;77(4):1253-1262. PMID: 36651183.
 278. **Terrault NA**, Slepian J, Kanner R, Gailloux K, Catalli L, McKinney J, Straley S, Morris P, Hluhanich R, Gonzalez-Flores A, Dodge J, Sarkar S. Strategies to increase primary care provider capacity for hepatitis C care: The California ECHO-PLUS study. J Viral Hepat. 2023;30(5):397-405. PMID: 36696286.
 279. Feld JJ, Wahed AS, Fried M, Ghany MG, Di Bisceglie AM, Perrillo RP, Khalili M, Yang X, Belle SH, Janssen HLA, **Terrault N**, Lok AS; Hepatitis B Research Network (HBRN). Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial. Am J Gastroenterol. 2023 Jul 1;118(7):1226-1236. PMID: 36728214
 280. Orandi BJ, McLeod MC, MacLennan PA, Lee WM, Fontana RJ, Karvellas CJ, McGuire BM, Lewis CE, **Terrault N**, Locke JE; US Acute Liver Failure Study Group. Association of FDA Mandate Limiting Acetaminophen (Paracetamol) in Prescription Combination Opioid Products and Subsequent Hospitalizations and Acute Liver Failure. JAMA. 2023;329(9):735-744. PMID: 36881033.

281. Wang AE, **Terrault NA**, Fong TL, Zhou K. Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system. *Hepatol Commun*. 2023 Mar 24;7(4):e0081. PMID: 36972389.
282. Ayyala-Somayajula D, Dodge JL, Farias A, **Terrault N**, Lee BP. Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States. *J Hepatol*. 2023;79(2):329-339. PMID: 36996942.
283. Razavi HA, Buti M, **Terrault NA**, Zeuzem S, Yurdaydin C, Tanaka J, Aghemo A, Akarca US, Al Masri NM, Alalwan AM, Aleman S, Alghamdi AS, Alghamdi S, Al-Hamoudi WK, Aljumah AA, Altraif IH, Asselah T, Ben-Ari Z, Berg T, Biondi MJ, Blach S, Braga WSM, Brandão-Mello CE, Brunetto MR, Cabezas J, Cheinquer H, Chen PJ, Cheon ME, Chuang WL, Coffin CS, Coppola N, Craxi A, Crespo J, De Ledinghen V, Duberg AS, Etzion O, Ferraz MLG, Ferreira PRA, Forns X, Foster GR, Gaeta GB, Gamkrelidze I, García-Samaniego J, Gheorghe LS, Gholam PM, Gish RG, Glenn J, Hercun J, Hsu YC, Hu CC, Huang JF, Janjua N, Jia J, Kåberg M, Kaita KDE, Kamal H, Kao JH, Kondili LA, Lagging M, Lázaro P, Lazarus JV, Lee MH, Lim YS, Marotta PJ, Navas MC, Naveira MCM, Orrego M, Osiowy C, Pan CQ, Pessoa MG, Raimondo G, Ramji A, Razavi-Shearer DM, Razavi-Shearer K, Ríos-Hincapié CY, Rodríguez M, Rosenberg WMC, Roulot DM, Ryder SD, Safadi R, Sanai FM, Santantonio TA, Sarrazin C, Shouval D, Tacke F, Tergast TL, Villalobos-Salcedo JM, Voeller AS, Yang HI, Yu ML, Zuckerman E; Polaris Observatory. Hepatitis D Double Reflex Testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. *J Hepatol*. 2023;79(2):576-580. PMID: 37030400.
284. Zhou K, Lim T, Dodge JL, **Terrault NA**, Wilkens LR, Setiawan VW. Population-attributable risk of modifiable lifestyle factors to hepatocellular carcinoma: The multi-ethnic cohort. *Aliment Pharmacol Ther*. 2023;58(1):89-98. PMID: 37051717.
285. Ghany MG, King WC, Hinerman AS, Lok AS, Lisker-Melman M, Chung RT, **Terrault N**, Janssen HLA, Khalili M, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Use of HBV RNA and to predict change in serological status and disease activity in CHB. *Hepatology*. 2023 Nov 1;78(5):1542-1557. PMID: 37074026
286. Huang DQ, Wilson LA, Behling C, Kleiner DE, Kowdley KV, Dasarathy S, Amangurbanova M, **Terrault NA**, Diehl AM, Chalasani N, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; NASH Clinical Research Network; Loomba R. Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study *Gastroenterology*. 2023;165(2):463-472.e5. PMID: 37127100.
287. Lee BP, Dodge JL, Mack WJ, Leventhal AM, **Terrault NA**. National Trends in Alcohol Use, Metabolic Syndrome, and Liver Disease From 1999 to 2018. *Ann Intern Med*. 2023;176(6):879-882. PMID: 37155990 .
288. Zhou K, Song Z, Rostomian N, Dodge JL, Stern MC, Setiawan VW, **Terrault NA**, Cockburn MG, Liu L. Association of nativity with survival among adults with hepatocellular carcinoma. *J Natl Cancer Inst*. 2023;115(7):861-869. PMID: 37160726.
289. Hahn JA, Ngabirano C, Fatch R, Emenyonu NI, Cheng DM, Adong J, Tumwegamire A, **Terrault NA**, Linas BP, Jacobson KR, Muyindike WR. Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. *AIDS*. 2023 Aug 1;37(10):1535-1543. PMID: 37260251.
290. Perrillo R, Lok AS, Leonard K, Ghany MG, **Terrault N**, Belle SH, Janssen HLA; Hepatitis B Research Network. Association of Alanine Aminotransferase Flares to Hepatitis B Surface Decline During Tenofovir Alone or With Pegylated Interferon Alfa. *Am J Gastroenterol*. 2023;118(11):2075-2079. PMID: 37307571.
291. Polaris Observatory Collaborators (Terrault). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. *Lancet Gastroenterol Hepatol*. 2023;8(10):879-907. PMID: 37517414.
292. Feld LD, Sarkar M, Au JS, Flemming JA, Gripshover J, Kardashian A, Muir AJ, Nephew L,

- Orloff SL, **Terrault N**, Rabinowitz L, Volerman A, Arora V, Farnan J, Villa E. Parental leave, childcare policies, and workplace bias for hepatology professionals: A national survey. *Hepatol Commun*. 2023;7(9):e0214. PMID: 37639705.
293. Lee BP, Dodge JL, **Terrault NA**. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. *Hepatology*. 2023 Sep 20. doi: 10.1097/HEP.0000000000000604. PMID: 37732946.
 294. Aleyadeh W, Verna EC, Elbeshbeshy H, Sulkowski MS, Smith C, Darling J, Sterling RK, Muir A, Akushevich L, La D, **Terrault N**, Fried MW, Feld JJ. Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study. *Am J Transplant*. 2023:S1600-6135(23)00796-7. PMID: 37871798
 295. Zhou K, Lit A, Kuo LS, Thompson LK, Dodge JL, Mehta N, **Terrault NA**, Ha NB, Cockburn MG. Neighborhood-level Social Determinants of Health and Waitlist Mortality for Liver Transplantation: The Liver Outcomes and Equity Index. *Transplantation*. 2023 Dec 5. doi: 10.1097/TP.0000000000004888. PMID: 38049937.
 296. Xu M, Mayemura CT, Kong N, Genyk YS, Kahn JA, **Terrault NA**. Low frequency of HBsAg reemergence in liver transplant recipients after stopping hepatitis B immune globulin: Implications for prophylaxis protocols. *Liver Transpl*. 2023 Dec 12. doi: 10.1097/LVT.0000000000000311. PMID: 38079257
 297. Xu M, **Terrault NA**. Hepatitis B virus elimination strategies. *Current Hepatology Reports*. 2024 Feb 21. doi: 10.1007/s11901-024-00658-3
 298. Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Anstee QM, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Gastaldelli A, Hagström H, Huang TTK, Ivancovsky Wajcman D, Kautz A, Kopka CJ, Krag A, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, **Terrault NA**, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM. A global action agenda for turning the tide on fatty liver disease. *Healthy Livers, Healthy Lives Collaborators*. *Hepatology*. 2024 Feb 1;79(2):502-523. doi: 10.1097/HEP.0000000000000545. PMID: 37540183
 299. Maldonado SS, Cedars MI, Yates KP, Wilson LA, Gill R, **Terrault NA**, Suzuki A, Sarkar MA. Antimüllerian hormone, a marker of ovarian reserve, is protective against presence and severity of NASH in premenopausal women. *Clin Gastroenterol Hepatol*. 2024 Feb;22(2):339-346.e5. doi: 10.1016/j.cgh.2023.08.020. PMID: 37678489
 300. Foley MK, Djerboua M, Kushner T, Biondi MJ, Feld JJ, **Terrault NA**, Flemming JA. Maternal neighbourhood-level social determinants of health and their association with pediatric hepatitis C screening among children exposed to hepatitis C in pregnancy. *Paediatr Perinat Epidemiol*. 2024 Feb;38(2):152-160. doi: 10.1111/ppe.13042. PMID: 38273801
 301. Lo Re V 3rd, Price JC, Schmitt S, **Terrault N**, Bhattacharya D, Arohson A. The obstacle is the way: Finding a path to hepatitis C elimination. *Clin Infect Dis*. 2024 May 16:ciae231. doi: 10.1093/cid/ciae231. PMID: 38752395
 302. Ayyala-Somayajula D, Dodge JL, Zhou K, **Terrault NA**, Yuan L. The impact of surging transplantation of alcohol-associated liver disease on transplantation for HCC and other indications. *Hepatol Commun*. 2024 Jul 5;8(7):e0455. doi: 10.1097/HC9.0000000000000455. PMID: 38967588
 303. **Terrault, N**. Treatment of hepatitis D – A future role for combination therapy. *N Engl J Med*. 2024 Jul 11;391(2):181-183. doi: 10.1056/NEJMe2406180. PMID: 38842503
 304. Dukewich M, Dodge JL, Lucey MR, Rice JP, Shetty K, Jakhete N, Im GY, Weinberg EM, Hsu C, Smith C, Ghobrial RM, Therapondos G, Shoreibah M, Aryan M, Eswaran S, Fix OK, Maddur H, **Terrault N**, Lee BP. The survival benefit of abstinence after harmful alcohol use following early liver transplant for severe alcohol-associated hepatitis: A

- multicenter ACCELERATE study. *Am J Gastroenterol*. 2024 Jul 12. doi: 10.14309/ajg.0000000000002956. PMID: 38994850
305. Tapper EB, Goldberg D, Parikh ND, **Terrault NA**, Welch N, Sharpton S, Hameed B, Khalili M, Stolz A, Verna EC, Brown RS Jr, Sanyal AJ, VanWagner L, Ladner DP, Moylan CA, Diehl AM, Jones PD, Loomba R, Dasarathy S, Simonetto DA, Shah VH, Bajaj JS; LCN Study Group. The liver cirrhosis network cohort study: Cirrhosis definition, study population, and endpoints. *Am J Gastroenterol*. 2024 Jul 17. doi: 10.14309/ajg.0000000000002953. PMID: 39018024
 306. Huang DQ, Wilson LA, Behling C, Amangurbanova M, Kleiner DE, Kowdley KV, Dasarathy S, **Terrault NA**, Diehl AM, Chalasani N, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J, Loomba R; NASH Clinical Research Network. Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study. *Hepatology*. 2024 Jul 19. doi: 10.1097/HEP.0000000000001015. PMID: 39028908
 307. Samala N, Xin Y, Wilson LA, Yates K, Loomba R, Hoofnagle JH, Chalasani N; NASH Clinical Research Network. Non-hispanic black persons with nonalcoholic fatty liver disease have lower rates of advanced fibrosis, cirrhosis, and liver-related events even after controlling for clinical risk factors and PNPLA3 genotype. *Am J Gastroenterol*. 2024 Sep 1;119(9):1857-1865. doi: 10.14309/ajg.0000000000002756. PMID: 38483303
 308. Lee BP, Witkiewitz K, Mellinger J, Anania FA, Bataller R, Cotter TG, Curtis B, Dasarathy S, DeMartini KS, Diamond I, Diazgranados N, DiMartini AF, Falk DE, Fernandez AC, German MN, Kamath PS, Kidwell KM, Leggio L, Litten R, Louvet A, Lucey MR, McCaul ME, Sanyal AJ, Singal AK, Sussman NL, **Terrault NA**, Thursz MR, Verna EC, Radaeva S, Nagy LE, Mitchell MC. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement. *Nat Rev Gastroenterol Hepatol*. 2024 Sep;21(9):626-645. doi: 10.1038/s41575-024-00936-x. PMID: 38849555
 309. Ayyala-Somayajula D, Bottyan T, Shaikh S, Lee BP, Cho SH, Dodge JL, **Terrault NA**, Han H. Safety of acamprostate for alcohol use disorder after liver transplant: A pilot randomized controlled trial. *Liver Transpl*. 2024 Sep 3. doi: 10.1097/LVT.0000000000000475. PMID: 39225670
 310. Edwards B, Ramirez S, Pappas J, Dodge JL, Han H, Kahn J, Ahearn A, **Terrault NA**, Lee BP. The university of southern California psychological checklist: A novel tool to remotely screen transplant candidates with alcohol-associated liver disease prior to hospital transfer. *Liver Transpl*. 2024 Sep 30. doi: 10.1097/LVT.0000000000000496. PMID: 39330947
 311. **Terrault NA**, Sterling R, Lok AS, Ghany MG, Feld JJ, Cloherty G, Wahed AS, Yang X. HBV RNA as a biomarker for safe antiviral discontinuation: A prospective study of nucleos(t)ide analogue withdrawal. *J Infect Dis*. 2024 Oct 30;jiae541. doi: 10.1093/infdis/jiae541. PMID: 39478672
 312. Goldberg D, Wilder J, **Terrault N**. Health disparities in cirrhosis care and liver transplantation. *Nat Rev Gastroenterol Hepatol*. 2024 Oct 31. doi: 10.1038/s41575-024-01003-1. PMID: 39482363
 313. Chalasani N, Vilar-Gomez E, Loomba R, Yates KP, Diehl AM, Neuschwander-Tetri BA, Dasarathy S, Kowdley KV, **Terrault N**, Wilson LA, Tonascia J, Sanyal AJ. PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. *Hepatology*. 2024 Nov 1;80(5):1212-1226. doi: 10.1097/HEP.0000000000000896. PMID: 38652636
 314. Vinaixa C, DiMaira T, Russo FP, Goldberg D, Mazzola A, Walabh P, Price J, Sagal S, Kirchner V, Shaker T, Krag A, Pruett T, Coilly A, **Terrault N**, Berenguer M. Use of HBsAg-positive donors in liver transplantation: An ILTS-EASL-AASLD multisociety survey. *Liver Transpl*. 2024 Nov 1;30(11):1116-1122. doi: 10.1097/LVT.0000000000000432.

PMID: 39018028

315. **Terrault N**, Lok AS. Quest for HBV functional cure: what have we learnt from silencing RNAs? *Gut*. 2024 Nov 5;gutjnl-2024-333763. doi: 10.1136/gutjnl-2024-333763. PMID: 39500554
316. Ayyala-Somayajula D, Dodge JL, Leventhal AM, **Terrault NA**, Lee BP. Trends in alcohol use after the COVID-19 pandemic: A national cross-sectional study. *Ann Intern Med*. 2024 Nov 12. doi: 10.7326/ANNALS-24-02157. PMID: 39527820
317. Arab JP, Díaz LA, Rehm J, Im G, Arrese M, Kamath PS, Lucey MR, Mellinger J, Thiele M, Thursz M, Bataller R, Burton R, Chokshi S, Francque SM, Krag A, Lackner C, Lee BP, Liangpunsakul S, MacClain C, Mandrekar P, Mitchell MC, Morgan MY, Morgan TR, Pose E, Shah VH, Shawcross D, Sheron N, Singal AK, Stefanescu H, **Terrault N**, Trépo E, Moreno C, Louvet A, Mathurin P. Metabolic dysfunction and alcoholic-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. *J Hepatol*. 2024 Nov 27:S0168-8278(24)02728-4. doi: 10.1016/j.jhep.2024.11.028. PMID: 39608457
318. Simonetto DA, Winder GS, Connor AA, **Terrault NA**. Liver transplantation for alcoholic-associated liver disease. *Hepatology*. 2024 Dec 1;80(6):1441-1461. doi: 10.1097/HEP.0000000000000978. PMID: 38889100
319. Flemming JA, Djerboua M, Chapman O, Ayonrinde O, **Terrault NA**. Epidemiology and outcomes of alcoholic-associated hepatitis in adolescents and young adults. *JAMA Netw Open*. 2024 Dec 2;7(12):e2452459. doi: 10.1001/jamanetworkopen.2024.52459. PMID: 39729318
320. **Terrault NA**, Vargas HE. Antivirals in preventing perinatal transmission of hepatitis B: Start and stop times are shifting. *Am J Gastroenterol*. 2024 Dec 10. doi: 10.14309/ajg.0000000000003177. PMID: 39656174

Refereed Reviews and Invited Editorials:

1. **Terrault N** and Pappas SC. Complications of Chronic Liver Disease. *Manitoba Medicine*. 61:153-56, 1991.
2. **Terrault N** and Baron DW. Investigating the Bleeding Ulcer. *The Canadian Journal of Diagnosis*. 9:21-37, 1992.
3. **Terrault N** and Greenberg GR. Crohn's Disease: From the Inside Out. *The Canadian Journal of Diagnosis*. 2:107-19, 1992.
4. **Terrault N** and Feinman SV. Interferon and Viral Hepatitis. *Transfusion Medicine Reviews*. 9(1):29-52, 1995.
5. Invited Editorial: **Terrault NA**, Wright TL. Interferon for Hepatitis C. *N Engl J Med*. 332:1509-11, 1995.
6. **Terrault N** and Wright TL. Hepatitis C Virus in the Transplant Setting. *Seminars in Liver Disease*. 15(1):92-100, 1995.
7. **Terrault NA**, Wright TL, Peirera BJ. Hepatitis C Infection in the Transplant Recipient. *Infectious Disease Clinics of North America*. 9 (4):943-964, 1995.
8. Garcia G, **Terrault NA**, Wright TL. Hepatitis C Virus Infection in the Immunocompromised Patient. *Seminars in Gastrointestinal Disease*. 6(1), 35-45, 1995.
9. **Terrault NA**. Treatment of Chronic Hepatitis B and Chronic Hepatitis C. *Rev Med Virol*. 6:215-28, 1996.
10. Invited Editorial: **Terrault NA**, Wright TL. Hepatitis B and Liver Transplantation. *Gut*. 40:568-71, 1997.
11. Invited Editorial: **Terrault, NA**. The emerging importance of hepatitis B virus surface gene mutants. *Viral Hepatitis Reviews*. 3:1-3, 1997.
12. Invited Editorial: **Terrault NA**. Can screening for hepatitis B and hepatitis C infection be recommended? *Adv Gastroenterol Hepatol Clin Nutr*. 2:82-84, 1997.
13. Invited Editorial: **Terrault NA**. Combined interferon and lamivudine therapy: is this the

- treatment of choice for patients with chronic hepatitis B virus infection? *Hepatology*. 32(3):675-7, 2000.
14. **Terrault, NA.** Hepatitis B and Liver Transplantation. *Clinics in Liver Disease*. 3:389-415, 1999.
 15. **Terrault, NA.** Hepatitis C and Liver Transplantation. *Sem Gastrointestinal Dis*. 11:96-114, 2000.
 16. **Terrault, NA.** Management of hepatitis B virus infection in liver transplant recipients: prospects and challenges. *Clinical Transplantation*. 14 (suppl 2):39-43, 2000.
 17. Tong MJ, **Terrault N**, Klintmalm G. Hepatitis B Transplantation: Special Conditions. *Sem Liver Dis*. 20 (Suppl 1):25-28, 2000.
 18. **Terrault NA.** Treatment of Chronic HBV Infection. *Current Treatment Options in Gastroenterology*. 4:493-502, 2001.
 19. Yao FYK, **Terrault NA.** Hepatitis C and Hepatocellular Carcinoma. *Current Treatment Options in Oncology*. 2:473-83, 2001.
 20. Heffernan D*, **Terrault N.** Treatment of Chronic Hepatitis B Virus Infection. *Pract Gastroenterol*. 25(10):41-54, 2001.
 21. Invited Editorial: **Terrault NA**, Ma Mang. Adding to the Hepatitis B Virus Arsenal: Alpha Glucosidase Inhibitor Derivatives. *Hepatology*. 33(6):1544-6, 2001.
 22. **Terrault NA.** Sexual activity as a risk factor for hepatitis C. *Hepatology*. 36(5 Suppl 1):S99-105, 2002.
 23. Peters MG, **Terrault NA.** Alcohol use and hepatitis C. *Hepatology*. 36 (5 Suppl 1):S220-5, 2002.
 24. **Terrault NA.** Treatment of recurrent hepatitis B infection in liver transplant recipients. *Liver Transpl*. 8(10 Suppl 1):S74-81, 2002.
 25. Invited Editorial: **Terrault N.** Motion - The available treatments for hepatitis C are cost effective: Arguments for the motion. *Can J Gastroenterol*. 16(10):705-9, 2002.
 26. **Terrault NA.** Treatment of recurrent hepatitis B infection in liver transplant recipients. *Liver Transpl*. 8(10 Suppl 1):S74-81, 2002.
 27. **Terrault NA.** Liver Transplantation in Patients with Hepatitis C. *Hepatology*. 89-112, 2002.
 28. **Terrault NA.** Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. *Liver Transpl*. 9(11):S95-S100, 2003.
 29. Roland ME, Adey D, Carlson LL, **Terrault NA.** Kidney and liver transplantation in HIV-infected patients: case presentations and review. *AIDS Patient Care STDS*. 17(10):501-7, 2003.
 30. Invited Editorial: Biggins SW*, **Terrault NA.** Should HCV-related cirrhosis be a contraindication for retransplantation? *Liver Transpl*. 9(3):236-8, 2003.
 31. **Terrault NA**, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. *Clin Liver Dis*. 7(3):537-50, 2003.
 32. Lai CL*, **Terrault NA.** Antiviral therapy in patients with chronic hepatitis B and cirrhosis. *Gastroenterol Clin North Am*. 33(3):629-54, 2004.
 33. Chainani-Wu N, Lozada-Nur F, **Terrault N.** Hepatitis C virus and Lichen Planus: A Review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 98(2):171-83, 2004.
 34. Straley SD*, **Terrault NA.** Chronic Hepatitis B. *Curr Treat Options Gastroenterol*. 7(6):477-489, 2004.
 35. Bell BP, Mast EE, **Terrault N**, Hutin YJ. Prevention of hepatitis C in Women. *Emerg Infect Dis*. 10(11):2035-6, 2004.
 36. Wong W, **Terrault N.** Update on chronic hepatitis C. *Clin Gastroenterol Hepatol*. 3:507-20, 2005.
 37. **Terrault N**, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. *Liver Transpl*. 11(7):716-732, 2005.

38. **Terrault NA.** Treatment of recurrent hepatitis C in liver transplant recipients. *Clin Gastroenterol Hepatol.* 3(10 Suppl 2):S125-31, 2005.
39. Biggins SW*, **Terrault NA** Treatment of recurrent hepatitis C after liver transplantation. *Clin Liver Dis.* 9(3):505-23, 2005.
40. Invited Editorial: **Terrault N.** Sex and Hepatitis C. *Am J Gastroenterology.* 100:825-826, 2005.
41. Biggins SW*, **Terrault NA** Management of recurrent hepatitis C in liver transplant recipients. *Infect Dis Clin North Am.* 20(1):155-74, 2006.
42. Bialek SR, **Terrault NA.** The changing epidemiology and natural history of hepatitis C virus infection. *Clin Liver Dis.* 10(4):697-715, 2006.
43. Kuo A*, **Terrault NA.** Management of hepatitis C in liver transplant recipients. *Am J Transplant.* 6(3):449-58, 2006.
44. **Terrault NA,** Berenguer M. Treating hepatitis C infection in liver transplant recipients. *Liver Transpl.* 12(8):1192-204, 2006.
45. Coffin CS*, **Terrault NA.** Management of hepatitis B in liver transplant recipients. *J Viral Hepat.* 14 Suppl 1:37-44, 2007.
46. **Terrault NA,** Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. *Clin J Am Soc Nephrol.* 2(3):563-75, 2007.
47. **Terrault NA,** Jacobson I. Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy. *Semin Liver Dis.* 27 Suppl 1:18-24, 2007.
48. Invited Editorial: Kuo A*, **Terrault NA.** Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters? *J Hepatol.* 46(3):359-61, 2007.
49. Invited Editorial: Irwin J*, **Terrault NA.** Cognitive Impairment in hepatitis C patients on antiviral therapy. *Gastroenterol Hepatol.* 4:65-67, 2008.
50. Samuel D, Weber R, Stock P, Duclos-Vallée JC, **Terrault N.** Are HIV-infected patients candidates for liver transplantation? *J Hepatol.* 2008;48(5):697-707, 2008.
51. **Terrault NA.** Hepatitis C therapy before and after liver transplantation. *Liver Transpl.* 14 Suppl 2:S58-66, 2008.
52. Nelson D, Davis GL, Everson GT, Fried MW, Harrison SA, Hassanein T, Jacobson I, Jensen DM, Lindsay KL, **Terrault N,** Zein N. Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy. *Clin Gastroenterol Hepatol.* 7(4):397-414, 2009.
53. **Terrault NA.** Benefits and Risks of Combination Therapy for Hepatitis B. *Hepatology.* 49:S122-S128, 2009.
54. Kuo A*, **Terrault NA.** Is Recurrent Hepatitis C Worse with Living Donation? *Curr Opin Organ Transplant.* 14(3):240-4, 2009.
55. Coffin C*, **Terrault NA.** Management of Patients Coinfected with HBV and HCV. *Expert Rev Anti Infect Ther.* 7:549-58, 2009.
56. Invited Editorial: Valadao R*, **Terrault NA.** Older Donors - Mounting Risks for the Hepatitis C-Infected Liver Transplant Recipient? *Liver Transplant.* 15(7):677-81, 2009.
57. Hou, JK, Velayos F, **Terrault N,** Mahadeva U. Viral Hepatitis and Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 16(6):925-32, 2010.
58. Invited Editorial: **Terrault N,** Khalili M. A glimpse of future hepatitis C virus treatment paradigms. *Hepatology.* 51(2):707-10, 2010.
59. Invited Editorial: Fox A*, **Terrault NA.** Individualizing hepatitis B infection prophylaxis in liver transplant recipients, *J Hepatology.* 56(5):1189-97, 2012.
60. Flemming JA, **Terrault NA.** Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection. *Infect Dis Clin North Am.* 26(4):903-15, 2012.
61. **Terrault N.** Liver transplantation in the setting of chronic HCV. *Best Practice & Research Clinical Gastroenterology.* 25(4):531-48, 2012.
62. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, **Terrault N,** Thomas D. Hepatitis C virus: a critical appraisal of new

- approaches to therapy. *Hepat Res Treat*. 2012:138302, 2012. PMID: 23094146.
63. Flemming JA*, **Terrault NA**. Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection. *Infect Dis Clin North Am*. 26(4):903-15, 2012. PMID: 23083823.
 64. Harbell J, **Terrault NA**, Stock P. Solid organ transplants in HIV-infected patients. *Curr HIV/AIDS Rep*. 10(3):217-25, 2013. PMID: 23893004.
 65. Invited Editorial: **Terrault N**. Prophylaxis in HBV-Infected Liver Transplant Patients: End of the HBIG Era? *Am J Gastroenterol*. 108(6):949-51, 2013. PMID: 2373591
 66. Invited Editorial: Sarkar M, **Terrault NA**. Ending Vertical Transmission of Hepatitis B: The Third Trimester Intervention. *Hepatology*. 60(2):448-51, 2014. PMID: 24668789, PMCID: PMC5938736
 67. Invited Editorial: **Terrault NA**, Stock PG. Management of hepatitis C in kidney transplant patients: on the cusp of change. *Am J Transplant*. 14(9): 1955-7, 2014 Sep. PMID: 25307029
 68. Invited Editorial: Stock PG, **Terrault NA**. HIV and liver transplantation: Hepatitis C is the last hurdle. *Hepatology*. 61(5): 1747-54, 2015. [Epub 2014 Oct 7]. PMID: 25292153
 69. Sarkar M, Watt KD, **Terrault N**, Berenguer M. Outcomes in Liver Transplantation: Does Sex Matter? *J Hepatol*. 62(4): 946-55, 2015. [Epub 2014 Nov 26]. PMID: 25433162.
 70. Saxena V*, **Terrault N**. Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients. *Clin Liver Dis*. 19(4):669-88, 2015. PMID: 26466655
 71. Campos-Varela I*, Peters MG, **Terrault NA**. Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting. *Clin Infect Dis*. 60(1):108-16, 2015. PMID: 25228702.
 72. Miro JM, Stock P, Teicher E, Duclos-Vallée JC, **Terrault N**, Rimola A. Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 Update. *J Hepatol*. 62(3):701-11, 2015. PMID: 25450714
 73. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, **Terrault NA**, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. *Gut*. 64(11):1824-33, 2015. PMID: 26449729
 74. Price JC, **Terrault NA**. Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. *Liver Transpl*. 21(4):423-34, 2015. PMID: 25604355.
 75. Invited Editorial: Saxena V*, **Terrault NA**. Hepatitis C Direct Antiviral Drugs and Hepatic Decompensation in Patients with Advanced Cirrhosis: Culprit or Innocent Bystander? *Dig Dis Sci*. 60(4):806-9, 2015. PMID: 25586091; PMCID: PMC4422509.
 76. Invited Editorial: Price JC, **Terrault NA**. Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective. *Liver Int*. 35(1):7-8, 2015. doi: 10.1111/liv.12679. No abstract available. PMID: 25183500
 77. Di Bisceglie AM, Lok AS, Martin P, **Terrault N**, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg? *Hepatology*. 61(2):703-11, 2015. PMID: 25412906
 78. Invited Editorial: **Terrault N**. Difficult-to-cure populations with chronic hepatitis C: Vanishing in the direct-acting antiviral era? *Hepatology*. 62(1):4-7, 2015. PubMed PMID: 25965110.
 79. Invited Editorial: Giard JM*, **Terrault NA**. Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival. *Clin Gastroenterol Hepatol*. 13:2002-4, 2015. PMID: 26192143
 80. Invited Editorial: **Terrault NA**. Real-World Experiences with Tenofovir Disoproxil Fumarate: Is this the "B-Ticket"? *Dig Dis Sci*. 61(10):2770-2, 2016.
 81. Nathanson MH, **Terrault N**. Hepatitis B surface antigen loss: Not all that we hoped it would be. *Hepatology*. 64:328-9, 2016. PMID: 27178231
 82. Invited Editorial: Saxena V*, **Terrault NA**. Treatment of Hepatitis C Infection in Renal Transplant Recipients: The Long Wait Is Over. *Am J Transplant*. 16:1345-7, 2016.

83. Invited Editorial: **Terrault NA**. The changing 'face' of wait-listed patients in the USA. *Curr Opin Organ Transplant*. 21(2):89-90, 2016. PMID: 26890533.
84. Hameed B, **Terrault NA**. Emerging Therapies for Non-Alcoholic Fatty Liver Disease. *Clin Liver Dis*. 20(2):365-85, 2016.
85. Chen T*, **Terrault N**. Treatment of chronic hepatitis C in patients with cirrhosis. *Curr Opin Gastroenterol*. 32:143-51, 2016. PMID: 27023162
86. Chen T*, **Terrault NA**. Perspectives on treating hepatitis C infection in the liver transplantation setting. *Curr Opin Organ Transplant*. 21:111-9, 2016. PMID: 26927201
87. **Terrault NA**, Hassanein TI. Management of the patient with SVR. *J Hepatol*. 65(1 Suppl):S120-9, 2016. PMID: 27641982
88. Giard JM*, **Terrault NA**. Women with Cirrhosis: Prevalence, Natural History, and Management. *Gastroenterol Clin North Am*. 45(2):345-58, 2016. PMID: 27261903
89. Hameed B, **Terrault N**. Emerging Therapies for Nonalcoholic Fatty Liver Disease. *Clin Liver Dis*. 20(2):365-85, 2016. PMID: 27063275
90. Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, **Terrault N**, Younossi Z. Hepatitis C virus infection. *Nat Rev Dis Primers*. 3:17006, 2017. PMID: 28252637
91. Ajmera VH*, **Terrault NA**, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. *Hepatology*. 65(6):2090-2099, 2017. PMID: 28100008
92. Zhou K*, **Terrault N**. Management of hepatitis B in special populations. *Best Pract Res Clin Gastroenterol*. 31(3):311-320, 2017. PMID: 28774413.
93. Lee BP*, **Terrault NA**. Early liver transplantation for severe alcoholic hepatitis: moving from controversy to consensus. *Curr Opin Organ Transplant*. 23(2):229-236, 2018. PMID: 29389821.
94. Invited Editorial: **Terrault NA**. Hepatitis C in Patients with Renal Disease: A Deeper Dive into the KDIGO Guideline. *Hepatology*. 68(5):2035-2038, 2018. doi:10.1002/hep.30047. Epub 2018 Oct 8. PubMed PMID: 29672896.
95. Invited Editorial: **Terrault NA**, Pageaux GP. A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over! *J Hepatol*. 69(4):767-768, 2018. doi: 10.1016/j.jhep.2018.07.020. Epub 2018 Aug 10. PubMed PMID: 30104027.
96. Invited Editorial: Kwong AJ*, **Terrault NA**. Use of hepatitis C viraemic organs in kidney transplantation: a need to hit the pause button? *Nat Rev Gastroenterol Hepatol*. 16(1):5-6, 2019. doi: 10.1038/s41575-018-0071-0. PMID: 30333527.
97. Invited Editorial: **Terrault N**. Is Low Level Viremia Acceptable During Antiviral Therapy of Patients With HBV Infection and Decompensated Cirrhosis? *Clin Gastroenterol Hepatol*. 16(12):1876-1878, 2018. doi: 10.1016/j.cgh.2018.09.010. Epub 2018 Sep PubMed PMID: 30213586.
98. Invited Editorial: Flemming JA, **Terrault NA**. Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B: One of These Things Is Not Like the Other. *JAMA Oncol*. 5(1):17-18, 2019. [Epub 2018 Sep 2]. doi: 10.1001/jamaoncol.2018.4039. PMID: 30267036
99. Coffin CS, Zhou K*, **Terrault NA**. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. *Gastroenterology*. 156(2):355-368.e3, 2019. doi: 10.1053/j.gastro.2018.11.037. Epub 2018 Nov 22. Review. PMID: 30472225.
100. Invited Editorial: Sharpton SR*, **Terrault NA**. Prior Bariatric Surgery in Liver Transplant Candidates: Unforeseen Consequences? *Liver Transpl*. 25(2):203-204, 2019. PMID: 30585696.
101. Invited Editorial: Lee BP*, **Terrault NA**. Liver-related mortality in the United States: hepatitis C declines, non-alcoholic fatty liver and alcohol rise. *Transl Gastroenterol Hepatol*. 22;4:19, 2019. doi: 10.21037/tgh.2019.03.04. eCollection 2019. PubMed PMID: 30976722; PubMed Central PMCID: PMC6458348.
102. Lee BP*, **Terrault NA**. Return to Alcohol Use After Liver Transplant: Patterns and

- Surveillance. *Clin Liver Dis (Hoboken)*. 12(6):160-164, 2019. doi: 10.1002/cld.756. eCollection 2018 Dec. Review. PubMed PMID: 30988935; PubMed Central PMCID: PMC6446457.
103. **Terrault NA**. Hepatitis C elimination: challenges with under-diagnosis and under-treatment. *F1000Res*. 8. pii: F1000 Faculty Rev-54, 2019. doi: 10.12688/f1000research.15892.1. eCollection 2019. Review. PubMed PMID: 30687501; PubMed Central PMCID: PMC6338244.
 104. Liang TJ, **Terrault N**. Viral Hepatitis and Hepatocellular Carcinoma. *Gastroenterology*. 2019 Jan;156(2):293, 2019. doi
 105. Piao C, **Terrault NA**, Sarkar S. Telemedicine: An Evolving Field in Hepatology. *Hepatol Commun*. 3(5):716-721, 2019. doi: 10.1002/hep4.1340. eCollection 2019 May. PubMed PMID: 31061958; PubMed Central PMCID: PMC6492471.
 106. Invited Editorial: Brandman D, **Terrault NA**. Alcohol use in patients with non-alcoholic fatty liver: a tangled web of causality. *Hepatobiliary Surg Nutr*. 8(3):277-279, 2019. doi: 10.21037/hbsn.2019.01.07. PubMed PMID: 31245413; PubMed Central PMCID: PMC6561883.
 107. Catalli L*, Martens SK, **Terrault NA**, Reeves JD. Novel NS5B Resistance-Associated Substitution Emerges Under Failing Sofosbuvir/Ledipasvir Therapy. *Clin Liver Dis (Hoboken)*. 13(3):74-78, 2019. doi: 10.1002/cld.768. eCollection 2019 Mar. Review. PubMed PMID: 30988941; PubMed Central PMCID: PMC6446458.
 105. Kim B, Kahn J, **Terrault NA**. Liver transplantation as therapy for hepatocellular carcinoma. *Liver Int*. 2020 Feb;40 Suppl 1:116-121. doi: 10.1111/liv.14346. PMID: 32077598
 106. Ayyala-Somayajula D*, Han H, **Terrault NA**. Selective use of liver transplantation for severe alcohol-associated hepatitis. *Expert Rev Gastroenterol Hepatol*. 2020 Mar;14(3):175-184. doi: 10.1080/17474124.2020.1733414. [Epub 2020 Mar 3.] PMID: 32077333
 107. Invited Editorial: **Terrault NA**, Ghany MG. Enhanced Screening for Hepatitis D in the USA: Overcoming the Delta Blues. *Dig Dis Sci*. 2020 Sep 5. doi: 10.1007/s10620-020-06584-w. Online ahead of print. PMID: 32889599
 108. Khemichian S, **Terrault NA**. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease. *Semin Thromb Hemost*. 46(6):682-692, 2020. doi: 10.1055/s-0040-1715451. Epub 2020 Aug 20. PMID: 32820479
 109. Kardashian A, Wilder J, **Terrault NA**, Price JC. Addressing Social Determinants of Liver Disease during the COVID-19 Pandemic and Beyond: A Call to Action. *Hepatology*. 2020 Nov 4. doi: 10.1002/hep.31605. Online ahead of print. PMID: 33150599
 110. Invited Editorial: **Terrault NA**, Sher L. Expanding the use of hepatitis C-positive donors and keeping recipient safety at the forefront. *Am J Transplant*. 20(3):627-628, 2020. doi: 10.1111/ajt.15745. [Epub 2020 Jan 13.] PMID: 31840402
 111. **Terrault NA**, Levy MT, Cheung KW, Jourdain G. Viral hepatitis and pregnancy. *Nat Rev Gastroenterol Hepatol*. 2020 Oct 12. doi: 10.1038/s41575-020-00361-w. Online ahead of print. PMID: 33046891
 112. Invited Editorial: Pimienta M, Dodge J, **Terrault NA**. The Internet as a Tool for Liver Transplant Programs to Combat Stigma Related to Alcohol Use Disorder. *Hepatol Commun*. 5(2):155-157, 2021. doi: 10.1002/hep4.1649. PMID: 33553965; PMCID: PMC7850306.
 113. Invited rebuttal: **Terrault NA**, Cheung KW, Levy MT, Jourdain G. Reply to 'Evidence against in utero transmission of hepatitis B virus'. *Nat Rev Gastroenterol Hepatol*. 18(6):445-446, 2021. doi: 10.1038/s41575-021-00456-y. PMID: 33888888.
 114. Burra P, Samuel D, Sundaram V, Duvoux C, Petrowsky H, **Terrault N**, Jalan R. Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. *J Hepatol*. 2021 Jul;75 Suppl 1:S178-S190. doi: 10.1016/j.jhep.2021.01.007. PMID: 34039488.

115. Singal AK, Kwo P, Kwong A, Liangpunsakul S, Louvet A, Mandrekar P, McClain C, Mellinger J, Szabo G, **Terrault N**, Thursz M, Winder GS, Kim WR, Shah VH. Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. *Hepatology*. 2021 Sep 8. doi: 10.1002/hep.32143. Epub ahead of print. PMID: 34496071.
116. Khemichian S, Kahn J, Terrault NA. Use of Hepatitis B Virus-Positive Organs in Organ Transplantation. *Clin Liver Dis*. 25(4):841-857, 2021. doi:10.1016/j.cld.2021.06.009. Epub 2021 Aug 5. PMID: 34593157.
117. Kim B, **Terrault NA**. Optimizing Hepatology Education in the Virtual World. *Clin Liver Dis* (Hoboken) 19(4):139-143, 2022. doi: 10.1002/cld.1168. PMID: 35505919; PMCID: PMC9053677.
118. Russo MW, Kwok R, Serper M, Ufere N, Hameed B, Chu J, Goacher E, Lingerfelt J, **Terrault N**, Reddy KR. Impact of the Corona Virus Disease 2019 Pandemic on Hepatology Practice and Provider Burnout. *Hepatol Commun*. 6(5):1236-1247, 2022. doi: 10.1002/hep4.1870. Epub 2021 Dec 28. PMID: 34783189; PMCID: PMC8652849.
119. Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, Kao JH, **Terrault N**, Lok AS, Reddy KR. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. *J Hepatol*. 16:S0168-8278(22)02935-X, 2022 doi: 10.1016/j.jhep.2022.07.003. Epub ahead of print. PMID: 35850281.
120. Lee BP, **Terrault NA**. Advocacy for Equity in Transplantation Access for Alcohol-Associated Liver Disease: How Research Changed Medi-Cal Policy. *Gastroenterology*. 163(3):539-542, 2022. doi: 10.1053/j.gastro.2022.05.013. Epub 2022 May 13. PMID: 35577123.
121. Choi HSJ, Tonthat A, Janssen HLA, **Terrault NA**. Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B. *Hepatol Commun*. 6(5):935-949, 2022 doi: 10.1002/hep4.1875. Epub 2021 Dec 10. PMID: 34894108; PMCID: PMC9035586.
122. **Terrault NA**, Williamson C. Pregnancy-Associated Liver Diseases. *Gastroenterology*. 2022;163(1):97-117. PMID: 35276220.
123. Kardashian A, Serper M, **Terrault N**, Nephew LD. Health disparities in chronic liver disease. *Hepatology*. 2023;77(4):1382-1403. PMID: 35993341.
124. Wedemeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor H, Kessler HH, Lenz O, Lütgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, **Terrault N**, Lampertico P; HDV RNA Assays Writing Group at the HBV Forum. HDV RNA assays: Performance characteristics, clinical utility, and challenges. *Hepatology*. 2023 Aug 28. doi: 10.1097/HEP.0000000000000584. PMID: 37640384
125. Martinello M, Solomon SS, **Terrault NA**, Dore GJ. Hepatitis C. *Lancet*. 2023;402(10407):1085-1096. PMID: 37741678.
126. **Terrault N**. Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis. *J Infect Dis*. 2023 Sep 22:jiad299. doi: 10.1093/infdis/jiad299. PMID: 37739784
127. Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, Maini MK, **Terrault NA**, Zoulim F. The scientific basis of combination therapy for chronic hepatitis B functional cure. *Nat Rev Gastroenterol Hepatol*. 2023;20(4):238-253. PMID: 36631717 Review.
128. Invited Editorial: So S, **Terrault N**, Connors EE. Universal Adult Hepatitis B Screening and Vaccination as the Path to Elimination. *JAMA*. 2023;329(19):1639-1640. PMID: 36897598
129. **Terrault NA**, Francoz C, Berenguer M, Charlton M, Heimbach J. Liver Transplantation 2023: Status Report, Current and Future Challenges *Clin Gastroenterol Hepatol*. 2023;21(8):2150-2166. PMID: 37084928 Review.
130. Huang DQ, **Terrault NA**, Tacke F, Gluud LL, Arrese M, Bugianesi E, Loomba R. Global

- epidemiology of cirrhosis - aetiology, trends and predictions Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. PMID: 36977794.
131. Lee BP, **Terrault NA**. Liver transplantation for alcohol-associated liver disease: A call for national standards of best practices to monitor and bridge disparities in access and outcomes. Am J Transplant. 2023 Aug;23(8):1097-1101. PMID: 37023857.
 132. Invited Editorial: The national hepatitis C elimination program-AASLD's coalition and call to action. American Association for the Study of Liver Diseases. Hepatology. 2023 Aug 1;78(2):371-374. PMID: 37165887.
 133. Forbes C, Lavoie L, Satram S, Shen L, Thanawala V, Arizpe A, **Terrault N**. Global importance of new treatment strategies to efforts to control hepatitis B virus. Expert Rev Anti Infect Ther. 2023;21(8):847-862. PMID: 37322901 Review.
 134. Peters MG, Yuen MF, **Terrault N**, Fry J, Lampertico P, Gane E, Hwang C, Stamm LM, Leus M, Maini MK, Mendez P, Lonjon-Domanec I, Berg T, Wang S, Mishra P, Donaldson E, Buchholz S, Miller V, Lenz O. Chronic Hepatitis B Finite Treatment: similar and different concerns with new drug classes. Clin Infect Dis. 2023 Aug 26:ciad506. doi: 10.1093/cid/ciad506. Online ahead of print. PMID: 37633256.
 135. Sawinski D, Lai JC, Pinney S, Gray AL, Jackson AM, Stewart D, Levine DJ, Locke JE, Pomposelli JJ, Hartwig MG, Hall SA, Dadhania DM, Cogswell R, Perez RV, Schold JD, Turgeon NA, Kobashigawa J, Kukreja J, Magee JC, Friedewald J, Gill JS, Loor G, Heimbach JK, Verna EC, Walsh MN, **Terrault N**, Testa G, Diamond JM, Reese PP, Brown K, Orloff S, Farr MA, Olthoff KM, Siegler M, Ascher N, Feng S, Kaplan B, Pomfret E. Addressing sex-based disparities in solid organ transplantation in the United States - a conference report. Am J Transplant. 2023 Mar;23(3):316-325. PMID: 36906294
 136. Reproductive health and liver disease: a patient-friendly summary of the 2021 AASLD guidance. Levy C, Brady CW, **Terrault N**, Stotts MJ, Sarkar M. Clin Liver Dis (Hoboken). 2023 Jan 23;21(1):19-35. PMID: 36937776
 137. Ending stigmatizing language in alcohol and liver disease: A liver societies' statement (Terrault). Hepatology 2023 Dec 1;78(6):1682-1683. PMID: 37767883

Books, Monographs, and Text Books:

1. **Terrault NA**. Sex and Hepatitis C. Handbook of Management of Issues in Hepatitis C Infection. Science Press Ltd, London, 2003.
2. No More Digestive Problems, Cynthia Yoshida with Debra Kotz. **N. Terrault** - chapter on Liver Diseases. Bantam Books, 2004.
3. Straley SD, **Terrault NA**. Immune-Mediated Manifestations of Chronic Liver Disease. In Hepatology: A Practical Approach, editors: Al Kaway, Shiffman, Wiesner. Elsevier Academic Press, 2004.
4. **Terrault NA**, Pessoa, MG. Pre- and Post-Transplant Management of Hepatitis C. Textbook in Transplant Hepatology. Trotter J and Everson G, editors, 2008.
5. **Terrault NA**. HBV, HCV and HIV in Liver Transplantation. In Sherlock and Dooley's Diseases of the Liver and Biliary System, 12th edition. Editors: James S Dooley, Anna Lok, Andrew Burroughs, Jenny Heathcote, 2011.
6. Lai J, **Terrault NA**. Recurrent Diseases in Liver Transplantation. *Zakim and Boyer Hepatology: A Textbook in Liver Disease*, 6th edition. Editors: Boyer, Manns and Sanyal. 2011.
7. Bambha K, **Terrault NA**. Long-Term Management of Recurrent Primary Liver Disease. In *Textbook of Clinical Gastroenterology and Hepatology*, 2nd edition. Editors: C. J. Hawkey, Jaime Bosch, Joel E. Richter, Guadalupe Garcia-Tsao, Francis. K. L. Chan, 2012.
8. Boyer T, Sanyal A, Lindor, K, **Terrault NA**: editors. 7th edition of Zakim and Boyer's Hepatology, A Textbook of Liver Disease. Publisher - Elsevier.
Plus Chapter: Saxena V, **Terrault NA**. Recurrent Primary Diseases After Liver

Transplantation 883-909, 2012.

9. Lucey MR, **Terrault N**, Ojo L, Hay JE, Neuberger J, Blumberg E, Teperman LW. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Liver Transpl*. 19(1):3-26, 2013. PMID 2328127
10. Soriano V, Young B, **Terrault N**. Report from the International Conference on Viral Hepatitis (ICVH), San Francisco, March 2016. *AIDS Rev*. 18(2):81-8, 2016. PMID: 27196355
11. **Terrault NA**, Bzowej N, Chang K-M, Hwang J, Jonas M, Murad MH. AASLD Guidelines for Treatment of Chronic Hepatitis B. *Hepatology*. 63(1):261-83, 2016. PMID: 26566064
12. Coffin C, **Terrault NA**. Treatment of HCV, HDV, or HIV Coinfection. In Hepatitis B Virus and Liver Disease. Jia-Horng Kao and Ding-Shinn Chen (Eds). Publisher: Springer Nature. 239-262, 2017.
13. **Terrault NA**, Berenguer M, Strasser SI, Gadano A, Lilly L, Samuel D, Kwo PY, Agarwal K, Curry MP, Fagiuoli S, Fung JYY, Gane E, Brown KA, Burra P, Charlton M, Pessoa MG, McCaughan GW. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. *Transplantation*. 101(5):956-967, 2017. PMID: 28437388
14. **Terrault NA**, McCaughan GW, Curry MP, Gane E, Fagiuoli S, Fung JYY, Agarwal K, Lilly L, Strasser SI, Brown KA, Gadano A, Kwo PY, Burra P, Samuel D, Charlton M, Pessoa MG, Berenguer M. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. *Transplantation*. (5):945-955, 2017. PMID: 28437387
15. Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, **Terrault N**, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. *Am J Transplant*. 17(11):2790-2802, 2017. doi: 10.1111/ajt.14381. PMID: 28556422
16. **Terrault NA**, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 67(4):1560-1599, 2018. doi: 10.1002/hep.29800. PubMed PMID: 29405329.
17. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (**Terrault**). *Clin Infect Dis*. 67(10):1477-1492, 2018. doi: 10.1093/cid/ciy585. PubMed PMID: 30215672.
18. Kahn J, **Terrault NA**. Use of HCV Positive Donors into HCV Negative Solid Organ Transplant Recipients. Textbook of Liver Transplantation. A Multidisciplinary Approach (Ed: Patrizia Burra), Springer Nature, in press.

Letters to the Editor:

1. Saxena V*, Monto A, **Terrault N**. Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals - authors' reply. *Aliment Pharmacol Ther* 39(12): 1428, 2014. PMID: 24849150
2. **Terrault NA**, Brown RS Jr, Lok AS, Wong JB, Bzowej NH, Chang KM, Hwang JP, Jonas MM, McMahon BJ. Reply. *Hepatology*. 68(4):1658-1660, 2018. doi: 10.1002/hep.30137. PubMed PMID: 30070717.
3. **Terrault NA**, Feld JJ, Lok ASF. Tenofovir to Prevent Perinatal Transmission of Hepatitis B. *N Engl J Med*. 378(24):2348-9, 2018. doi: 10.1056/NEJMc1805396. PubMed PMID: 29900725.

4. Lee BP, Im GY, Lucey MR, **Terrault NA**. Reply. *Gastroenterology*. 156(1):286-287, 2019. doi: 10.1053/j.gastro.2018.11.044. Epub 2018 Nov 22. PubMed PMID: 30472234.
5. **Terrault NA**, Hassanein TI. Reply. *Gastroenterology*. 156(3):825-826, 2019. doi: 10.1053/j.gastro.2019.01.024. Epub 2019 Jan 16. PubMed PMID: 30659833.
6. **Terrault NA**, Feld JJ. Safety First: Favoring Prophylactic/Preemptive Over Delayed Treatment in D+/R- Transplants. *Hepatology*. 72(2):787,2022. doi: 10.1002/hep.31181. PMID: 32060932.
7. Campos-Varela I, Price JC, Dodge JL, **Terrault NA**. Transplantation, HIV Serostatus, and Registry Data: Room for Improvement. *Am J Transplant*. 22(9):2283-2284, 2022. doi: 10.1111/ajt.17062. Epub 2022 Apr 25. PMID: 35429220
8. Levy MT, **Terrault NA**. Caesarean section or non-breastfeeding for prevention of MTCT- beware of sending the wrong message. *J Viral Hepat*. 2020 Dec 11. doi: 10.1111/jvh.13455. Online ahead of print. PMID: 33305401
9. Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, **Terrault NA**, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R. Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' reply. *Aliment Pharmacol Ther*. 56(1):182-183, 2022. doi: 10.1111/apt.16972.
10. Wang AE, Hsieh E, Turner BJ, **Terrault N**. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts. *J Gen Intern Med*. 2022 Apr 28. doi: 10.1007/s11606-022-07628-9. Epub ahead of print. PMID: 35484367.
11. Williamson C, **Terrault N**. Response to Letter to Editor: Bile and Liver in Pregnancy: no one Split apart what God has Joined Together. *Gastroenterology* 2022 Sep 28;S0016-5085(22)01084-8. doi: 10.1053/j.gastro.2022.09.026.
12. Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening. Rinella ME, **Terrault N**, Neuschwander-Tetri B, Loomba R. *Hepatology*. 2023 Nov 1;78(5):E91-E92. doi: 10.1097/HEP.0000000000000469. Epub 2023 May 22. PMID: 37203291.
13. Reply: Rinella ME, **Terrault N**, Neuschwander-Tetri B, Loomba R, Abdelmalek M. Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate? *Hepatology*. 2023;78(6):E103-E104. PMID: 37199166.
14. Reply: Recognizing the new nomenclature requires a comprehensive analysis of the prevalence, severity, and long-term outlook for SLD and subclassifications Lee BP, Dodge JL, **Terrault NA**. *Hepatology*. 2023 Oct 31. PMID: 37906684
15. Reply: Lazarus JV, Newsome PN, Francque SM, Kanwal F, **Terrault NA**, Rinella ME. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology*. 2023 Nov 20. Online ahead of print. PMID: 37983810.
16. Reply: Newsome P, Rinella ME, Lazarus JV, **Terrault N**. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease". *Hepatology*. 2024 Jan 1;79(1):E5-E6. PMID: 37651218.
17. Reply: Rinella ME, Castro Narro GE, Krag A, **Terrault N**, Newsome PN. Reply: From NAFLD to MASLD: Promise and pitfalls of a new definition. *Hepatology*. 2024 Feb 1;79(2):E16-E17. doi: 10.1097/HEP.0000000000000705. PMID: 38112434
18. Reply: Rinella ME, Narro GEC, Krag A, **Terrault N**, Newsome PN. Reply: From NAFLD to MASLD: Promise and pitfalls of a new definition. *Ann Hepatol*. 2024 Jul-Aug;29(4):101178. doi: 10.1016/j.aohp.2023.101178. Epub 2023 Dec 19. PMID: 38944461
19. Reply: Ghany MG, King WC, Hinerman AS, Lok ASF, Lisker-Melman M, Chung RT, **Terrault N**, Janssen HLA, Khalili M, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Reply: The exact predictive value of HBcAg and HBV RNA in serological status and disease activity in CHB. *Hepatology*. 2024 Nov 1;80(5):E82-E84. doi: 10.1097/HEP.0000000000000963. PMID: 38861678

Non-Refereed Journal Articles, reviews, or other communications:

1. **Terrault NA.** Liver Transplantation in Patients with Hepatitis C. *Update in Hepatology*. 89-112, 2002.
2. Straley S, **Terrault NA.** Treatment of Chronic Hepatitis B. *Current Hepatitis Reports*. 2(2):49-59, 2003.
3. **Terrault NA.** Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. *Liver Transpl*. 9(11):S95-S100, 2003.
4. Roland ME, Adey D, Carlson LL, **Terrault NA** Kidney and liver transplantation in HIV-infected patients: case presentations and review. *AIDS Patient Care STDS*. 17(10):501-7, 2003.
5. **Terrault NA.** Sex and Hepatitis C. *Handbook of Management of Issues in Hepatitis C Infection*. Science Press Ltd, London, 2003.
6. **Terrault N.** Liver Diseases (chapter). No More Digestive Problems. Cynthia Yoshida with Debra Kotz (authors). Bantam Books, 2004.
7. Agudelo E, **Terrault N.** Optimizing Therapy in Treatment: Naïve Genotype 1 Patients. *Hepatitis Reports*. 7(2): 64-71, 2008.
8. Flemming JA and **Terrault NA.** *HIV and Liver Disease – Book Review*. *Gastroenterology*. 143(1):268-269, 2012.
9. **Terrault N,** Monto A, Stinchon MR, Rusie E, Moreo K. New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting. *Expo.J Manag Care Spec Pharm*. 21(9):S1-S17, 2015. PubMed PMID: 26308363.
10. Soriano V, Young B, **Terrault N.** *Report from the International Conference on Viral Hepatitis (ICVH)*, San Francisco, March 2016. *AIDS Rev*. 18(2):81-8, 2016. PMID: 27196355.
11. **Terrault NA.** Care of Patients Following Cure of Hepatitis C Virus Infection. *Gastroenterol Hepatol (N Y)*. 14(11):629-634, 2018. PubMed PMID: 30538603; PubMed Central PMCID: PMC6284341
12. **Terrault NA,** Dufour JF, Schwabe RF, Wong VW. Breakthroughs in hepatology. *J Hepatol*. 76(6):1247-1248, 2022. doi: 10.1016/j.jhep.2022.04.001
13. **Terrault N,** Shah VH, Heller T. In Memoriam-Hugo R. Rosen. *Gastroenterology* 2022 13:S0016-5085(22)00953-2. doi: 10.1053/j.gastro.2022.08.027. Online ahead of print.

Media and Television appearances:

Date	Title of presentation	Venue
2001	Hepatitis C and risk of acquisition via tattooing	KRON TV
2008	Hepatitis B and C	Google's Knol:A Unit of Knowledge
2015	Hepatitis C Treatment in Non-Liver Solid Organ Transplant Recipients	Webinar, Hosted by American Society of Transplantation
2015	The Great Debate In Treatment Eligibility for HCV Patients	Hosted by PRIME®
2017	Annual CCO Hepatitis Update	Webinar, Hosted by Clinical Care Options®
2017	HCV Among Women of Childbearing Age	Webinar, Hosted by HepCure
2017	Elimination of Hepatitis C in Northern California: ECHO-Plus	YouTube, recorded MetaECHO 2017, Albuquerque NM

2018	Annual CCO Hepatitis Update	Webinar, Hosted by Clinical Care Options®
2018	Update on HBV treatment guidelines	Webinar, Hosted by American Association for the Study of Liver Diseases
2019	“Curing” Hepatitis C is Not the End of Patient Care	<i>Medscape</i>
2019	Lancet Gastroenterology & Hepatology	Profile Focus: The Amazing Liver, with Norah Terrault
2022	Hepatitis Delta Cascade of Care	Webinar, Hosted by GILEAD™
2022	Hepatitis Delta Social Stigma and Linkage to Care	Webinar, Hosted by GILEAD™
2022	Less Than 1 in 3 Patients With Hepatitis C in the US Receive a Cure	<i>Los Angeles Times</i>
2023	Hepatitis C is a Slow-Moving Killer That Can Be Stopped. What's Getting in the Way?	<i>Los Angeles Times</i>
2023	The New Word in Liver Disease: The Story Behind NAFLD's Rebranding as MASLD	<i>Medscape</i>
2023	MASLD, MASH Projected to Grow by 23% in the US Through 2050	<i>Medscape</i>